

AD \_\_\_\_\_

Award Number: W81XWH-07-1-0308

TITLE: Dengue Virus-Like Particle Vaccine

PRINCIPAL INVESTIGATOR: Charles Rinaldo, PhD

CONTRACTING ORGANIZATION: University of Pittsburgh Medical Center  
Pittsburgh, PA 15213

REPORT DATE: July 2011

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE (DD-MM-YYYY)</b> 01-07-2011		<b>2. REPORT TYPE</b> Final		<b>3. DATES COVERED (From - To)</b> 16 JUL 2007-15 JUN 2011	
<b>4. TITLE AND SUBTITLE</b>  Dengue Virus-Like Particle Vaccine				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b> W81XWH-07-1-0308	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Charles Rinaldo, PhD  E-Mail: rinaldocr@upmc.edu				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  University of Pittsburgh Medical Center Pittsburgh, PA 15213				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>  Abstract on next page.					
<b>15. SUBJECT TERMS</b>  Subject terms on next page.					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>19b. TELEPHONE NUMBER (include area code)</b>
U	U	U	UU	84	USAMRMC

**14. ABSTRACT**

The aim of the project was to develop and validate Dengue virus (DENV) VLP based vaccines for the elicitation of broadly reactive immune responses. This approach built on expertise and tools already developed by the members of the University of Pittsburgh's Center for Vaccine Research for Emerging Diseases and Biodefense. Synthetic genes were generated by GeneArt and cloned into the Center's expression plasmid. Gene cassettes were generated for all 4 subtypes of dengue virus. Expression of these genes was verified by direct transfection of 293T cells. Cell lysates and supernatants were harvested and SDS-PAGE performed followed by immunoblotting. While vaccines were effective at eliciting high titer IgG to homologous virus, virus-like particles for dengue virus were more efficient for eliciting neutralizing antibodies. A tetravalent VLP vaccine was efficient at eliciting antibodies against all 4 subtypes of dengue virus. Data obtained from these mouse models can be used as the basis for future non-human primate and human vaccine and challenge studies.

**15. SUBJECT TERMS**

dengue virus, virus-like particles, neutralizing antibodies, cell-mediated immunity, vaccine, baculovirus, DNA vaccine

## Table of Contents

<b>Cover Page</b> .....	<b>1</b>
<b>Standard Form 298</b> .....	<b>2</b>
<b>Introduction</b> .....	<b>4</b>
<b>Body</b> .....	<b>4</b>
<b>Key Research Accomplishments</b> .....	<b>10</b>
<b>Reportable Outcomes/Project Bibliography</b> .....	<b>10</b>
<b>Conclusions</b> .....	<b>11</b>
<b>References</b> .....	<b>11</b>
<b>Appendices</b> .....	<b>12</b>
APPENDIX 1 .....	13
Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice .....	13
APPENDIX 2 .....	27
<i>Hemagglutinin Displayed Baculovirus Protects Against Highly Pathogenic Influenza</i> .....	27
APPENDIX 3 .....	27
<i>Baculovirus-produced Influenza Virus-like Particles in Mammalian Cells Protect Mice from Lethal Influenza Challenge</i> .....	27
APPENDIX 4 .....	28
<i>Dengue Virus</i> .....	28
APPENDIX 5 .....	29
<i>West Nile Virus</i> .....	29

## Introduction

A major problem in the development of effective dengue virus (DENV) vaccines is the diverse strains of virus in circulation that do not readily offer cross-protective immunity due to variant viral envelope (E) proteins.

Our hypothesis is that Consensus DENV E proteins, presented to the immune system on a virus-like particle (VLP), will elicit broader immunity against diverse primary E proteins and provide broader neutralization activity against heterologous DENV isolates compared to a mixture of primary E constructs.

This project proposed to construct and compare the immune responses generated with several dengue VLP vaccine strategies: (1) a mixture of four VLPs, each with a primary envelope sequence; (2) a mixture of four VLPs, each with a serotype consensus envelope sequence; and (3) a chimeric VLP with all four envelope sequences on a single particle (primary or consensus envelope sequences). For each VLP construct strategy, two different delivery systems were employed: an *in vivo* "genetic VLP" DNA/particle prime-boost vaccine delivery system and an *in vitro* baculovirus-expressed "purified VLP" vaccine delivery system.

## Body

**The approved Statement of Work is as follows:**

**STATEMENT OF WORK:** Independently, and not as an agent of the Government, the Contractor shall furnish all necessary services, qualified professional, technical, and administrative personnel, material, equipment and facilities, not otherwise provided by the Government under the terms of this contract, as needed to perform the tasks set forth below.

Specifically the Contractor shall provide:

- 1. Dengue virus-like particles.** The Contractor shall develop and validate Dengue virus (DENV) VLP based vaccines for the elicitation of broadly reactive immune responses. This approach will build on expertise and tools already developed by the members of the University of Pittsburgh's Center for Vaccine Research for Emerging Diseases and

Biodefense. Data obtained from these mouse models will be used as the basis for future non-human primate and human vaccine and challenge studies.

1 (a) DNA plasmids expressing VLPs from mammalian cells. The Contractor shall construct vaccines that elicit immune responses against DENV isolates representing each serotype. Two vaccine approaches are described in the proposal. The first vaccine strategy uses DNA plasmids expressing the Capsid (C), pre-membrane (prM), and envelope (E) gene segments from DENV. DNA plasmids will be constructed in Year 1 using gene segments representing each of the 4 DENV serotypes (wild type or consensus). Plasmids will be transfected mammalian cells *in vitro* resulting in VLP secretion followed by ultracentrifugation purification. Mice will be primed with DNA plasmids expressing each vaccine intradermally by gene gun and then boosted with the same purified VLPs intranasally. Serum and bronchoalveolar lavage (BAL) will be assayed for antibody responses and spleens and lymph nodes (LN) for cellular responses. Mice will be vaccinated with a single vaccine expressing VLPs representing a single serotype or all four vaccines representing each serotype. Immune responses elicited in mice vaccinated with a single vaccine will be compared to the tetravalent VLP vaccination. Anti-DENV antibodies will be assayed for specificity to DENV proteins by ELISA, the affinity to DENV protein by surface plasmon resonance (SPR), and the ability to inhibit DENV infection (neutralization). Cellular responses will be assayed against C, prM/M, and E proteins from cells collected in the spleen and LNs. The elicited immune responses will be assayed for the ability to recognize viral proteins representing each of the four serotypes of DENV. The data generated by these experiments will be deposited in the Center Database where they will be accessible by all members of the Center for Vaccine Research. These *in vivo* experiments should be completed within the first 36 of the start of the contract.

1 (b) Purification of VLPs from baculovirus vectors. The Contractor shall construct vaccines that elicit immune responses against DENV isolates representing each serotype. The second vaccine strategy uses bacmids expressing the C, prM, and E from wild type or consensus gene segments for packaging in baculovirus. Each baculovirus vector will be used to infect Sf9 insect cells and the expressed DENV genes will secrete VLPs into the supernatant, which will be purified by ultracentrifugation as vaccine immunogens. VLPs will contain either a single DENV E protein representing a single DENV serotype or a single VLP will contain all four DENV E proteins representing all four DENV serotypes. Mice will be

vaccinated with purified VLPs intranasally and the same immune analysis will be performed as described in 1(a) and the data will be deposited in the Center Database. These experiments should be completed in Years 3 and 4 of the contract.

**Table 1: SOW Milestones with Due Dates**

<u>Milestone</u>	<u>Baseline Plan Date</u>	<u>Rev Plan Date</u>	<u>Act Comp Date</u>	<u>Remark</u>
Gene Synthesis	16-Jan-08		16-Jan-08	Aim 1
Plasmid Construction	16-Jan-08	31-May-08	31-May-08	Aim 1
VLP Purifications	16-Jul-08	30-Sep-08	30-Sep-08	Aim 1
VLP Characterization	16-Jul-08	30-Sep-08	21-Nov-08	Aim 1
Vaccinations	16-Jan-09	15-Mar-09	15-Mar-09	Aim 1
Bacmid Construction	16-Jul-09		10-Apr-09	Aim 2
Baculovirus Infection	16-Jul-09	15-May-09	20-May-09	Aim 2
Vaccinations	16-Oct-09		16-Oct-09	Aim 1
Determine Ab reactivity & maturity	16-Jan-10		16-Jan-10	Aim 1
VLP Purification	16-Jan-10		16-Jan-10	Aim 2
VLP Characterization	16-Jan-10		16-Jan-10	Aim 2
Determine the breadth of NAbs	16-Apr-10		16-Apr-10	Aim 1
Vaccinations	16-Apr-10		16-Apr-10	Aim 2
Determine the breadth of T cell response	16-Jul-10		16-Jul-10	Aim 1
Vaccinations	16-Jan-11		16-Jan-11	Aim 2
Determine Ab reactivity & maturity	16-Apr-11		16-Apr-11	Aim 2
Determine the breadth of NAbs	16-Apr-11		16-Apr-11	Aim 2
Determine the breadth of T cell response	16-Jul-11		16-Apr-11	Aim 2

### Summary of Work Completed During the 4-Year Contract

The following individuals worked on experiments, as outlined in the Statement of Work, during the 4 year period of performance: Dr. Ted M. Ross, Dr. Nikolaos Vasilakis, Dr. Shannan Rossi, Dr. Jared Evans, Dr. Xian-Chun Tang, Mr. Matthew Dunn, Ms. Nicole Eleatty, and Mrs. Hai-Rong Lu. There were several areas of progress in the development of a Dengue virus-like particle vaccine including the design of consensus E sequences for each serotype of Dengue, the generation of virus-like particle vaccines, and determination of broadly reactive immunity associated with these vaccines. These consensus sequences were designed using over 200 sylvatic and contemporary Dengue E amino acid sequences and the most common amino acid was engineered at each location. These sequences were combined into one opening reading frame to generate a C, prM, E gene cassette to express the virus-like particle. These synthetic genes were generated by GeneArt and cloned into our expression plasmid. Gene cassettes were generated for all 4 subtypes of dengue virus. Expression of these genes was verified by

direct transfection of 293T cells. Cell lysates and supernatants were harvested and SDS-PAGE performed followed by immunoblotting.

In addition to mammalian gene expression systems, each gene cassette was cloned into a bacmid expression vector from Invitrogen and protein expression was verified. The baculovirus system for protein and dengue particle expression was established by Dr. Xianchun Tang. Dr. Tang effectively grew Sf9 insect cells in spinner flasks and amplified baculovirus in these cell cultures. He generated bacmids for efficient production of dengue virus-like particles from infected insect cells. However, the efficiency of particle purification and inactivating the baculovirus by beta-propiolactone inactivation methods proved quite difficult. Dr. Tang moved to working with a more efficient system, influenza virus, and he productively produced various types of VLPs for influenza. These accomplishments led to 2 first author publications (see appendix). However, after 18 months of experimentation and discussion with colleagues, flavivirus VLPs for dengue virus were not expressed or efficiently purified and the approach was abandoned in favor of an alternative method using yeast, described below.

Initially, the team started with the DENV-2 isolate as a prototype for the additional vaccines. The plasmids were constructed and the protein expressed as detected by western blot. However, the efficiency of secretion was poor. Therefore, the construct was modified to express the VLP gene segments in two ways: 1) the addition of NS3B/NS4 to efficiently cleavage the capsid and 2) the construction of the prM/E construct with the C proteins provided in *trans*. It was determined that the VLPs could not express without viral proteases, which were not part of the original vaccines. The team decided to work out the conditions of VLP expression using a related flavivirus, West Nile virus. Particles could be released as subviral particles (SVPs) from mammalian cells using the prM-E cassette only. SVPs were generated for West Nile virus and all 4 dengue virus subtypes. In order to retain the capsid in our VLPs, we invited Dr. Jared Evans and his lab to join the team to express out C-prM-E gene cassettes in a yeast-based expression system, *Pichia pastoris*, that allows for efficient proteolytic cleavage of the capsid protein from the prM-E gene product. Once again, the system was first used with West Nile virus to work out conditions, and then it was moved to dengue virus. All four subtypes of dengue virus were produced as SVPs from mammalian cells and VLPs from yeast.

All four dengue virus prototype strains were produced in Vero cells and plaque titered, as well as immunohistochemically stained for expression. All viruses efficiently expressed and virus



could be detected for 16 days post-infection. These viruses will be necessary to determine vaccine efficacy in neutralization assays.

For immunogenicity studies, female BALB/c mice (n=10/group; age 6-8 weeks) were purchased from Harlan Sprague Dawley, (Indianapolis, IN, USA), immunized with each DNA vaccine plasmid by gene gun (particle bombardment with 2 µg DNA coated on gold bullets) or with purified SVPs and then boosted with the same dose on weeks 3 and 6. In addition, a tetravalent combination of all 4 dengue vaccines was also used for vaccination. Blood was collected from anesthetized mice via the retro-orbital route on weeks 5 and 8 post vaccination and then centrifuged at 6000 rpm for 10 min to separate the serum. Sera were transferred to new vials and frozen at -20°C.

A quantitative ELISA was performed to assess anti-DIII specific IgG in serum of vaccinated mice. Individual wells of a 96 microtiter plate were coated overnight at 4°C with dengue DIII proteins produced from transfected 293T cells and then blocked (25°C for 2 hr) with PBS supplemented with Tween-20 (0.05%) and nonfat dry milk (5%). Each serum sample was serially diluted and incubated (25°C for 2 hr). Following serial washes with PBS Tween-20 (0.05%), samples were incubated (25°C for 1 hr) with HRP conjugated goat anti-mouse IgG (1:5000) or one of four IgG subclasses (IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, or IgG<sub>3</sub>) (Southern Biotechnology, Birmingham, AL) diluted in PBS Tween-20 (0.05%) and nonfat dry milk (5%). Unbound antibody was removed and after additional washes samples were incubated with TMB substrate, and the colorimetric change was measured as the optical density at 405 nm using a plate reader (Biotek Powerwave XS, Winooski, VT USA). The O.D. value of the age-matched naïve sera was subtracted from the OD values of the antisera from the vaccinated mice. Results were recorded as the geometric mean titer (GMT) ± the standard error of the mean (SEM).

Vaccinations with the dengue SVP vaccines produced high titer anti-E DENV antibodies specific to each subtype and across subtypes. Purified VLPs elicited high titer antibody to the individual Denv-1 and Denv-3 E proteins. Mice vaccinated Denv-2 and Denv-4 were more likely to have high titers to themselves, but there were across reactive IgG titers against all 4 dengue viruses.

Neutralization titers showed similar results. The yeast-based VLPs were not tested in immunogenicity studies due to lack of funds. The tetravalent vaccine has been produced and

the VLPs were used to vaccinate mice showed broadly reactive IgG titers and neutralization titers against all 4 subtypes of dengue.

We also compared our SVP vaccines against two alternative strategies produced in the Ross Laboratory, DIII and Ecto E (E80) based dengue vaccines. The SVP strategy appears more efficient in producing serum IgG and neutralizing antibodies to dengue virus than DIII or Ecto E versions. No T cell responses were ever detected using any of the dengue vaccines produced in the Ross or Evans laboratories.

Table 2: Neutralizing Titers elicited by Dengue Vaccines in Mice

Sample	Notation	Neutralizing Titers against Serotype (PRNT50)			
		<u>DENV-1</u>	<u>DENV-2</u>	<u>DENV-3</u>	<u>DENV-4</u>
<b>SVP-DNA</b>					
DENV-1	A	X	>1:160	<1:10	X
DENV-2	B	X	>1:320	<1:10	X
DENV-3	C	X	1:40	1:320	X
DENV-4	D	X	<1:10	<1:10	X
Tetravalent	E	X	>1:160	1:20	X
Mock	F	X	<1:10	<1:10	X
<b>Purified SVP</b>					
DENV-1	G	X	1:80	<1:10	X
DENV-2	H	X	>1:320	<1:10	X
DENV-3	I	X	1:20	>1:160	X
DENV-4	J	X	<1:10	<1:10	X
Tetravalent	K	>1:320	>1:320	>1:160	1:40
<b>Ecto E-C3d</b>					
DENV-1	L	1:20	1:20	1:10	1:20
DENV-2	M	1:20	X	1:10	1:40
DENV-3	N	<1:10	<1:10	1:10	<1:10
DENV-4	O	1:20	X	1:10	1:160
Tetravalent	P	1:40	X	1:10	1:10
<b>DIII-C3d</b>					
Tetravalent DII+SVP					
boost	R	<1:10	X	<1:10	<1:20
Tetravalent	S	<1:10	X	<1:10	1:10
Tetravalent DII+SVP					
boost	T	1:10	X	<1:10	<1:10

X = not completed

## Key Research Accomplishments

- Establishment of Dengue virus program in the Ross and Evans laboratories in Center for Vaccine at the University of Pittsburgh.
- Generation of subvirion particle using consensus E proteins.
- Establishment of a yeast-based expression system at the University of Pittsburgh.
- Establishment of a baculovirus expression system in the Ross Laboratory at the University of Pittsburgh.
- Elicitation of high titer anti-dengue antibodies, with neutralization activity, across subtypes of dengue with a single consensus E gene product.

## Reportable Outcomes/Project Bibliography

**No manuscripts were submitted that are related to the Statement of Work.**

**Published manuscripts related to establishing expression systems funded by this work include:**

- *Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM. Enhancement of Anti-DIII Antibodies by the C3d Derivative P28 Results in Lower Viral Titers and Augments Protection in Mice. 2010. Virology J. 7:95-106.*
- *Tang X-C, Lu H-R, Ross TM. Hemagglutinin Displayed Baculovirus Protects Against Highly Pathogenic Influenza. 2010. Vaccine. 28:6821-6831.*
- *Tang X-C, Lu H-R, Ross TM. Baculovirus-produced Influenza Virus-like Particles in Mammalian Cells Protect Mice from Lethal Influenza Challenge. 2011. Viral Immunol. 24:1-9.*

**Two book chapters were derived based upon the Dengue and West Nile virus projects inspired including:**

- *Ross TM. Dengue Virus. 2010. Clin Lab Med. 30(1):149-160.*
- *Rossi SL, Ross TM, Evans JD. West Nile Virus. 2010. Clin Lab Med. 30(1):47-65.*

**One manuscript is in preparation that is related to the Statement of Work:**

- *Ross TM, Tang X-C, Lu H-R, Strong LS, Evans JD. Elicitation of broadly reactive anti-dengue neutralizing antibodies by virus-like particle based consensus E vaccine. 2011. In preparation.*

## **Invention Disclosures**

- *Title: Universal Dengue Vaccine; Internal Reference Number 02226; Status: Marketing-Active*

**Funding Applied for:** None

## **Personnel Receiving Pay from the Research Effort**

- UPMC Personnel: Charles R. Rinaldo, PhD, Principal Investigator  
No other UPMC personnel received direct pay from this award.
- A subcontract with the University of Pittsburgh covered all other personnel directly involved with the execution of this contract.

## **Employment Opportunities Received for University of Pittsburgh Personnel:**

- Dr. Nikoloas Vasilakis: Assistant Professor, University of Texas Medical Branch-Galveston.
- Dr. Shannan Rossi: Post-Doctoral Fellow, University of Texas Medical Branch-Galveston.
- Dr. Xian-Chun Tang: Post-Doctoral Fellow, Harvard University Medical Center-Boston.

## **Conclusions**

While all vaccines were effective at eliciting high titer IgG to homologous virus, virus-like particles for dengue virus are more efficient to elicit neutralizing antibodies. A tetravalent VLP vaccine was efficient at eliciting antibodies against all 4 subtypes of dengue virus.

## **References**

None

# Appendices

# ***APPENDIX 1***

*Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice*

*2010. Virology J. 7:95-106*

*Dunn, MD, Rossi, SL, Carter, DM, Vogt, MR,  
Mehlhop, E, Diamond, MS, Ross, TM*



RESEARCH

Open Access

# Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice

Matthew D Dunn<sup>1</sup>, Shannan L Rossi<sup>1,2</sup>, Donald M Carter<sup>1</sup>, Matthew R Vogt<sup>3</sup>, Erin Mehlhop<sup>3</sup>, Michael S Diamond<sup>3</sup> and Ted M Ross<sup>\*1,2</sup>

## Abstract

Antibodies generated against West Nile virus (WNV) during infection are essential for controlling dissemination. Recent studies have demonstrated that epitopes in all three domains of the flavivirus envelope protein (E) are targets for neutralizing antibodies, with determinants in domain III (DIII) eliciting antibodies with strong inhibitory properties. In order to increase the magnitude and quality of the antibody response against the WNV E protein, DNA vaccines with derivatives of the WNV E gene (full length E, truncated E, or DIII region, some in the context of the pre-membrane [prM] gene) were conjugated to the molecular adjuvant P28. The P28 region of the complement protein C3d is the minimum CR2-binding domain necessary for the adjuvant activity of C3d. Delivery of DNA-based vaccines by gene gun and intramuscular routes stimulated production of IgG antibodies against the WNV DIII region of the E protein. With the exception of the vaccine expressing prM/E given intramuscularly, only mice that received DNA vaccines by gene gun produced protective neutralizing antibody titers (FRNT80 titer >1/40). Correspondingly, mice vaccinated by the gene gun route were protected to a greater level from lethal WNV challenge. In general, mice vaccinated with P28-adjuvanted vaccines produced higher IgG titers than mice vaccinated with non-adjuvanted vaccines.

## Introduction

West Nile virus (WNV) is a single-stranded positive polarity enveloped RNA virus and member of the Flavivirus genus of the *Flaviviridae* family. The genome (11 kb) encodes for three structural proteins (Capsid [C] [1], pre-membrane [prM] that is cleaved to form a mature membrane [M] [2] and Envelope [E] [1]) and seven nonstructural gene products (NS1, 2A, 2B, 3, 4A, 4B and 5). WNV is transmitted by mosquitoes and causes morbidity and mortality in birds, horses, and humans. Since 1999, there have been over 29,000 cases that reached clinical attention and resulted in greater than a thousand deaths <http://www.cdc.gov/ncidod/dvbid/westnile/surv&control.htm> within the United States as reported to the Centers for Disease Control and Prevention. As the geographic distribution of this virus continues to expand, naïve human

populations are put at greater risk, making the need for a licensed vaccine and/or antiviral treatment pressing [3].

The host immune response is critical for limiting virus spread and disease. Results from genetically engineered mice indicate that both the innate (*e.g.*, interferon) and the adaptive (B and T cells) immune responses control WNV infection [4]. The production of antibodies is essential to protection against WNV infection [5], and passive antibody transfer of anti-WNV neutralizing antibodies can prevent or treat lethal infection [6]. The primary target of the neutralizing antibody response is the E protein, which is the most accessible structural glycoprotein on the surface of the virion [7]. Structural analysis of the soluble ectodomain of flavivirus E proteins reveals three domains [8,9]. Domain I is an 8-stranded  $\beta$ -barrel that participates in the conformational changes associated with the acidification of the endosome. Domain II, which contains 12  $\beta$ -strands, has important roles in dimerization, trimerization, and virus-mediated fusion [10-12]. Domain III adopts an immunoglobulin-like fold that contains the most distal projecting loops on the

\* Correspondence: [tmr15@pitt.edu](mailto:tmr15@pitt.edu)

<sup>1</sup> Center for Vaccine Research, University of Pittsburgh, 9047 Biomedical Science Tower 3, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA  
Full list of author information is available at the end of the article



mature virion [13,14], and has been hypothesized to contain a binding site for cell attachment [15]. Even though neutralizing antibodies are generated against epitopes in all three domains, many highly neutralizing antibodies cluster to epitopes in DIII [16].

Our laboratory and others have demonstrated that the fusion of C3d to an antigen results in enhanced immunogenicity of the fused antigen [5,16,17,19,21,24,31,32,35,36]. C3d is the final degradation product of the third component of complement (C3). The most commonly proposed mechanisms for C3d adjuvanticity involves C3d binding to the complement receptor 2 (CR2) that is located on the surface of follicular dendritic cells (FDC), B cells, and T cells in many species (for review, see [17]). C3d stimulates antigen presentation by FDCs and helps to maintain immunological B cell memory. On B cells, C3d interacts with CR2, CD19 and CD81 surface molecules. CD19 has a long intracellular tail that triggers a signaling cascade that results in cell activation and proliferation. Simultaneous ligation of CR2 by C3d and surface immunoglobulin by antigen activates two signaling pathways that synergize to activate B cells, thereby leading to enhanced antibody secretion against the fused antigen. Multimers of a 28 amino acid peptide of C3d (P28), which contains the predicted minimum CR2 binding domain, have been demonstrated to have similar adjuvant properties as the entire C3d molecule [18]. The P28 molecule is ~9% the size of the entire C3d molecule and therefore, is an attractive adjuvant to elicit enhanced B cell responses to a vaccine antigen.

Currently, there are no effective anti-WNV treatments and there are no Food and Drug Administration (FDA)-licensed vaccines for humans. The FDA has approved a WNV vaccine for horses and other exotic animals, based upon a formalin-inactivated killed virus (WNV Innovator™, Fort Dodge Animal Health), but these require annual boosting. Several experimental vaccines for humans based upon live-attenuated virus, purified protein, viral vectors, or DNA plasmids are under development (see reviews [19-21]) although none has advanced beyond phase II. In theory, WNV E DIII protein is an attractive target for vaccine development because many strongly protective MAbs (in vitro and in vivo) against flaviviruses, including WNV have been localized to this region DIII (reviewed in [22]). Moreover, previous studies have demonstrated the recombinant WNV DIII is a plausible vaccine candidate when administered as a recombinant protein [23], but less effective when expressed from a DNA plasmid [24]. In this study, we developed candidate WNV DNA vaccines with greater immunogenicity and protection using DIII or truncated E proteins conjugated to the molecular adjuvant P28.

## Materials and methods

### Virus and cell lines


WNV (TX114 strain), isolated from a blue jay in Texas in 2002 was used for all studies except for the passive antibody transfer experiment. The virus was propagated once in Vero cells, aliquotted, and then frozen at -80°C. For the passive antibody transfer experiments, the lineage 1 New York WNV strain 3000.0259 that was isolated in 2000 was passaged once in C6/36 *Aedes albopictus* cells to generate an experimental stock. 293T (human embryonic kidney) and Vero (African green monkey kidney) cells were maintained in DMEM with 10% FBS and 1% penicillin/streptomycin (P/S). Raji cells stably expressing DC-SIGNR were maintained as described [25].

### Construction and expression of DNA vaccine plasmids

The WNV prM/E eukaryotic expression vector, pCBWN, has been previously described [26] and encodes the prM and E gene segments (accession number [DQ211652](#)) from the strain NY99-6480 strain [26]. To generate an Ecto E DNA vaccine, the glycine residue at position 706 was converted by mutagenesis to a TAG stop codon (Fig. 1A) [27]. The DIII of E (amino acids 296-415) was cloned in frame with the tPA leader sequence in pTR600 (Fig. 1A). A second set of plasmids were constructed to express Ecto E or DIII fused in frame with P28 [18,27]. Each gene sequence encoding for two functional copies of P28 was cloned at the 3' end of Ecto E or DIII using unique restriction endonuclease sites. A BamHI restriction endonuclease site was introduced using site directed mutagenesis immediately 5' to the TAG stop site. A (Gly<sub>4</sub>-Ser)<sub>2</sub> linker was cloned in between each P28 gene. All DNA vaccine plasmids were amplified in *Escherichia coli*, purified using anion-exchange resin columns (Qiagen, Valencia, CA) and stored at 20°C in dH<sub>2</sub>O. Plasmids were verified by appropriate restriction enzyme digestion and sequencing.

293T cells were transfected with 30 µg of DNA using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). Cell culture supernatants were collected 48 hrs post-transfection. Approximately 1.5% of sample volume was loaded onto a 10% polyacrylamide/SDS gel. The resolved proteins were transferred onto a Immobilon PVDF membrane (Millipore, Temecula, CA) and incubated with a 1:5000 dilution of the WNV specific monoclonal antibody (mAb 8150, Chemicon, Temecula, CA) in PBS containing 0.05% Tween-20 and 5% nonfat dry milk. After extensive washing, bound antibodies were detected using a 1:10,000 dilution of horseradish peroxidase-conjugated goat anti-mouse antiserum, and visualized by chemiluminescence (Western Lightning™, Perkin Elmer, Waltham, MA).





### Virus titrations and immunohistochemistry

All virus titrations were performed on Vero cell monolayers. Briefly, cells were incubated with indicated serial dilutions of virus or mouse serum for 1 hour at 37°C. Subsequently, the virus/serum inocula were removed and replaced with a semi-solid overlay of carboxy-methylcellulose in OptiMEM or 1% low melting point agarose (Sea-Plaque) in  $\alpha$ -MEM (Invitrogen) supplemented with 3 or 4% FBS. Cultures were incubated for 24-72 hours prior to fixation with a 50:50 v/v mixture of methanol and acetone or 10% formaldehyde. For plaque assays, staining was performed with 1% (w/v) crystal violet in 20% ethanol and scored visually on a light box. For focus formation assays, foci were visualized by immunohistochemistry.

Immunohistochemistry was performed on fixed and dried cell monolayers by first rehydrating with 3% FBS in PBS (blocking buffer) for 1 hour, then replacing the media with a monoclonal antibody specific to WNV E protein (7H2; BioReliance Corporation, Rockville, MD) diluted in blocking buffer and incubated for at least 1 h. The primary antibody solution was removed and monolayers were washed thrice in PBS prior to adding the goat anti-mouse secondary antibody conjugated to peroxidase diluted in blocking buffer. After 1 h, monolayers were washed thrice in PBS again. WNV-infected cells were visualized by adding the peroxidase substrate (Enzo Diagnostics, Farmingdale, NY).

### Vaccination and Viral Challenge

Female C57BL/6 mice ( $n = 5-8$  mice per group; aged 6-8 weeks) were purchased from Harlan Sprague Dawley, (Indianapolis, IN, USA), immunized with each DNA vaccine plasmid intramuscularly (IM, 50  $\mu$ g DNA injection into thigh) or by gene gun (particle bombardment with 2  $\mu$ g DNA coated on gold bullets) and then boosted with the same dose on weeks 3 and 6. In some cases 0.2  $\mu$ g or 0.02  $\mu$ g of vaccine plasmid as a dose response was administered in a mixture of vector plasmid to keep a total of 2  $\mu$ g total DNA vaccine. Blood was collected from anesthetized mice via the retro-orbital route on weeks 5 and 8 post vaccination, then centrifuged at 6000 rpm for 10 min to separate the serum. Sera were transferred to new vials and frozen at -20°C.

For challenge, naïve or vaccinated mice administered 1000 focus forming units (FFU) of WNV (TX114 strain) in a volume of 0.1 ml by the intraperitoneal route. WNV was diluted in a filtered solution of 10% fetal bovine serum (FBS) in phosphate buffered saline (PBS) prior to the mice infections (diluent). Mice were weighed daily to determine percent weight loss, and monitored to determine the severity of sickness. Moribund mice (severe lethargy, hunched posture and ruffled fur) were euthanized by CO<sub>2</sub> asphyxiation and recorded as dead for the next day. All mouse experiments were performed in

accordance and with approval of the Washington University or University of Pittsburgh Animal Studies guidelines under BSL-3 conditions.

### Passive transfer of antiserum to naïve mice

Five week old C57BL/6 mice (Jackson Laboratories) were infected by subcutaneous route with 10<sup>2</sup> PFU of WNV 3000.0259 diluted in Hank's Balanced Salt Solution containing 1% heat-inactivated FBS. For antibody protection studies, one day prior to infection mice were treated by IP injection with indicated amounts of immune (gene gun vaccinated mice) or naïve serum diluted in 100  $\mu$ l PBS. Mice were monitored daily for 21 days for morbidity and mortality.

### Enzyme-Linked Immunoabsorbant Assay (ELISA)

A quantitative ELISA was performed to assess anti-DIII specific IgG in serum of vaccinated mice. Individual wells of a 96 microtiter plate were coated overnight at 4°C with WNV DIII proteins produced from transfected 293T cells and then blocked (25°C for 2 hr) with PBS supplemented with Tween-20 (0.05%) and nonfat dry milk (5%). Each serum sample was serially diluted and incubated (25°C for 2 hr). Following serial washes with PBS Tween-20 (0.05%), samples were incubated (25°C for 1 hr) with HRP conjugated goat anti-mouse IgG (1:5000) or one of four IgG subclasses (IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, or IgG<sub>3</sub>) (Southern Biotechnology, Birmingham, AL) diluted in PBS Tween-20 (0.05%) and nonfat dry milk (5%). Unbound antibody was removed and after additional washes samples were incubated with TMB substrate, and the colorimetric change was measured as the optical density at 405 nm using a plate reader (Biotek Powerwave XS, Winooski, VT USA). The O.D. value of the age-matched naïve sera was subtracted from the OD values of the antisera from the vaccinated mice. Results were recorded as the geometric mean titer (GMT)  $\pm$  the standard error of the mean (SEM).

### Focus Neutralization Reduction Assay (FRNT)

Sera from individual mice were heat inactivated at 56°C for 30 min. In some cases, sera from moribund or surviving mice following WNV infection were pooled. Pooled sera were diluted 1:10 in DMEM supplemented with 1% FBS, P/S and HEPES, and serially diluted 2-fold thereafter. Pooled naïve sera from uninfected, unvaccinated C57BL/6 mice were used as a negative control. The 7H2 antibody, which neutralizes WNV in tissue culture [16], was diluted in naïve mouse sera and used as a positive control. Each dilution was incubated in an equal volume of media containing WNV for 1 h at 37°C. The virus-antibody solutions were then placed in duplicate wells in a 24-well plate containing a confluent Vero monolayer and incubated at 37°C for 1 h. Monolayers were rinsed free of

unbound virus-antibody solution, rinsed an additional time with PBS, and then covered with the CMC overlay. After 48 hours, monolayers were fixed with a 50:50 v/v methanol and acetone solution. WNV foci were detected by immunohistochemistry as described above. Titer was determined as the dilution in which there was 50% (FNRT<sub>50</sub>) or 80% (FNRT<sub>80</sub>) or greater reduction in the number of WNV foci by immunohistochemical staining.


## Results

### Construction of WNV Vaccine Plasmids

DNA plasmids were constructed that contained either the complete E gene (in context with the precursor viral gene prM "prM/E") or portions of the E gene (ectodomain (Ecto) or domain III (DIII)) (Fig 1A). A second set of plasmids was generated with these same gene sequences conjugated to two copies of the molecular adjuvant P28 to enhance antibody responses to the conjugated antigen (Fig. 1A). All of these gene cassettes were cloned directly downstream of a cytomegalovirus promoter to drive efficient transcription. Each plasmid efficiently expressed the E gene insert in transiently transfected 293T cells as determined by Western blot of clarified cell supernatant with a WNV-specific anti-E MAbs (Fig 1B). DNA plasmids expressing DIII only produced a protein ~10-20 kD in size. The addition of P28 resulted in an expressed protein of ~30 kD (Fig 1B; lanes 1 and 2). Ecto E (~65 kD) and Ecto E-P28 (~70 kD) were efficiently secreted into the supernatants of transiently transfected cells (Fig 1B; lanes 3 and 4). In addition, a 65 kD protein representing E was detected in supernatants from cells transiently transfected with DNA expressing the prM/E gene cassette, which produces subviral particles (SVPs) (Fig 1B; lane 5). As expected, mock-transfected or vector-only transfected cell supernatants showed no reactivity with WNV anti-E MAbs.

### The molecular adjuvant P28 enhances the anti-WNV antibody response

Mice were vaccinated with the panel of DNA vaccines via one of two routes: gene gun (GG) or intramuscular (IM) at weeks 0, 3, and 6. On week 8, serum samples were collected and the anti-WNV DIII antibody levels were tested by ELISA from individual clarified sera samples (Fig. 2). C57BL/6 mice immunized with all of the DNA plasmids via the gene gun route developed high titers of anti-WNV DIII antibodies. In contrast, mice vaccinated by an intramuscular route with DIII-DNA had significantly lower total IgG titers that were significantly enhanced by conjugation of P28 (Fig. 2A). The enhancement effect was observed following gene gun administration of plasmids only at lower doses of vaccine (Fig 2B). Mice vaccinated IM with Ecto E, Ecto E-P28 or prM/E developed similar titers (Fig 2A).



To characterize further the immune response elicited by these vaccines, the IgG subtypes of the elicited anti-DIII antibodies were determined (Table 1). Gene gun DNA vaccination elicited primarily a T-helper (Th)-2 (characterized by IgG1 isotype), whereas DNA plasmids administered intramuscularly elicited more of a Th-1 response (characterized by IgG2 isotype). C57BL/6 mice immunized by gene gun with DIII- or DIII-P28-DNA elicited predominately IgG<sub>1</sub> and IgG<sub>2b</sub>. Similar antibody isotypes were elicited with Ecto E and Ecto E-P28 expressing plasmids. Interestingly, the prM/E plasmid elicited a broader IgG isotype profile via both ID and IM

**Table 1: Anti-DIII Antibody Isotypes**

C57BL/6				
Gene Gun	IgG1	IgG2a*	IgG2b	IgG2c
DIII	0.44	N.A.	0.18	0.00
DIII-P28	0.43	N.A.	0.24	0.00
Ecto E	0.41	N.A.	0.19	0.00
Ecto E-P28	0.38	N.A.	0.12	0.01
prM/E	0.44	N.A.	0.36	0.18
C57BL/6				
Intramuscular	IgG1	IgG2a	IgG2b	IgG2c
DIII	0.13	N.A.**	0.01	0.04
DIII-P28	0.41	N.A.	0.14	0.02
Ecto E	0.23	N.A.	0.08	0.00
Ecto E-P28	0.23	N.A.	0.04	0.01
prM/E	0.25	N.A.	0.20	0.11

\*IgG2a isotype not expressed in C57BL/6 mice.


\*\*N.A. = Not applicable since the IgG2a subtype is not expressed in C57BL/6 mice.


routes and included anti-DIII antibodies of the IgG<sub>2c</sub> subclass.

**Protection of mice against lethal WNV challenge**

At week 10 (4 weeks from the final vaccination), C57BL/6 mice were challenged with a lethal dose (10<sup>3</sup> FFU) of WNV. All unvaccinated and 80% of vector-only vac-

nated mice (IM) infected with WNV died by day 11 post-challenge (Fig. 3). The vector-only vaccinated mouse that survived challenge nonetheless showed signs of morbidity (hunchback posture and fur ruffling) and lost ~15% of body weight, but recovered by 1 month post infection (Fig. 4). All mice vaccinated with the prM/E plasmid construct survived lethal challenge (Fig. 3) and did not lose





weight, regardless of the vaccination route. In general, mice vaccinated by gene gun had higher rates of survival and less weight loss compared to mice vaccinated intramuscularly. Eighty percent of mice vaccinated ID with DIII-DNA survived challenge with little weight loss (Fig. 3A and 4) whereas, no mice vaccinated IM with DIII-DNA survived challenge (Fig. 3B,  $p < 0.004$ ). All of these mice lost weight prior to succumbing to infection (Fig. 4C). Conjugation of P28 to DIII enhanced the survival rate to 60% when the DNA was administered IM (Fig. 3B,  $p < 0.046$ ). Interestingly, the disparity in survival between ID and IM vaccination routes was also apparent in mice vaccinated with Ecto E DNA (Fig. 3). Eighty percent of mice vaccinated ID or IM with Ecto E-DNA survived challenge, and conjugation of P28 to Ecto E increased the survival rate (100%) of ID-vaccinated animals, but slightly decreased rate in IM-vaccinated mice (60%, Fig 3). Although these survival results were not statistically dif-

ferent between these groups, survival did correlated with weight loss, as mice that lost more weight had the highest morbidity and mortality (Fig. 4).


To determine if protection against WNV challenge prospectively correlated with a reduction in viremia, the sera at day 2 post-infection in each vaccine group was analyzed for infectious virus by a focus forming assay. Vaccinated C57BL/6 mice that survived infection (Fig. 5) had viremia that was at or below the limit of detection at day 2 post-challenge. With the exception of one mouse vaccinated with the Ecto E vaccine, all mice that died had a viremia at day 3 of greater than  $4 \times 10^2$  FFU/ml (Fig 5).

#### Neutralization titers

Sera from mice immunized with the DNA vaccines were assayed for the ability to neutralize WNV infection in cell culture (Table 2). Serum samples collected at week 8 and again at 1 month post challenge (week 14 of study) were divided into two groups: (1) mice that survived subsequent lethal challenge and (2) mice that did not survive challenge (obtained from terminally moribund mice immediately prior to euthanasia). Mice vaccinated with any of the DNA vaccines by gene gun that survived challenge had high neutralizing titers at eight weeks (1/80-1/320; FRNT<sub>80</sub>), whereas those that died from challenge had lower titers  $<1/20$  (Table 2). In contrast to gene gun vaccination, only mice vaccinated with prM-E DNA intramuscularly had high neutralizing titers, which again correlated with survival. Mice vaccinated via gene gun with DNA plasmids expressing DIII, Ecto E, or these immunogens conjugated to P28 had titers  $<1/20$  (FRNT<sub>80</sub>) did not survive infection. Similar results were observed using a FRNT<sub>50</sub>, albeit the titers were higher than FRNT<sub>80</sub>. Regardless of the route of vaccination, mice that survived challenge exhibited an immunological boost by 14 weeks since neutralizing titers rose following infection (FRNT<sub>80</sub>; 1/320-1/1280).

#### Passive sera transfer protects mice from virus infection

Although several mice immunized with DIII plasmids survived infection, it remained unclear mechanistically whether this was due to antibodies or possibly, memory CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses To determine if anti-DIII antibodies alone could afford protection against WNV infection, pooled antiserum from each gene gun vaccinated group was transferred intraperitoneally into naive 5 week-old C57BL/6 mice, which were then challenged with  $10^2$  PFU of WNV (Fig. 6). Fifty to seventy percent of mice administered sera from mice vaccinated with DIII, Ecto E or Ecto E-P28 survived challenge 21 days post-infection. Sera from mice vaccinated with DIII-P28 or prM-E showed greater (80-90%) survival compared to DIII alone, although this did not attain statistical significance. As expected, nearly all mice (10% survival)



administered naïve sera succumbed to virulent WNV infection.

### Discussion

Although it has been a decade since the emergence of WNV in North America, there remains no effective, licensed vaccine to combat WNV induced disease in humans. Although candidate vaccines have not advanced beyond phase I and II clinical trials for humans [19,28], there are currently approved inactivated and DNA vaccines licensed for use in horses and geese. Since neutralizing antibodies may serve as a primary protective function against challenge [5], recent vaccine strategies have focused on using the ectodomain of E or different domains within E to elicit neutralizing anti-WNV antibodies [23,24,26,29-33]. Recent attention has been focused on DIII as a potential immunogen because struc-

tural and functional studies suggest that many protective antibodies against WNV recognize this highly conserved epitopes within this region. Some DIII-specific neutralizing antibodies are particularly potent in blocking viral fusion and escape from the endosome [34,35].

In this study, a series of DNA-based vaccines expressing the full length E, Ecto E or the DIII domain of E were fused to the molecular adjuvant P28 to enhance antibody titers. The addition of P28 to DIII or Ecto E increased the anti-DIII IgG antibody titer in C57BL/6 mice. However, a high anti-DIII antibody titer was not sufficient to completely protect against WNV infection. Mice vaccinated with nearly all gene gun delivered vaccines elicited similar high-titer anti-DIII antibodies, however, only the prM/E and Ecto E-P28 vaccinated mice were completely protected from lethal challenge.

**Table 2: FRNT and Mouse Survival**


Sample	Group	Survival [# pooled/# in vaccinated group]	FRNT50*	FRNT80	FRNT50	FRNT80
GG			Pre-infection		Post-infection	
1	DIII	Yes [4/5]	640	80	2560	320
2	DIII	No [1/5]	<20	<20		
3	DIII-P28	Yes [3/5]	320	80	1280	320
4	DIII-P28	No [2/5]	40	20		
5	ectoE	Yes [4/5]	320	320	2560	640
6	ectoE	No [1/5]	40	<20		
7	ectoE-28	Yes [5/5]	640	320	2560	640
8	prM/E	Yes [5/5]	320	160	1280	640
9	naive	No [5/5]	20	<20		
IM			Pre-infection		Post-infection	
10	DIII	No [5/5]	<20	<20		
11	DIII-p28	Yes [3/5]	20	<20	1280	640
12	DIII-p28	No [2/5]	20	<20		
13	ectoE	Yes [4/5]	40	20	2560	1280
14	ectoE	No [1/5]	20	<20		
15	ectoE-p28	Yes [3/5]	40	20	2560	640
16	ectoE-p28	No [2/5]	<20	<20		
17	prM/E	Yes [5/5]	320	160	2560	640
18	vector	Yes [1/5]	40	<20	640	80
19	vector	No [4/5]	<20	<20		

\* Titers shown as the reciprocal titer

Several studies have previously demonstrated the immunogenicity of the E protein DIII domain [23,29,36-40]. However, immunization of purified recombinant DIII has not consistently elicited high-titer neutralizing antibodies, thereby indicating that the neutralizing epitope may be poorly immunogenic in the context of a soluble protein, or that a dominant non-neutralizing epitope is present on the soluble DIII but is not exposed in the context of the virion. Expression of DIII from a DNA vaccine plasmid also has been less than optimal in eliciting neutralizing antibodies. The results from our study suggest that DIII may be less efficiently secreted from transfected cells (data not shown), which may in part explain the lowered immune responses seen during vaccination with DIII alone. Conjugation of P28 may assist DIII protein secretion from transfected cells, helping to explain why the P28-conjugated vaccines elicited higher DIII-specific antibody titers (by ELISA) and higher protection against lethal challenge than non-con-

jugated vaccines in some cases. Although the use of molecular adjuvants, such as P28, did not skew the antibody repertoire, they did increase the efficacy of the response of DIII-based DNA vaccines. An analogous increase in overall titer was observed when JEV or WNV DIII was linked to IL-15 [24].

Prospective studies have shown a direct correlation between the level of neutralizing antibody prior to challenge, the magnitude of viremia, and survival rates in mice [5]. Nonetheless, some mice vaccinated IM with DIII-P28, Ecto E, and Ecto E-P28 were protected from challenge despite the absence of high-titer pre-challenge neutralizing antibodies ( $FRNT_{80} \leq 20$ ). Although further mechanistic studies are required, we suggest three possible explanations: (a) non-neutralizing antibodies are protective through complement and/or Fc $\gamma$ R-dependent functions. Indeed, we have previously seen this phenotype with mAbs against WNV NS1, which is absent from the virion [41]; (b) the *in vitro* neutralization assay does



not accurately reflect possible neutralization of virus *in vivo*. Antibodies that block virus attachment of one cell type (e.g., Vero cells) may not function effectively against a second more physiologically relevant cell type (e.g., dendritic cells). Of note, differences in neutralization potency among cell types were observed with mAbs against epitopes in DI and DII of WNV E protein [42]; and/or (c) T cell responses to peptide epitopes in the E protein independently contribute to protection. The isotype of the polyclonal antibody in part determines the effector functions of the anti-WNV antibodies and identifies the T helper cell bias (required for antibody class switching). Antibodies of the IgG2a/c and IgG2b subclass fix complement proteins C1q and C3 and can opsonize and inhibit flavivirus infection [43-45]. IgG2a/c bind Fc $\gamma$ RI with high avidity facilitating enhanced uptake of virus-antibody complexes by macrophages. The predominant IgG isotype detected was IgG1 indicating a Th2 bias. However, IgG2b was detected in almost all vaccine groups, with a strong level of this isotype and IgG2c detected in prM/E vaccinated mice (Table 1), which may help to explain the effectiveness of these vaccines. C57BL/6 mice do not express IgG2a, if this isotype was associated with protection, could have been an explanation for the inconsistent protection with these vaccines.

C3d and P28 have been used as effective molecular adjuvants to elicit high titer antibodies against other pathogens [18,27,46-53]. This study extends this platform to WNV, and likely other flaviviruses due to the similarity in E protein structure and function within the genus. Interestingly, gene gun administration of DNA plasmids elicited higher titer antibody responses and broader protection against WNV infection than through the IM

route. For mice that were vaccinated gene gun, there was a clear correlation between viral neutralization titers and survival. This correlate was less apparent in IM-vaccinated mice, with most mice surviving infection having low neutralization titers. This discrepancy in survival may be explained, at least in part, by the types of cells that internalize the DNA plasmids and express and/or present these antigens. Muscle cells and infiltrating appear to internalize plasmid DNA following IM administration [54]; these cell types may not efficiently secrete these viral proteins. Gene gun differs from intramuscular or intradermal injection of DNA with a needle and syringe in that it results in direct delivery of the vaccine into the intracellular environment [55]. Gene gun delivery of DNA plasmids is complex and can involve both non-professional antigen presenting cells (APC), such as keratinocytes and professional APCs, such as Langerhans cells [56] and [57]. Compared to other routes of delivery, gene gun inoculations can induce both antibody and CD8<sup>+</sup> T cell responses with substantially lower doses of DNA. The effectiveness of this system is likely related to the use of a delivery technology that deposits DNA directly into cells [55] and [57] as well as the immune competence of the epidermis as a delivery site [58] and [59]. Skin cells likely traffic to the draining lymph nodes where the expressed proteins are processed and presented to immune cells [60,61].

Passive transfer studies with serum from vaccinated mice to naive mice established that antibody generated after immunization was sufficient for protection. The percentage of mice surviving challenge after passive transfer appeared similar to the percentage of vaccinated mice that survived after direct challenge. Although further studies with depleting anti-CD4 and CD8 mAbs are required to precisely evaluate the contribution of T cells to protection in these vaccinated mice, it is noteworthy that for C57BL/6 mice, the immunodominant H-2b T cell epitopes for WNV fall outside of DIII [62-64].

In general, immunogens based upon Ecto E elicited better protective responses than those based upon DIII. Likely, WNV E proteins contain multiple neutralizing epitopes in separate domains and therefore, a broader panel of neutralizing antibodies can be generated. The prM/E plasmid produces SVPs, which are effective immunogens since they contain conformationally relevant prM and E protein [14,65,66]. However, Ecto E-P28 elicited comparable immune responses and protection as prM/E when delivered ID, indicating that DNA vaccination can be as effective as the prM/E vaccines currently used for animal vaccines.

The results from the WNV vaccines described in this report indicate that DIII can be an effective immunogen when expressed from a DNA plasmid, when conjugated to a molecular adjuvant like P28 and delivered as a gene



gun based DNA vaccine. The mechanism of delivery could account for the induction of protective responses. Gene gun elicits a T cell helper type 2 (Th2) bias, as indicated by the predominance of elicited IgG<sub>1</sub>, which may be just as an important factor in eliciting neutralizing antibodies as the immunogen epitopes. Nonetheless, our studies have not yet shown that DIII elicits superior neutralizing responses when conjugated to a C3d molecular adjuvant. Although further studies are warranted, we speculate that this is due to the presence of immunodominant non-neutralizing epitopes on the A-B loop that is normally solvent inaccessible [67]. Reverse genetic studies are underway to create DIII variants that lack this immunodominant epitope and thus, focus the immune response on the lateral ridge epitope, which is recognized by highly neutralizing antibodies. By combining this molecular approach with the addition of P28, alone or with other vaccine modalities, we believe it will be possible to create a catalogue of safe immunogens that elicit high-titer neutralizing antibody responses against all flaviviruses.

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

MDD and DMC constructed and characterized the vaccines, MDD and SLR performed animal vaccinations, SLR performed virological analysis, and MDD, SLR, MRV, EM immune analysis. MDD, SLR, MSD, and TMR wrote the manuscript. MSD and TMR conceived the studies and participated in experimental design and coordination. All authors read and approved the manuscript.

#### Acknowledgements

We thank Robert Tesh for providing the TX114 strain of WNV through the World Arbovirus Collection. We would like to thank Jared Evans for helpful comments and discussion. We acknowledge T. Oliphant for performing some of the preliminary experiments for this manuscript. This work was supported by a Department of Defense award W81XWH-07-1-0319 to TMR and NIH grant U01 AID61373 to MSD. SLR is supported on the NIH T32-AID60525 Infectious Diseases and Immunology Training Grant.

#### Author Details

<sup>1</sup>Center for Vaccine Research, University of Pittsburgh, 9047 Biomedical Science Tower 3, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA, <sup>2</sup>Department of Microbiology and Molecular Genetics, University of Pittsburgh, 9047 Biomedical Science Tower 3, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA and <sup>3</sup>Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, 660 South Euclid Ave., Box 8051, St. Louis, MO 63110, USA.

Received: 24 January 2010 Accepted: 12 May 2010  
Published: 12 May 2010

#### References

1. West Nile virus activity—United States, 2007. *MMWR Morb Mortal Wkly Rep* 2008, **57**:720-723.
2. Takahashi H, Ohtaki N, Maeda-Sato M, Tanaka M, Tanaka K, Sawai H, Iihikawa T, Takamizawa A, Takasaki T, Hasegawa H, et al. Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus. *Microbes Infect* 2009, **11**:1019-1028.
3. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehroop E, Marri A, Chung KM, et al. Development of a humanized

- monoclonal antibody with therapeutic potential against West Nile virus. *Nat Med* 2005, **11**:522-530.
4. Samuel Diamond. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity and viral evasion. *J Virol* 2006, **80**:9349-9360.
5. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. *J Virol* 2003, **77**:2578-2586.
6. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. *J Exp Med* 2003, **198**:1853-1862.
7. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ. Structure of West Nile virus. *Science* 2003, **302**:248.
8. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. Crystal structure of the West Nile virus envelope glycoprotein. *J Virol* 2006, **80**:11467-11474.
9. Kanai R, Kar K, Anthony K, Gould LH, Ledizet M, Fikrig E, Marasco WA, Konki RA, Modis Y. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. *J Virol* 2006, **80**:11000-11008.
10. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. *Proc Natl Acad Sci USA* 2003, **100**:6986-6991.
11. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. *Nature* 2004, **427**:313-319.
12. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. *Nature* 1995, **375**:291-298.
13. Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, Mukhopadhyay S, Baker TS, Strauss JH, Rossmann MG, Kuhn RJ. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. *Nat Struct Biol* 2003, **10**:907-912.
14. Zhang Y, Corver J, Chipman PR, Zhang W, Pietnev SV, Sedlak D, Baker TS, Strauss JH, Kuhn RJ, Rossmann MG. Structures of immature flavivirus particles. *Embo J* 2003, **22**:2604-2613.
15. Bhardwaj S, Holbrook M, Shipe RE, Barrett AD, Witpwich S. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. *J Virol* 2001, **75**:4002-4007.
16. Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. *J Virol* 2002, **76**:13097-13100.
17. Toopanta FR, Ross TM. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. *Immunol Res* 2006, **36**:197-210.
18. Bower JFR, TM. A minimum CR2 binding domain of C3d enhances immunity following vaccination. *Advances in experimental medicine and biology* 2006, **587**:249-264.
19. Hall RA, Khromykh AA. West Nile virus vaccines. *Expert Opin Biol Ther* 2004, **4**:1295-1305.
20. Hall RA, Khromykh AA. ChimeriVax-West Nile vaccine. *Curr Opin Mol Ther* 2007, **9**:498-504.
21. Widman DG, Frollov I, Mason PW. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. *Adv Virus Res* 2008, **72**:72-126.
22. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. *Cell Host Microbe* 2007, **1**:135-145.
23. Martina BE, Koraka P, Doel P van den, van Amerongen G, Rimmelzwaan GF, Osterhaus AD. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. *Vaccine* 2008, **26**:153-157.
24. Ramanathan MP, Kutzler MA, Kuo YC, Yan J, Liu H, Shah V, Bawa A, Selling B, Saidesai NY, Kim JJ, Weiner DB. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. *Vaccine* 2009, **27**:4370-4380.
25. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. *Cell Host and Microbe* 2007, **1**:135-145.
26. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning M. West Nile virus recombinant DNA vaccine protects mouse

- and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. *J Virol* 2001, **75**:4040-4047.
27. Ross TM, Xu Y, Bright RA, Robinson HL: C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. *Nat Immunol* 2000, **1**:127-131.
  28. Martin JE, Pierson TC, Hubika S, Rucker S, Gordon U, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, et al.: A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase I clinical trial. *J Infect Dis* 2007, **196**:1732-1740.
  29. Chu JH, Chiang CC, Ng ML: Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. *J Immunol* 2007, **178**:2699-2705.
  30. Lustig S, Olshevsky U, Ben-Nathan D, Lachmi BE, Malkinson M, Kobiler D, Halevy M: A live attenuated West Nile virus strain as a potential veterinary vaccine. *Viral Immunol* 2000, **13**:401-410.
  31. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ: Equine vaccine for West Nile virus. *Dev Biol (Basel)* 2003, **114**:221-227.
  32. Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Charneck RM: Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. *Virology* 2003, **314**:190-195.
  33. Tesh RB, Arroyo J, Travassos Da Rosa AP, Guzman H, Xiao SY, Monath TP: Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. *Emerg Infect Dis* 2002, **8**:1392-1397.
  34. Thompson BS, Moesker B, Smit JM, Wilschut J, Diamond MS, Fremont DH: A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. *PLoS Pathog* 2009, **5**:e1000453.
  35. Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, Diamond MS: Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. *J Virol* 2009, **83**:6494-6507.
  36. Alka, Bharati K, Malik YP, Vratil S: Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. *Med Microbiol Immunol* 2007, **196**:227-231.
  37. Mota J, Acosta M, Argente R, Figueroa R, Mendez A, Ramos C: Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. *Vaccine* 2005, **23**:3469-3476.
  38. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS: Induction of epitope-specific neutralizing antibodies against West Nile virus. *J Virol* 2007, **81**:11828-11839.
  39. Ramanathan MP, Kuo YC, Seling BH, Li Q, Sardesai NY, Kim JJ, Weiner DB: Development of a novel DNA SynCan tetravalent dengue vaccine that elicits immune responses against four serotypes. *Vaccine* 2009, **27**:6444-6453.
  40. Verma SK, Kumar S, Gupta N, VEDI S, Bhattacharya SM, Lakshmana Rao PV: Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice. *Vaccine* 2009, **27**:6905-6909.
  41. Chung KM, Thompson BS, Fremont DH, Diamond MS: Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. *J Virol* 2007, **81**:9551-9555.
  42. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, et al.: Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. *J Virol* 2006, **80**:12149-12159.
  43. Mehroop E, Ansaiah-Sobrinho C, Johnson S, Engle M, Fremont DH, Pierson TC, Diamond MS: Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. *Cell Host Microbe* 2007, **2**:417-426.
  44. Mehroop E, Nelson S, Jost CA, Gorlatov S, Johnson S, Fremont DH, Diamond MS, Pierson TC: Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. *Cell Host Microbe* 2009, **6**:381-391.
  45. Yamanaka A, Kosugi S, Konishi F: Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. *J Virol* 2008, **82**:927-937.
  46. Bower JF, Green TD, Ross TM: DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. *Virology* 2004, **328**:292-300.
  47. Bower JF, Sanders KL, Ross TM: C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. *Curr HIV Res* 2005, **3**:191-198.
  48. Bower JF, Yang X, Sodroski J, Ross TM: Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d. *J Virol* 2004, **78**:4710-4719.
  49. Green TD, Montefiori DC, Ross TM: Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. *J Virol* 2003, **77**:2046-2055.
  50. Green TD, Newton BR, Rota PA, Xu Y, Robinson HL, Ross TM: C3d enhancement of neutralizing antibodies to measles hemagglutinin. *Vaccine* 2001, **20**:242-248.
  51. Mitchell JA, Green TD, Bright RA, Ross TM: Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. *Vaccine* 2003, **21**:902-914.
  52. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL: Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. *AIDS Res Hum Retroviruses* 2001, **17**:829-835.
  53. Toapanta FR, Ross TM: Mouse strain-dependent differences in enhancement of immune responses by C3d. *Vaccine* 2004, **22**:1773-1781.
  54. Robinson HL: Nucleic acid vaccines: an overview. *Vaccine* 1997, **15**:785-787.
  55. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D: In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. *Proc Natl Acad Sci USA* 1990, **87**:9568-9572.
  56. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr: DNA-based immunization by in vivo transfection of dendritic cells. *Nat Med* 1996, **2**:1122-1128.
  57. Eisenbraun MD, Fuller DH, Haynie JR: Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. *DNA Cell Biol* 1993, **12**:791-797.
  58. Falo LD Jr: Targeting the skin for genetic immunization. *Proc Assoc Am Physicians* 1999, **111**:211-219.
  59. Tuting T, Storkus WJ, Falo LD Jr: DNA immunization targeting the skin: molecular control of adaptive immunity. *J Invest Dermatol* 1998, **111**:183-188.
  60. Byrne SN, Halliday GM, Johnston LJ, King NJ: Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. *J Invest Dermatol* 2001, **117**:702-709.
  61. Johnston LJ, Halliday GM, King NJ: Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. *J Invest Dermatol* 2000, **114**:560-568.
  62. Brien JD, Uehrlaub JL, Nikolich-Zugich J: Protective capacity and epitope-specificity of CD8(+) T cells responding to lethal West Nile virus infection. *Eur J Immunol* 2007, **37**:1855-1863.
  63. Brien JD, Uehrlaub JL, Nikolich-Zugich J: West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. *J Immunol* 2008, **181**:8568-8575.
  64. Purtha WE, Myers N, Mitaksov V, Sitati E, Connolly J, Fremont DH, Hansen TH, Diamond MS: Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. *Eur J Immunol* 2007, **37**:1845-1854.
  65. Qiao M, Athok M, Bernard KA, Palacios G, Zhou ZH, Lipkin WI, Liang TJ: Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. *J Infect Dis* 2004, **190**:2104-2108.
  66. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG: Structure of immature West Nile virus. *J Virol* 2007, **81**:6141-6145.

67. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS: Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. *J Virol* 2007, **81**:12816-12826.

doi: 10.1186/1743-422X-7-95

**Cite this article as:** Dunn *et al.*, Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice *Virology Journal* 2010, **7**:95

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



# APPENDIX 2

*Hemagglutinin Displayed Baculovirus Protects  
Against Highly Pathogenic Influenza*

*2010. Vaccine. 28:6821-6831*

*Tang, X-C, Lu, H-R, Ross, TM*



## Hemagglutinin Displayed Baculovirus Protects Against Highly Pathogenic Influenza

Xian-Chun Tang<sup>a,b</sup>, Hai-Rong Lu<sup>a</sup>, Ted M. Ross<sup>a,b,\*</sup>

<sup>a</sup> Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 15261, USA

<sup>b</sup> Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA 15261, USA

### ARTICLE INFO

#### Article history:

Received 6 June 2010

Received in revised form 11 July 2010

Accepted 6 August 2010

Available online 18 August 2010

#### Keywords:

Influenza  
vaccine  
H5N1  
baculovirus display

### ABSTRACT

Baculovirus (BV) replicating in insect cells can express a foreign gene product as part of its genome. The influenza hemagglutinin (HA) can be expressed from BV and displayed on the surface of baculovirus (HA-DBV). In this study we first generated six recombinant baculoviruses that expressed chimeric HAs with segments of the BV glycoprotein (gp64). The signal peptide (SP) and cytoplasmic tail (CT) domains of gp64 can enhance the display of HA from A/PR8/34 on BV surface, while the transmembrane (TM) domain of gp64 impairs HA display. Different doses of either live or  $\beta$ -propiolactone (BPL)-inactivated HA-DBV were administered to BALB/c mice. Live HA-DBV elicited higher hemagglutination-inhibition (HAI) titers than BPL-inactivated HA-DBV, and provided sterilizing protection. A second generation recombinant BV simultaneously displaying four HAs derived from four subclades of H5N1 influenza viruses was constructed. This tetravalent H5N1 HA-DBV vaccine elicited HAI titers against all four homologous H5N1 viruses, significantly decreasing viral lung titers of challenged mice and providing 100% protection against lethal doses of homologous H5N1 viruses. Moreover, mice vaccinated with HA-DBV had high levels of IFN $\gamma$ -secreting and HA-specific CD8<sup>+</sup> T cells. Taken together, this study demonstrates that HA-DBV can stimulate strong humoral, as well as cellular immune responses, and is an effective vaccine candidate for influenza.

© 2010 Elsevier Ltd. All rights reserved.

### 1. Introduction

Each year, seasonal influenza causes over 300,000 hospitalizations and 36,000 deaths in the US alone [1]. The emergence of the novel H1N1 influenza virus in 2009 demonstrated how quickly a new influenza pandemic can sweep across the world. The spread of highly pathogenic H5N1 viruses in birds and coincident infections in humans have raised the concerns that H5N1 viruses may cause a new pandemic in humans. Vaccination is an effective method to prevent influenza infection. There are two influenza vaccine approaches licensed in the US; the inactivated, split vaccine and the live-attenuated virus vaccine. Inactivated vaccines can efficiently induce humoral immune responses but generally only poor cellular immune responses.

**Abbreviations:** AcMNPV, *Autographa californica* multiple nucleopolyhedrovirus; BEVS, baculovirus expression vector system; BPL,  $\beta$ -propiolactone; CT, cytoplasmic tail; CTL, cytotoxic T lymphocytes; DBV, displayed baculovirus; HA, hemagglutinin or hemagglutination assay; HAI, hemagglutination inhibition; IFU, infectious unit; PFU, plaque form unit; SP, signal peptide; TM, transmembrane; VLP, virus-like particle.

\* Corresponding author. 9047 Biomedical Science Tower 3, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA. Tel.: +1 412 648 8666; fax: +1 412 624 4440.

E-mail address: [tmr15@pitt.edu](mailto:tmr15@pitt.edu) (T.M. Ross).

Baculoviruses are a family of large rod-shaped enveloped viruses with a large circular double-stranded DNA genome (80–200 kb). Baculoviruses infect some insects, but not mammals [2]. *Autographa californica* multiple nucleopolyhedrovirus (AcMNPV) is the most well studied baculovirus and most extensively used for protein expression because the polyhedron (PH) and p10 promoters are efficient promoters [3]. Compared to other protein expression approaches, the baculovirus expression vector system (BEVS) produces abundant protein yields with appropriate eukaryotic glycosylation and other modifications. Recently, this system has also been used for virus-like particle (VLP) production for vaccines against HIV, HPV and influenza [4–6]. However, the BV-derived VLPs are always accompanied with BV contamination. Therefore, separating VLPs from contaminating BV is one of the obstacles that need to be overcome.

Due to its low cytotoxicity and absence of pre-existing antibodies [7,8], AcMNPV has emerged as a potent vaccine vector [9–13]. Foreign immunogens or peptides can be displayed on the envelope of AcMNPV by fusion with the baculovirus major envelope protein gp64 [14,15]. Based on the baculovirus display system, some efficient vaccines have been studied not only for viral diseases, but also for parasitic disease, such as, classical swine fever virus [16], influenza virus [12,17–19], avian reovirus [11], bovine herpesvirus [20], *Plasmodium berghei* [13,14], and *Plasmodium fal-*

**Table 1**  
Primers used for PR8-HA displaying constructs

Primer	Primer sequence (5'-3')	Primer annotation
A	CGCTGATCAGCCACC <u>ATG</u> CTACTGGTAAATCAGTCACAC	Forward primer for gp64 Signal peptide with <i>Bcl</i> I site
B	CGAGTCGTCGACAGCCCTGAATTCGGATCCCGCAAAGGCAGAATGCCGC	Reverse primer for gp64 Signal peptide with multiple cloning sites
C	CAGGCCTGTCGACAGCTCGCGGCCGCTTCATGTTGGTCATGTAG	Forward primer for gp64 TM-CT with multiple cloning sites
D	AAGCGGCCGTTAATATTGCTATTACGGTTTCTAATC	Reverse primer for gp64 TM-CT with <i>Eag</i> I site
E	CAAGTCGACGCCACCATGAAGGCAACCTACTGGTCC	Forward primer for HA of PR8 virus with <i>Sal</i> I site
F	CTCGCGGCCGCTCAGATGCATATTCTGCATCC	Reverse primer for HA of PR8 virus with <i>Nor</i> I site
G	GCGGGATCCGACAGACAATATGTATAGGC	Forward primer for PR8 HA without SP (with <i>Bam</i> H I)
H	AAGCGGCCGCAATCTGATAGATCCCAATTGTC	Reverse primer for PR8 HA without TM, CT (with <i>Nor</i> I)
I	GGCTCTAGATTAAATGTCATTACGGTTTCTACACATCCAGAAACTGATTCC	Reverse primer for PR8 HA with CT of gp64 (with <i>Xba</i> I)

Underlined sequences are restriction enzyme sites. Bolded sequences are start or stop codons.

*ciparum* [8]. Most BV display strategies rely on gp64 protein which is the major envelope protein of baculovirus. Both influenza HA and baculovirus gp64 are type I transmembrane glycoproteins comprised of an amino-terminal signal peptide domain, carboxy-proximal transmembrane domain and cytoplasmic tail domain. Both proteins mediate viral entry into the host cells and efficient virion budding [21,22]. HA and gp64 proteins get incorporated into the infected host cell membrane. During the budding process, the budding virions pick up the protein as the constituent viral envelope [19,23]. Therefore, influenza HA can be displayed on the surface of baculovirus [12, 17, 19,24]. In this study, we investigated how the SP, TM, CT domains of gp64 influenced HA incorporation into BV. HA-DBVs protected mice against virus challenge even with low doses of vaccine. Moreover, we constructed a recombinant baculovirus simultaneously displaying four HAs derived from four subclades of H5N1 influenza. Vaccination with the tetravalent HA-DBVs stimulated strong humoral and cellular immune responses and protected mice against lethal H5N1 influenza virus challenges.

## 2. Materials and methods

### 2.1. Cells and viruses

*Spodoptera frugiperda* (Sf9) cells were propagated at 28 °C in Sf-900II serum free medium. Cells were infected by each recombinant baculoviruses at a multiplicity of infection (MOI) of 0.1–1.0 and virus supernatants were collected 4 days post-infection. Influenza viruses used in this study included the subtype H1N1, A/Puerto Rico/8/1934 (PR8), or the PR8-reassortant H5N1 viruses representing A/Vietnam/1203/2004 (VN/04), A/Indonesia/5/05 (IN/05), A/Whooper Swan/244/Mongolia/05 (WS/05), and A/Anhui/1/05 HA (AH/05). Each reassortant virus expressed the HA and NA derived from H5N1 viruses and the internal protein genes came from A/PR8/1934 donor virus. Each virus was used to infect mice as previously described [25].

### 2.2. Construction of plasmids and recombinant baculoviruses


The SP, TM, and CT domains of the gp64 gene were amplified from Bacmid DNA by PCR. The full-length or ectodomain of HA genes from mouse-adapted PR8 were amplified by PCR from one plasmid containing full-length HA of the PR8 virus. A series of plasmids encoding the SP, TM, CT regions of gp64 and various portions of HA were generated using the following strategy. Nine primers (A–I as shown in Table 1) were used to generate the chimeric HA-gp64 genes. Primers A and B were used to amplify the gene fragment encoding the gp64 SP. Primers C and D were used to amplify the gene fragment encoding gp64 TM and CT. Primers E and F were used to amplify full-length HA of PR8. Primers G and H were used to amplify the ectodomain of PR8 HA (without SP, TM and CT). Primers E and I were used to amplify PR8 HA, but the CT derived from gp64. Primers E and H were used to amplify PR8 HA without TM and CT. Primers G and F were used to amplify PR8 HA without SP. Primers

G and I were used to amplify PR8 HA without SP, and CT deriving from gp64. Appropriate fragments were serially inserted into pFastBac transfer vector (Invitrogen, Carlsbad, CA) in frame. Thus, each construct expresses chimeric PR8 HA proteins (Fig. 1A and B). All recombinant baculoviruses were generated using the Bac-to-Bac system (Invitrogen, Carlsbad, CA) and designated as Bac-HA, Bac-spHA, Bac-spHAct, Bac-HAct, Bac-HActmct, Bac-spHActmct.

The recombinant virus selection and amplification were performed following standard protocols. The infectious titers of recombinant baculoviruses were determined by the BacPAK Baculovirus Rapid Titer Kit (Clontech, Mountain View, CA) and are expressed as infectious units per milliliter (ifu/ml).

### 2.3. Purification of HA-displayed baculovirus

The recombinant baculoviruses were produced by infecting Sf9 cells at an MOI of 0.1. Supernatants were collected 4 days after



**Fig. 1.** Schematic illustration of the HA-pseudotyped baculovirus. (A) Modified transfer vector with SP, TM, CT domain sequences of gp64 and multiple cloning sites. (B) Schematic diagram of chimeric HA constructs. All components derived from HA are shown in dark gray while those from gp64 are shown in shadow.

infection and were clarified by centrifugation at 3000 g for 10 min at 4 °C to remove cell debris. Viral particles were precipitated via ultracentrifugation (100,000xg through 20% glycerol, w/v) for 4 h at 4 °C. The pellets were subsequently resuspended in PBS and stored at 4 °C. The viral titer was determined using the BacPAK Baculovirus Rapid Titer Kit.

#### 2.4. Hemagglutination assay for HA-displayed baculoviruses

A series of 2-fold dilutions of HA-displayed baculovirus in PBS were prepared and incubated at 25 °C for 30 min with 50 µl of 1% turkey red blood cells (tRBCs), or 1 h with 50 µl of 1% horse red blood cells (hRBCs) (Lampire Biologicals, Pipersville, PA, USA). The extent of hemagglutination was inspected visually, and the highest dilution capable of agglutinating red blood cells was determined.

#### 2.5. Hemadsorption assays

Insect Sf9 cells (infected or uninfected with recombinant baculovirus containing HA genes or no HA genes) were diluted to a concentration of  $1 \times 10^6$  cell/ml in PBS. 100 µl of cells were mixed with 10 µl of 1% red blood cells and shaken gently for 10 min at room temperature. Then 10 µl of the suspension was pipetted on a glass plate and observed under a microscopy [26].

#### 2.6. Western blot analysis

The supernatants from rBV infected Sf9 cells or purified baculoviruses were subjected to Western blot analysis. Mouse Anti-PR8 HA polyclonal antibody (produced in our lab) and mouse anti-vp39 monoclonal antibody (kindly provided by Professor Matt Welch from University of California, Berkeley) was used to detect proteins. The primary antibodies were detected with goat anti-mouse monoclonal antibodies conjugated with horseradish peroxidase (1:5000, SouthernBiotech, Birmingham, Alabama).

#### 2.7. Vaccinations

Female BALB/c mice (*Mus musculus*, females, 6–8 weeks) were purchased from Harlan Sprague Dawley (Indianapolis, IN, USA). Mice were housed in microisolator units and allowed free access to food and water and were cared for under USDA guidelines for laboratory animals. Mice (10 groups, 15 mice per group) were vaccinated with live or BPL inactivated Bac-spHAct at 3 different doses ( $1 \times 10^8$ ,  $2 \times 10^7$ , and  $4 \times 10^6$  ifu/mouse) or with wild-type (wt) baculovirus ( $1 \times 10^8$  ifu), mammalian cell derived VLPs (6 µg) and PBS as control via intramuscular injection at week 0 and boosted with the same doses at week 3 (Table 2). The mammalian cell derived VLPs were produced by simultaneously transfecting 293T cells with three plasmids encoding HA, NA, and M1 genes of PR8 virus respectively as previously described [27]. The choice of dose is based on previous studies in our laboratory (unpublished data).

#### 2.8. Hemagglutination inhibition (HAI) assays

Blood samples were collected from anesthetized mice via retro-orbital plexus puncture before immunization and at 2 weeks after each immunization (week 2, 5). After the blood samples were clotted and centrifuged, serum samples were collected. The HAI assay was used to assess functional antibodies to HA able to inhibit agglutination of erythrocytes. To inactivate non-specific inhibitors, aliquots of each serum sample were treated with receptor-destroying enzyme (RDE; Denka Seiken Co., Japan) overnight at 37 °C, heat-inactivated at 56 °C for 30 min, diluted to 1:5 with PBS [28]. RDE-treated sera (25 µl) were diluted serially two-fold in v-bottom 96-well microtiter plates. An equal volume

of influenza virus, adjusted to approximately 8 HA units/50 µl was added to each well. The plates were covered and incubated at room temperature for 30 min followed by the addition of 50 µl freshly prepared 1% tRBCs or hRBCs in PBS. The plates were mixed by agitation, covered, and allowed to set for 30 min or 1 hr at 25 °C. The HAI titer was determined by the reciprocal of the last dilution that contained non-agglutinated RBCs. Positive and negative serum controls were included on each plate.

#### 2.9. Challenge and viral load

Challenge infections were performed as previously described [25]. At 3 weeks after the final immunization, ketamine-anesthetized mice were intranasally infected with 1,500 plaque forming units (pfu) of A/PR/8/1934 virus (equivalent to  $10 \times$  the 50% lethal dose [LD<sub>50</sub>]) in 50 µl of PBS. Mice were weighed daily and analyzed for disease (i.e. weight loss, ruffling fur, inactivity). Mice that lost greater than 20% of body weight were humanely euthanized. One day 3 and 6 post-challenge, five mice from each group were sacrificed and the lungs were harvested. The tissues were homogenized (the lung from one mouse was homogenized in 1 ml PBS), and viral load was determined by plaque assay on Madin-Darby canine kidney (MDCK) cells as previously described [25].

#### 2.10. Construction of multiple-HA-displayed baculovirus

In order to introduce four expression cassettes into baculovirus, pFastBac Dual plasmid was firstly modified to contain two PH promoters and two multiple cloning sites (p2PH). The SP region of gp64 with Flag or His tag was inserted into p2PH to make the transfer vector p2PHsp. Two pairs of compatible restriction sites (Asc I–Mlu I, Spe I–Avr II) were introduced into p2PHsp as shown in Figure 2A. Appropriate ectodomain of HAs from four H5N1 influenza viruses were PCR amplified from the following virus strains: A/Vietnam/1203/2004 (clade 1), A/Indonesia/5/05 (clade 2.1), A/Whooper Swan/244/Mongolia/05 (clade 2.2), A/Anhui/1/05 HA (clade 2.3). The four-HA plasmid pHA1.0/2.1/2.2/2.3 was constructed in two stages (Fig. 2B). (i) We first constructed two dual-HA plasmids. HA fragments of VN/04 and IN/05 were cloned into one p2PHsp to obtain plasmid pHA1.0/2.1. HA fragments of WS/05 and AH/05 were cloned into another p2PHsp to obtain plasmid pHA2.2/2.3. (ii) The fragment containing the HA2.2 and HA2.3 cassettes, along with their promoter-terminator, was excised with Asc I and Avr II from pHA2.2/2.3 and cloned in between the Mlu I and Spe I sites in the pHA1.0/2.1 to obtain the four-HA plasmid pHA1.0/2.1/2.2/2.3 (p4HA). Recombinant baculoviruses were generated using the Bac-to-Bac system and designated as Bac-HA1.0/2.1, Bac-HA2.2/2.3 and Bac-HA1.0/2.1/2.2/2.3 (Bac-4HA). Multiple-HA-displayed baculoviruses were propagated and purified as above. Protein expression was checked by Western-blot, hemagglutination assay and hemadsorption assay.

#### 2.11. Evaluation for the tetravalent H5N1 vaccine candidate in mouse model

Mice (9 groups, 12 mice per group) were intramuscularly vaccinated with Bac-HA2.2, Bac-4HA, or wt BV ( $1 \times 10^7$  ifu/mouse) at week 0 and 3 (Table 2). Serum was collected at weeks 2 and 5 to determine anti-HA-specific antibody titer. For virus challenge, anesthetized mice were infected intranasally with 5000 pfu of A/VN/04, A/IN/05, or A/WS/05 viruses in 50 µl of PBS per mouse at 3 weeks after the final immunization. Five mice from each group were sacrificed on day 3 post-challenge for examining virus replication in lungs. Five mice in each group were monitored daily for survival and morbidity post infection. Mice that lost greater than

**Table 2**  
Mouse study groups and protective efficacy

Vaccines used in each mouse group	Immunization dose (ifu)	Virus and dose used for challenge (pfu)	Clinical signs <sup>††</sup>	Protection (%)
<b>PR8 HA-displayed BV</b>				
G1: Live Bac-spHAct	1x10 <sup>8</sup>	A/PR8 (1.5x10 <sup>3</sup> )	Healthy	100
G2: Live Bac-spHAct	2x10 <sup>7</sup>	A/PR8 (1.5x10 <sup>3</sup> )	Healthy	100
G3: Live Bac-spHAct	4x10 <sup>6</sup>	A/PR8 (1.5x10 <sup>3</sup> )	Healthy	100
G4: Live wt baculovirus	1x10 <sup>8</sup>	A/PR8 (1.5x10 <sup>3</sup> )	Sick (+++)	0
G5: Inactivated Bac-spHAct	1x10 <sup>8</sup>	A/PR8 (1.5x10 <sup>3</sup> )	Healthy	100
G6: Inactivated Bac-spHAct	2x10 <sup>7</sup>	A/PR8 (1.5x10 <sup>3</sup> )	Healthy	100
G7: Inactivated Bac-spHAct	4x10 <sup>6</sup>	A/PR8 (1.5x10 <sup>3</sup> )	Sick (+)	100
G8: Inactivated wt baculovirus	1x10 <sup>8</sup>	A/PR8 (1.5x10 <sup>3</sup> )	Sick (+++)	0
G9: PR8 VLP <sup>*</sup>	6 µg	A/PR8 (1.5x10 <sup>3</sup> )	Healthy	100
G10: PBS		A/PR8 (1.5x10 <sup>3</sup> )	Sick (+++)	0
<b>H5N1 HA-displayed BV</b>				
G1: Live Bac-HA2.2	1x10 <sup>7</sup>	A/VN/04 (5x10 <sup>3</sup> )	Sick (++)	50
G2: Live Bac-HA2.2	1x10 <sup>7</sup>	A/IN/05 (5x10 <sup>3</sup> )	Sick (++)	40
G3: Live Bac-HA2.2	1x10 <sup>7</sup>	A/WS/05 (5x10 <sup>3</sup> )	Healthy	100
G4: Live Bac-HA1.0/2.1/2.2/2.3	1x10 <sup>7</sup>	A/VN/04 (5x10 <sup>3</sup> )	Healthy	100
G5: Live Bac-HA1.0/2.1/2.2/2.3	1x10 <sup>7</sup>	A/IN/05 (5x10 <sup>3</sup> )	Healthy	100
G6: Live Bac-HA1.0/2.1/2.2/2.3	1x10 <sup>7</sup>	A/WS/05 (5x10 <sup>3</sup> )	Healthy	100
G7: Live wt baculovirus	1x10 <sup>7</sup>	A/VN/04 (5x10 <sup>3</sup> )	Sick (+++)	0
G8: Live wt baculovirus	1x10 <sup>7</sup>	A/IN/05 (5x10 <sup>3</sup> )	Sick (+++)	0
G9: Live wt baculovirus	1x10 <sup>7</sup>	A/WS/05 (5x10 <sup>3</sup> )	Sick (+++)	0

<sup>\*</sup> VLP was produced by transfecting 293T cells with three plasmids expressing HA, NA and M1 of PR8 virus.


<sup>††</sup> Mice with +++ signs showed severe illness. Clinical signs were determined by body weight losses and mouse symptoms of illness. +++, lost in body weight of over 20% and ruffling fur; ++, some mice died and some had only 10–20% weight loss with ruffling fur; +, 10–20% decreases in body weight, with ruffling fur; healthy, < 5% body weight changes and no ruffling fur.

20% of body weight were euthanized. The ability of each vaccine to protect against homologous or heterologous challenge was compared to separate groups of wt-baculovirus vaccinated control mice that were subsequently challenged with each reassortant virus. The remaining mice in each group were used to determine the elicitation of anti-HA specific cellular responses by murine IFN $\gamma$  enzyme linked immunospot (IFN $\gamma$ -ELISPOT) assay (R & D Systems, Minneapolis, MN, USA) and MHC class I pentamer staining (ProImmune, Oxford, UK).

### 2.12. IFN $\gamma$ -ELISPOT assays

Spleens were harvested from vaccinated mice at day 6 and day 9 post-challenge and splenocytes were isolated for IFN $\gamma$ -ELISPOT

assays as previously described [29]. Briefly, pre-coated anti-IFN $\gamma$  plates were incubated (25 °C for 2 h) with cRPMI (200 ml) and then incubated with freshly isolated splenocytes (5 × 10<sup>5</sup>/well). Splenocytes were stimulated with the single peptides representing the immunodominant H2-Kd CD8<sup>+</sup> T cell epitopes HA<sub>533</sub> and NP<sub>147</sub> or as a negative control the unpecific Ova<sub>257</sub> peptide (Pepscan Presto, Leystad, Netherlands). Both HA<sub>533</sub> and NP<sub>147</sub> peptides were originally derived from the PR8 (H1N1) virus, but they are conserved in H5N1 influenza viruses [29]. Additional wells were stimulated with PMA (50ng)/ionomycin (500ng) or were mock stimulated. In addition, IL-2 was added to all wells (10 units/ml). After 48 h stimulation, plates were washed with PBS-Tween (3 ×) and were incubated overnight at 4 °C with anti-mIFN $\gamma$  antibody. The plates were washed and then incubated (25 °C for 2 h) with streptavidin



**Fig. 2.** Construction of four-unit transfer vector pHA1.0/2.1/2.2/2.3 (A) Dual-PH promoter transfer vector with SP of gp64 and two multiple cloning sites. (B) Stepwise construction of pHA1.0/2.1/2.2/2.3



conjugated to alkaline phosphatase. Following extensive washing, cytokine/antibody complexes were incubated at room temperature with BCIP/NBT chromagen until spots appeared. The plates were rinsed with dH<sub>2</sub>O and air-dried at 25 °C. Spots were counted by an ImmunoSpot ELISPOT reader (Cellular Technology Ltd., Cleveland, OH, USA).

### 2.13. Flow cytometry

In order to detect influenza-specific CD8<sup>+</sup> T cells, MHC class I pentamer staining was employed. The CD8<sup>+</sup> T cell responses to NP<sub>147</sub> are dominant followed by HA<sub>533</sub> responses in influenza virus infected BALB/c mice. Lung lymphocytes were isolated from infected mice at day 6 and 9 post-challenge as previously described [29]. The cells were washed with FACS buffer (PBS, 1% FBS, 0.1% sodium azide) and then blocked with anti-CD16/CD32 mouse Fc receptor block (BD Biosciences, San Jose, CA, USA), followed by staining with a murine MHC-I encoded allele Kd-specific pentamer for the HA<sub>533</sub> epitope or NP<sub>147</sub> epitope conjugated to phycoerythrin (PE). Lymphocytes were subsequently stained with anti-CD8 antibodies conjugated to Pacific Blue, anti-CD3 antibodies conjugated to PerCP and anti-CD19 antibodies conjugated to APC-Cy7 (BD Biosciences, San Jose, CA, USA). The cells are then incubated with a viability dye (Molecular Probes, Invitrogen, Eugene, OR, USA). Once the surface staining was complete the cells were washed with FACS buffer, then fixed in 1% formalin/PBS and the cells were acquired using a LSRII flow cytometer (BD Biosciences, San Jose, CA, USA).

## 3. Results


### 3.1. Construction of recombinant baculoviruses

In order to investigate the gp64 components that may influence incorporation of HA on to baculovirus, six novel chimeric genes were constructed. The coding sequences for the signal peptide, transmembrane and cytoplasmic tail domains of HA were replaced with those of gp64 (Fig. 1B): Bac-HA, expressing full length HA; Bac-spHA, expressing ectodomain of HA with SP derived from gp64; Bac-spHAct, expressing ectodomain of HA with SP and CT derived from gp64; Bac-HAct, expressing HA with CT derived from gp64; Bac-HAtmct, expressing ectodomain of HA with TM and CT derived from gp64; Bac-spHAtmct, expressing ectodomain of HA with SP, TM and CT derived from gp64. All constructs were derived from the mouse adapted influenza virus A/PR/8/34 (H1N1). The hypothesis was that the SP of the gp64 would facilitate the translocation of the chimeric HA to the insect cell plasma membrane and the TM and CT domains of gp64 will stabilize the chimeric HA incorporated into virus envelope.

### 3.2. Confirmation of HA expression and incorporation into baculovirus

To determine whether the HA expressed by BV is properly translocated to the insect cell surface, BV infected and uninfected insect cells were incubated with tRBCs for agglutination. Approximately 80% RBCs were absorbed on the insect cells infected with baculoviruses containing HA genes. In contrast, no RBC absorption was observed for the uninfected insect cells or cells infected with baculovirus without HA gene (supplemental Figure 1). Therefore, the HA proteins expressed in insect cells were translocated to the cell surface, were properly folded maintaining their hemagglutination activity.

To confirm the expression of each chimeric HA, Sf9 cells were infected with these recombinant baculoviruses at a MOI ~1.0, and harvested at 4 days post-infection and the expressed HAs were




**Fig. 3.** Western-blot assay of HA-displayed baculovirus. (A) Supernatants from infected Sf9 cells probed with HA and vp39 antibodies. (B) Pelleted rBV by ultracentrifugation probed with HA and vp39 antibodies. (C) Supernatants after ultracentrifugation of rBV probed with HA antibody.

quantified by scanning densitometry (Fig. 3A). Equivalent concentrations of recombinant baculoviruses were loaded in each well and the amount of incorporated HA was normalized to vp39 (the major baculovirus capsid protein). HA proteins were expressed at similar levels by all the six constructs (Fig 3A).

To confirm that each HA was incorporated on the envelope of baculoviruses, supernatants from infected Sf9 cells were used to perform hemagglutination assay. All recombinant baculovirus containing HA gene bound tRBCs, but baculoviruses without an HA gene did not agglutinate tRBCs. Furthermore, at the same titer of baculovirus ( $5 \times 10^7$  ifu/ml), Bac-spHAct had the highest HA titer (1:64) while Bac-spHAtmct and Bac-HAtmct had the lowest HA titer (1:2), indicating that the different domains of gp64 (SP, TM and CT) affected the efficiency of HA incorporation into baculovirus. In order to verify whether all expressed HAs are incorporated into baculovirus, HA-DBVs from infected Sf9 cells were pelleted by ultracentrifugation and the supernatants and pelleted fractions were analyzed. Four DBV pellets from cells infected with Bac-HA, Bac-spHA, Bac-spHAct, and Bac-HAct incorporated similar amounts of each chimeric HA, while two DBV pellets (Bac-HAtmct and Bac-spHAtmct) incorporated about 50% less HAs (Fig. 3B). Supernatants from Bac-spHAtmct and Bac-HAtmct had some unbound HAs while the other four constructs did not have detectable HAs after ultracentrifugation (Fig. 3C). Therefore, Bac-spHAct was chosen as the template for further vaccine studies.

### 3.3. HA-DBVs elicit hemagglutination-inhibition activity

Mice (BALB/c, n=15/group) were vaccinated with either 1) live HA-DBV (Bac-spHAct) with the HA derived from the A/PR/8/34, 2) the same BV inactivated with BPL, 3) wt BV, 4) purified PR8 VLPs produced in mammalian cells or 5) mock vaccinated with PBS. Serum samples were evaluated for the ability to inhibit PR8 influenza virus induced hemagglutination of tRBCs. All Bac-spHAct vaccinated mice had detectable HAI titer against PR8 virus from serum collected at week 2 and 5 (Fig. 4). Two weeks after the first vaccination, the average HAI titers for live Bac-spHAct groups ( $1 \times 10^8$ ,  $2 \times 10^7$ , and  $4 \times 10^6$  ifu/mouse) were between 118 and 373, while the average HAI titers for BPL-inactivated Bac-spHAct groups ( $1 \times 10^8$ ,  $2 \times 10^7$ , and  $4 \times 10^6$  ifu/mouse, same doses but inactivated) were between 38 and 56. Following the second vaccination, HAI titers increased from the first dose (~10 fold) in mice vaccinated with live Bac-spHAct vaccine, while the HAI titers



**Fig. 4.** Hemagglutination-inhibition (HAI) titers. Mice ( $n = 15$ /group) immunized intramuscularly with live/inactivated Bac-spHAct, wt BV, VLPs or mock vaccination. Week 2 (W2), and week 5 (W5) serum HAI antibody responses were assessed against PR8 virus. Bars indicate geometric mean titer (GMT)  $\pm$  SEM.

from mice vaccinated with BPL-inactivated Bac-spHAct vaccines did not increase significantly. Mice that were immunized with the live Bac-spHAct vaccinated groups had significant higher HAI titers than the mice vaccinated with the BPL-inactivated Bac-spHAct. Remarkably, the live Bac-spHAct vaccinated mice had higher HAI titers compared to VLP-vaccinated mice after the primary and boost immunization. As expected, there were no HA inhibiting antibody responses elicited in mice that were immunized with wt BV.


#### 3.4. Viral titers in lungs of vaccinated mice post challenge

Lung viral titers were determined at days 3 and 6 post-challenge (Fig. 5). Unvaccinated mice and mice vaccinated with live or inactivated wt BV had high viral titers in their lungs ( $\sim 1 \times 10^6$  pfu/ml). Mice which were immunized with a mammalian cell-derived VLP vaccine showed a 1000-fold reduction of viral titer. However, mice vaccinated with live Bac-spHAct, irrespective of the dose, did not have detectable virus ( $<10$  pfu/ml) in their lungs. In contrast, mice vaccinated with inactivated Bac-spHAct had virus titers that ranged from  $1 \times 10^3$  to  $1 \times 10^5$  pfu/ml at day 3 (Fig. 5A). By day 6, mice vaccinated with inactivated Bac-spHAct with  $1 \times 10^8$  ifu


showed a reduction in lung viral titer, whereas mice vaccinated with a lower dose of inactivated Bac-spHAct maintained similar viral titers as day 3 (Fig. 5B). Since mice vaccinated with the live HA-DBV elicited immune response that blocked PR8 virus infection, even if immunized with a very low dose ( $4 \times 10^6$  ifu/mouse). Therefore, additional studies were performed using a live HA-DBV regimen.

#### 3.5. Immunization with Bac-spHAct confers protection from lethal PR8 virus challenge

To evaluate the protective efficacy of different vaccine strategies of Bac-spHAct, mice were challenged intranasally with a lethal dose of PR8 virus. All mice vaccinated with either live or BPL inactivated wt BV or non-vaccinated mice lost greater than 20% of their original body weight and died from complications associated with infection by day 5–8 post challenge (Fig. 6). All mice vaccinated with live Bac-spHAct or VLP vaccines were protected from lethal challenge without weight loss, regardless of vaccination dose (Fig. 6A and B). In contrast, mice vaccinated with inactivated Bac-spHAct lost some weight following challenge (Fig. 6C), and one out of five mice vaccinated with the lowest dose of inactivated Bac-spHAct



**Fig. 5.** Virus titers in lungs at day 3 and 6 post-challenge. Mice ( $n = 5$ /group) immunized intramuscularly with live/inactivated Bac-spHAct, wt BV, VLPs or mock vaccination. At week 3 after the final immunization, immunized mice were intranasally infected with a lethal dose of mouse-adapted PR8 virus ( $10$  LD $_{50}$ ). Mice were sacrificed on day 3 (A) and day 6 (B) post-challenge and lungs were collected for plaque assay.



**Fig. 6.** Protection of mice from lethal PR8 challenge. At week 3 after the final immunization, immunized mice ( $n = 5$ /group) were intranasally infected with a lethal dose of mouse-adapted PR8 virus ( $10 \text{ LD}_{50}$ ). Mice were monitored daily for 14 days. (A) Body weight changes of mice immunized with live Bac-spHAct, wt BV, VLP, PBS. (B) Percent survival of mice immunized with live Bac-spHAct, wt BV, VLP, PBS. (C) Body weight changes of mice immunized with BPL-inactivated Bac-spHAct, wt BV, VLP, PBS. (D) Percent survival of mice immunized with BPL-inactivated Bac-spHAct, wt BV, VLP, PBS.

( $4 \times 10^6$  ifu/mouse) died after challenge (Fig. 6D). All the other mice vaccinated with Bac-spHAct survived from challenge.

### 3.6. HAI antibody titers elicited by Bac-HA2.2 or Bac-4HA vaccines


Since the comparison of PR8 HA-displayed constructs indicated that SP and CT domains of gp64 can enhance the HA incorporation into baculovirus, HA-DBV were constructed to contain chimeric HAs derived from four subclades of H5N1 influenza viruses which were fused with SP and CT domains of gp64. The HA displayed on the surface of baculovirus maintain hemagglutination activity. Mice were vaccinated with live H5N1 HA-DBV ( $1 \times 10^7$  ifu/mouse) of either a monovalent HA-DBV (Bac-HA2.2) or a tetraivalent HA-DBV (Bac-4HA). Two weeks after primary vaccination, the HAI titers to all H5N1 viruses were undetectable or low ( $<1:10$ ), regardless of the vaccine administered (data not shown). At week 5 following the second vaccination, mice vaccinated with the monovalent HA-DBV (Bac-HA2.2) had an average HAI titer of 1:100 against A/WS/05, low ( $\leq 1:20$ ) HAI titer against heterologous viruses (VN/04, IN/05, AH/05). In contrast, mice vaccinated with the tetraivalent HA-DBV (Bac-4HA) had HAI titers against all four viruses (average HAI titers: 116 against VN/04, 120 against IN/05, 90 against WS/05, 80 against AH/05), with a seroconversion rate ranging from 86–94%. As expected, wt BV vaccinated mice had no detectable HAI titers (Fig. 7).

### 3.7. Protection against heterologous or homologous H5N1 viral challenge


To test whether immunization protects mice from a lethal infection with reassortant H5N1 influenza viruses, mice that received either Bac-HA2.2, Bac-4HA, or wt BV vaccine were challenged intranasally with lethal doses of either VN/04, IN/05 or WS/05 viruses (Fig. 8 and Table 2). All mice vaccinated with Bac-4HA were protected from death following lethal challenge with VN/04, IN/05 or WS/05 reassortant viruses. All mice vaccinated with Bac-HA2.2

were protected from lethal challenge with homologous WS/05, whereas only 60% of the mice infected with heterologous VN/04 and 40% of mice infected with IN/05 were protected. All mice vaccinated with wt BV lost greater than 20% of their original weight and had to be euthanized or died from complications associated with infection by day 6–9 post-challenge.


Lung viral titers at day 3 post-challenge were analyzed to determine virus replication in the lung (Fig. 9). The wt BV immunized mice groups showed high viral titer ( $\sim 1 \times 10^6$  pfu/ml), regardless of the challenge virus, while significantly lower viral titers were detected in the Bac-4HA vaccinated groups. High titers of virus replication were also observed in the mice that received Bac-HA2.2, albeit lower than the titers observed in mice immunized with wt BV. These results indicate that Bac-4HA can induce protective immune responses that can protect from challenge with




**Fig. 7.** Hemagglutination-inhibition (HAI) titers against H5N1 viruses. Mice ( $n = 36$ /group) were immunized intramuscularly with Bac-HA2.2, Bac-4HA, wt BV. Week 5 serum HAI antibody responses were assessed against VN/04, IN/05, WS/05, AH/05 viruses. Bars indicate geometric mean titer (GMT)  $\pm$  SEM.



**Fig. 8.** Protection of mice from lethal H5N1 viruses' challenge. At week 3 after the final immunization, immunized mice ( $n = 5$ /group) were intranasally infected with a lethal dose of VN/04, IN/05, WS/05 viruses. Mice were monitored daily for 13 days. (A) Body weight changes after challenge. (B) Percent survival after challenge.



**Fig. 9.** Virus titers in lungs at day 3 post-challenge. Mice ( $n = 5$ /group) were immunized intramuscularly with Bac-HA2.2, Bac-4HA, wt BV. At week 3 after the 2nd immunization, immunized mice were intranasally infected with a lethal dose of VN/04, IN/05, WS/05. Mice were sacrificed on day 3 post-challenge and lungs were collected for plaque assay. \*  $p < 0.05$ , \*\*  $p < 0.01$ .



**Fig. 10.** IFN $\gamma$ -ELISPOT assays. Splenocytes were collected on day 6 and 9 post-infection with IN/05. Each sample was stimulated with HA<sub>533</sub>, NP<sub>147</sub>, and Ova peptides. The spot number from Ova peptide stimulation was subtracted.

VN/04, IN/05 or WS/05 influenza viruses, while Bac-HA2.2 can induce partial protective immune responses against heterologous virus (VN/04, IN/05).

### 3.8. Cell-mediated immunity elicited by HA-DBV

We determined the magnitude of T-cell responses induced by HA-DBV using IFN $\gamma$ -ELISPOT and flow cytometry. Splenocytes were harvested at 6 and 9 days post challenge and stimulated *in vitro* with H2d-restricted CD8<sup>+</sup> T cell specific peptide HA<sub>533</sub> [29]. As expected, after HA peptide stimulation, wt BV vaccinated mice had T cell responses similar to the negative controls (unstimulated or stimulated with irrelevant peptide) (Fig. 10). In contrast, mice vaccinated with Bac-HA2.2 or Bac-4HA vaccines had significant higher IFN $\gamma$  responses (300–460 spots/ $1 \times 10^6$  cells) following HA peptide stimulation (Fig. 10). After NP<sub>147</sub> peptide stimulation, IFN $\gamma$  responses were detected at low levels in all vaccinated mice on day 6 post infection, which is to be expected since the NP epitope is not present in the vaccine. The ELISPOT assay was performed also on day 9 post challenge, which is the peak of the T cell response during a primary infection. With HA<sub>533</sub> peptide stimulation, mice vaccinated with Bac-HA2.2 or Bac-4HA had 400–700 spots while mice vaccinated with wt BV had only 130 spots per  $1 \times 10^6$  cells, this is expected because the T cell response in HA-DBV vaccinated mice is a recall

response which must be stronger than primary response in wt BV vaccinated mice. With NP<sub>147</sub> peptide stimulation, mice vaccinated with Bac-HA2.2 or Bac-4HA had 150 spots while mice vaccinated with wt BV had 400 spots per  $1 \times 10^6$  cells. This disparity is most likely due to the fact that wt BV vaccinated mice were not protected from infection with the influenza virus which resulted in a robust activation of influenza specific T cell responses, whereas in the HA-DBV vaccinated mice a large proportion of the challenge virus was neutralized by antibodies or cleared by influenza specific T cells, therefore resulting in a lower frequency of NP specific T cells on day 9 post challenge.

To determine the influenza specific T cell response in lung, lung cells were collected at day 6 and 9 post-challenge with IN/05 and analyzed via staining with a pentamer specific for T cells recognizing the HA<sub>533</sub> or NP<sub>147</sub> epitopes [29] (supplemental Figure 2A & B). On day 6 post-challenge, the percentage of NP-pentamer<sup>+</sup>/CD8<sup>+</sup> T cells in all vaccinated/infected mice was similar to unvaccinated/uninfected mice and 2.6% HA-pentamer<sup>+</sup>/CD8<sup>+</sup> T cells were detected in the lungs of mice vaccinated with Bac-HA2.2 and Bac-4HA. As expected, there were no HA-pentamer<sup>+</sup>/CD8<sup>+</sup> T cells in wt BV vaccinated mice (Table 3). On day 9 post-challenge, HA-DBV vaccinated mice had 4.6–5.4% NP-pentamer<sup>+</sup>/CD8<sup>+</sup> T cells in their lungs, whereas wt BV vaccinated mice had 15% of their lung lymphocytes stain positive for the NP-pentamer. This revealed same

**Table 3**  
Percentage of pentamer positive CD8<sup>+</sup> T cells in lung

Challenge after vaccination	Day 6 post infection			Day 9 post infection		
	Bac-HA2.2	Bac-4HA	wt BV	Bac-HA2.2	Bac-4HA	wt BV
HA pentamer <sup>+</sup> /CD8 <sup>+</sup> (%)	2.6	2.6	0.1	26.1	20.8	1.3
NP pentamer <sup>+</sup> /CD8 <sup>+</sup> (%)	0.2	0.5	0.6	5.4	4.6	15

phenomenon as IFN $\gamma$ -ELISPOT results on day 9 post-challenge. In contrast, 26.1% of cells collected from mice vaccinated with Bac-HA2.2 and 20.8% from Bac-4HA vaccinated mice were HA-pentamer<sup>+</sup>/CD8<sup>+</sup>, and only 3.1% were detected HA-pentamer<sup>+</sup>/CD8<sup>+</sup> in wt BV vaccinated mice, since recall immune responses in the former were stronger than primary immune responses in the later.

#### 4. Discussions

In this study, we investigated the efficiency of influenza HA displayed on the surface of baculovirus and its utility as a vaccine candidate. Baculovirus surface display has been extensively used for the analysis of protein-protein interaction [30], drug screening [31], monoclonal antibody generation [32], as well as vaccine production [9,11,13,18]. Initially, vaccines were developed that fused epitopes or peptides to the envelope protein of AcMNPV, gp64, which resulted in surface display of these peptides on the baculovirus surface. Subsequently, it was found that some native viral envelope proteins can be displayed on the baculovirus surface, even without the fusion with gp64, such as HIV-1 gp120 [14], influenza HA [24], vesicular stomatitis virus glycoprotein [33]. However, so far no comprehensive studies have investigated whether fusion of native proteins results in efficient display on the baculovirus surface as a delivery vehicle for vaccines. In this study, the SP, TM, and CT domains of gp64 were examined to enhance foreign antigen display on the baculovirus surface. The signal peptide of the membrane protein plays an important role in directing protein to the endoplasmic reticulum membrane and trafficking [34]. The TM domain of baculovirus envelope is critical for protein trafficking, membrane anchoring, membrane fusion, and viral budding [35,36]. The CT domain of a viral envelope protein may influence envelope incorporation and virus budding, since the CT domains interact with the components of viral core [37,38]. The CT domain of gp64 has been shown to enhance the incorporation of influenza HA into baculovirus [19]. It is not known if SP and TM domains of gp64 have similar functions. Therefore, we constructed six recombinant baculoviruses expressing six chimeric or native HAs. All six HAs were expressed, translocated to the infected cell surface and incorporated into baculovirus envelope. Importantly, all constructs expressed HA at similar levels (Fig. 3A), suggesting the substitutions of these three domains does not significantly affect HA expression. However, not all expressed HA were incorporated into mature baculovirus with equal efficiency (Fig. 3B & C). The HA containing TM domain of gp64 resulted in unbound HA, indicating that TM domain of HA is important for HA incorporating into virions. Roth *et al.* reported that substitutions of TM domains of HA with VSV-G and herpes simplex virus glycoprotein C had minimal effect on the HA ectodomain [39], but the replacement or mutation in the TM domain of HA affected its folding, stability, and virus-cell membrane fusion [21,36,40]. Hemagglutination titer of influenza virus can reflect the abundance of properly folded hemagglutinin on a viral particle. At an equivalent virus titer, Bac-spHAct had the highest hemagglutination titer. Therefore, it was chosen for subsequent mouse study.

We investigated the efficacy of HA-DBV as an influenza vaccine. There is a direct correlation between the HAI titers and protection against influenza challenge. Yang *et al.* reported that HA displayed BV can successfully elicit functional antibodies although they did not analyze protection by challenging the immunized mice [19]. Recently, Prabakaran *et al.* reported that intranasal or gastrointestinal delivery of HA-DBV protected mice against H5N1 influenza virus infection [12,18]. All these studies indicated that HA-DBV was a promising influenza vaccine candidate. In this study, we investigated the dosage of HA-DBV as a vaccine candidate in mouse model

and compared live and inactivated HA-DBV. Our results indicated that live HA-DBV elicited strong humoral immune responses as indicated by the HAI titers, even at a low dose ( $4 \times 10^6$  ifu/mouse), whereas, the inactivated HA-DBV induced low HAI titers. After challenge, viral titers in lungs were determined on day 3 and day 6 post-challenge. We found that all mice vaccinated with live Bac-spHAct had undetectable viral titers in their lungs on day 3 and 6 post challenge, suggesting that antibodies induced by live Bac-spHAct conferred sterilizing immunity. Most mice vaccinated with inactivated Bac-spHAct had detectable lung virus titers by day 3 post challenge. Some mice in the VLP-vaccinated group had detectable viral titers in their lungs, indicating that the efficacy of the live HA-DBV is superior to the VLP vaccine, which is most likely the result of the strong adjuvant property of baculovirus. All wt BV-vaccinated mice had lung viral titers similar to unvaccinated mice. Viral lung titers correlated with protection; mice with low viral titers were protected. Even though baculoviruses are unable to replicate in mammalian cells, only the live HA-DBV vaccines, not the inactivated ones, elicited high titer protective immune responses. This may be due to two reasons. First, the BPL-inactivation process may affect the conformation of displayed HA proteins. The hemagglutination titer of Bac-spHAct was reduced following BPL-inactivation. Second, the adjuvant effect of BVs can be observed with low number of virions ( $10^4$ – $10^3$  pfu/mouse), but totally abolished if BVs were inactivated by UV irradiation, treatment with Triton X-100, or binary ethylenimine [41].

BV contains a large genome (80–200 kb) [3]. This enables insertion of large foreign DNA fragments or construction of multivalent vaccines. Influenza viruses have many serotypes in nature. A single influenza infection may be sufficient to provide lifelong immunity to the invading strain or serotype, but cannot provide protection against emerging serotypes. H5N1 avian influenza virus has the potential to emerge as a pandemic threat in humans. So far, H5N1 influenza viruses are divisible into 10 clades on the basis of phylogenetic analysis of HA genes [42]. The cross-clade protections are very poor, so multivalent H5N1 influenza vaccines are critically important for preventing its spread. The major human infections were caused by clades 1, 2.1, 2.2 and 2.3. Therefore, we constructed an rBV that expressed four HAs derived from these four subclades of H5N1 influenza viruses. In a mouse study, we found that monovalent H5N1 vaccine induced poor cross-clade antibody responses, but multivalent H5N1 vaccine elicited broadly-reactive antibody responses against all the HA subtypes included in the DBV. These correlated with protection rates and viral titers in lung. Some mice did not have detectable HAI titers, but survived from lethal dose virus challenge, which may be result of cellular immune responses clearing some virally infected cells. Previous studies have reported that virus-specific CTL play an important role in the recovery and protection during influenza virus infection, especially when a protective antibody titer is absent [43,44].

To investigate influenza-specific T cell responses elicited by HA-DBV, IFN $\gamma$ -ELISPOT and MHC-I pentamer staining were performed. On day 6 post-challenge, the recall of HA-specific IFN $\gamma$ -secreting memory T cells were detected in HA-DBV vaccinated mice, but not in wt BV vaccinated mice. Little or no NP-specific IFN $\gamma$ -secreting T cells were detected in all vaccinated mice since the NP protein was not included in the HA-DBV [45,46]. On day 9 post infection, which is close to the peak of the primary response, NP-specific IFN $\gamma$ -secreting T cells can be measured. Meanwhile, there was a much higher frequency of HA-specific IFN $\gamma$ -secreting T cells in HA-DBV vaccinated mice compared to wt BV vaccinated mice. Similarly, the frequency of HA-pentamer positive CD8<sup>+</sup> T cells was significantly higher in HA-DBV vaccinated mice compared to wt BV vaccinated mice on both day 6 and 9 post-challenge. These data indicated that HA-specific CD8<sup>+</sup> T cells were induced by the HA-DBV vaccine and memory T cells were present in the immunized

mice. Even though cellular immune responses cannot confer sterilizing immunity, they are able to reduce the severity of infection and lower morbidity and mortality rates [47], and antigen-specific memory T cells are able to rapidly respond to a secondary virus infection [45]. Furthermore, cellular immune responses to the conserved epitopes contained in vaccines may provide cross-protective immunity against different subtypes of influenza virus infection [48–50].

Baculoviruses have strong adjuvant activity to promote humoral and cellular immune responses against coadministered antigens, activate dendritic cells maturation, induce the production of cytokines, chemokines, and type I IFNs [41,51–53]. Viral DNA is responsible for the adjuvant properties of BVs [41]. Intranasal vaccination of wt BV can stimulate robust innate immune responses in the respiratory tract that protect mice against lethal doses challenge of mouse-adapted PR8 [52] and H5N1 influenza viruses (data not shown). After two intramuscular immunizations, mice vaccinated with mammalian cell-derived influenza VLPs (1 µg) coadministered with 10<sup>5</sup> pfu live wt BV had HAI titers 1:80–1:320. In contrast, mice vaccinated with the VLPs (1 µg) alone or VLPs with inactivated wt BV did not have detectable HAI titer (data not shown) implying that contaminating BVs may play an important role in the strong immunogenicity of baculovirus vector-derived VLP vaccines [54,55]. In influenza VLPs have been expressed from BV expression system. During the process of removing of contaminating BVs from the influenza VLP preparation may reduce the effectiveness of the influenza VLP vaccine because influenza HA molecules that are displayed on the BV surface, are eliminated from the final product [55]. This might be true for other enveloped VLPs, because envelope proteins from other viruses may be displayed on the surface of BV.

BV cannot replicate in mammalian cells and they are not cytotoxic [56], therefore, the use of BV as a potential adjuvant should be considered. However, similar to other viral vectors, antibodies against BV may prevent its widespread use due to anti-BV antibodies. It is remarkable that low doses (10<sup>3</sup> pfu/mouse) of BVs act as an effective adjuvant [41]. Therefore, reducing BV concentration and elongating vaccination intervals may prevent memory responses to BV administration.

DBVs have several advantages as a vaccine platform. DBVs are easy to generate, grow efficiently without the addition of fetal calf serum, and they are stable under refrigeration. Displayed proteins, expressed from either insect and mammalian cells have similar protein processing and post-translational modifications and they form native structures on the BV surface. The baculovirus genome allows for insertion of large foreign DNA segments or the construction of multivalent vaccines. There is little or no observable cytopathic effect following administration of high doses of BV. Taken together, HA-DBV may be a promising vaccine platform for multiple infectious disease pathogens.

## Acknowledgments

This work was supported by a Department of Defense award W81XWH-07-1-0319 and NIH grant U01AI077771 to TMR. We thank Dr. Matt Welch for providing anti-vp39 monoclonal antibody, Kirsten Schneider-Ohrum, Brendan Giles, and Jared Evans for helpful discussions.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.vaccine.2010.08.040.

## References

- [1] Simonsen L, Taylor TH, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. *The Lancet Infectious Diseases* 2007 Oct;7(10):658–66.
- [2] Blissard GW. Baculovirus–insect cell interactions. *Cytotechnology* 1996;20(1–3):73–93.
- [3] Miller LK. Insect baculoviruses: powerful gene expression vectors. *Bioessays* 1989 Oct;11(4):91–5.
- [4] Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. *Journal of virology* 1993 Dec;67(12):6929–36.
- [5] Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. *Journal of virology* 2001 Jul;75(13):6154–65.
- [6] Gheysen D, Jacobs E, de Foresta F, Thiriart C, Francotte M, Thines D, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. *Cell* 1989 Oct 6;59(1):103–12.
- [7] Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. *Nature biotechnology* 2005 May;23(5):567–75.
- [8] Strauss R, Huser A, Ni S, Tuve S, Kiviati N, Sow PS, et al. Baculovirus-based Vaccination Vectors Allow for Efficient Induction of Immune Responses Against Plasmodium falciparum Circumsporozoite Protein. *Mol Ther* 2007 Jan;15(1):193–202.
- [9] Fan H, Pan Y, Fang L, Wang D, Wang S, Jiang Y, et al. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice. *Journal of virological methods* 2008 Jun;150(1–2):21–6.
- [10] Feng Q, Liu Y, Qu X, Deng H, Ding M, Lau TL, et al. Baculovirus surface display of SARS coronavirus (SARS-CoV) spike protein and immunogenicity of the displayed protein in mice models. *DNA and cell biology* 2006 Dec;25(12):668–73.
- [11] Lin YH, Lee LH, Shih WL, Hu YC, Liu HJ. Baculovirus surface display of sigmaC and sigmaB proteins of avian reovirus and immunogenicity of the displayed proteins in a mouse model. *Vaccine* 2008 Nov 25;26(50):6361–7.
- [12] Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, et al. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. *Virology* 2008 Oct 25;380(2):412–20.
- [13] Yoshida S, Kawasaki M, Hariguchi N, Hirota K, Matsumoto M. A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. *Infection and immunity* 2009 May;77(5):1782–9.
- [14] Boublík Y, Di Bonito P, Jones IM. Eukaryotic virus display: engineering the major surface glycoprotein of the *Autographa californica* nuclear polyhedrosis virus (AcNPV) for the presentation of foreign proteins on the virus surface. *Bio/technology (Nature Publishing Company)* 1995 Oct;13(10):1079–84.
- [15] Oker-Blom C, Airene KJ, Grabherr R. Baculovirus display strategies: Emerging tools for eukaryotic libraries and gene delivery. *Briefings in functional genomics & proteomics* 2003 Oct;2(3):244–53.
- [16] Xu XG, Liu HJ. Baculovirus surface display of E2 envelope glycoprotein of classical swine fever virus and immunogenicity of the displayed proteins in a mouse model. *Vaccine* 2008 Oct 9;26(43):5455–60.
- [17] Jin R, Lv Z, Chen Q, Quan Y, Zhang H, Li S, et al. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of *Bombyx mori*. *PLoS ONE* 2008;3(12):e3933.
- [18] Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. *Journal of virology* 2010 Apr;84(7):3201–9.
- [19] Yang DG, Chung YC, Lai YK, Lai CW, Liu HJ, Hu YC. Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. *Mol Ther* 2007 May;15(5):989–96.
- [20] Peralta A, Molinari P, Conte-Grand D, Calamante G, Taboga O. A chimeric baculovirus displaying bovine herpesvirus-1 (BHV-1) glycoprotein D on its surface and their immunological properties. *Applied microbiology and biotechnology* 2007 May;75(2):407–14.
- [21] Monsma SA, Blissard GW. Identification of a membrane fusion domain and an oligomerization domain in the baculovirus GP64 envelope fusion protein. *Journal of virology* 1995 Apr;69(4):2583–95.
- [22] Oomens AG, Blissard GW. Requirement for GP64 to drive efficient budding of *Autographa californica* multicapsid nucleopolyhedrovirus. *Virology* 1999 Feb 15;254(2):297–314.
- [23] Tani H, Nishijima M, Ushijima H, Miyamura T, Matsuura Y. Characterization of cell-surface determinants important for baculovirus infection. *Virology* 2001 Jan 5;279(1):343–53.
- [24] Liu L, Yu L, Kwang J. Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. *Biochemical and biophysical research communications* 2007 Jun 29;358(2):404–9.
- [25] Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, et al. Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle. *PLoS ONE* 2008;3(1):e1501.
- [26] Wang K, Holtz KM, Anderson K, Chubert R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine. *Vaccine* 2006 Mar 15;24(12):2176–85.

- [27] Chen BJ, Leser GP, Morita E, Lamb RA. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. *Journal of virology* 2007 Jul;81(13):7111–23.
- [28] Crevar CJ, Ross TM. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. *Virology journal* 2008;5:131.
- [29] Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. *PLoS ONE* 2009;4(6):e6032.
- [30] Sakihama T, Sato T, Iwanari H, Kitamura T, Sakaguchi S, Kodama T, et al. A simple detection method for low-affinity membrane protein interactions by baculoviral display. *PLoS ONE* 2008;3(12):e4024.
- [31] Makela AR, Oker-Blom C. The baculovirus display technology—an evolving instrument for molecular screening and drug delivery. *Combinatorial chemistry & high throughput screening* 2008 Feb;11(2):86–98.
- [32] Lindley KM, Su JL, Hodges PK, Wisely GB, Bledsoe RK, Condreay JP, et al. Production of monoclonal antibodies using recombinant baculovirus displaying gp64-fusion proteins. *Journal of immunological methods* 2000 Feb 3;234(1–2):123–35.
- [33] Kitagawa Y, Tani H, Limn CK, Matsunaga TM, Moriishi K, Matsuura Y. Ligand-directed gene targeting to mammalian cells by pseudotype baculoviruses. *Journal of virology* 2005 Mar;79(6):3639–52.
- [34] Rapoport TA. Transport of proteins across the endoplasmic reticulum membrane. *Science (New York, NY)* 1992 Nov 6;258(5084):931–6.
- [35] Li Z, Blissard GW. Functional analysis of the transmembrane (TM) domain of the *Autographa californica* multicausid nucleopolyhedrovirus GP64 protein: substitution of heterologous TM domains. *J Virol* 2008 Apr;82(7):3329–41.
- [36] Lazarovits J, Shia SP, Ktistakis N, Lee MS, Bird C, Roth MG. The effects of foreign transmembrane domains on the biosynthesis of the influenza virus hemagglutinin. *The Journal of biological chemistry* 1990 Mar;265(8):4760–7.
- [37] Schnell MJ, Buonocore L, Boritz E, Ghosh HP, Chernish R, Rose JK. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. *The EMBO journal* 1998 Aug 10;17(5):1289–96.
- [38] Suomalainen M, Liljestrom P, Garoff H. Spike protein-nucleocapsid interactions drive the budding of alphaviruses. *Journal of virology* 1992 Aug;66(8):4737–47.
- [39] Roth MG, Doyle C, Sambrook J, Gething MJ. Heterologous transmembrane and cytoplasmic domains direct functional chimeric influenza virus hemagglutinins into the endocytic pathway. *The Journal of cell biology* 1986 Apr;102(4):1271–83.
- [40] Doyle C, Sambrook J, Gething MJ. Analysis of progressive deletions of the transmembrane and cytoplasmic domains of influenza hemagglutinin. *The Journal of cell biology* 1986 Oct;103(4):1193–204.
- [41] Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. *J Immunol* 2007 Feb 15;178(4):2361–9.
- [42] Abdel-Ghaffar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al. Update on avian influenza A (H5N1) virus infection in humans. *The New England journal of medicine* 2008 Jan 17;358(3):261–73.
- [43] McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. *The New England journal of medicine* 1983 Jul 7;309(1):13–7.
- [44] Graham MB, Braciale TJ. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. *The Journal of experimental medicine* 1997 Dec 15;186(12):2063–8.
- [45] Hikono H, Kohlmeier JE, Ely KH, Scott I, Roberts AD, Blackman MA, et al. T-cell memory and recall responses to respiratory virus infections. *Immunological reviews* 2006 Jun;211:119–32.
- [46] Kedzierska K, La Gruta NL, Turner SJ, Doherty PC. Establishment and recall of CD8+ T-cell memory in a model of localized transient infection. *Immunological reviews* 2006 Jun;211:133–45.
- [47] Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. *Immunity* 1998 Jun;8(6):683–91.
- [48] Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. *Emerging infectious diseases* 2006 Jan;12(1):48–54.
- [49] Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusci V, et al. Evolutionarily conserved protein sequences of influenza A viruses, avian and human, as vaccine targets. *PLoS ONE* 2007;2(11):e1190.
- [50] Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, Schumacher R, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. *The Journal of clinical investigation* 2008 Oct;118(10):3478–90.
- [51] Abe T, Kaname Y, Wen X, Tani H, Moriishi K, Uematsu S, et al. Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. *Journal of virology* 2009 Aug;83(15):7629–40.
- [52] Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. *J Immunol* 2003 Aug 1;171(3):1133–9.
- [53] Nishibe Y, Kaneko H, Suzuki H, Abe T, Matsuura Y, Takaku H. Baculovirus-mediated interferon alleviates dimethylnitrosamine-induced liver cirrhosis symptoms in a murine model. *Gene therapy* 2008 Jul;15(13):990–7.
- [54] Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. *Journal of virology* 2007 Apr;81(7):3514–24.
- [55] Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. *Vaccine* 2005 Dec 30;23(50):5751–9.
- [56] Kenoutis C, Efroze RC, Swevers L, Lavdas AA, Gaitanou M, Matsas R, et al. Baculovirus-mediated gene delivery into mammalian cells does not alter their transcriptional and differentiating potential but is accompanied by early viral gene expression. *Journal of virology* 2006 Apr;80(8):4135–46.

# APPENDIX 3

*Baculovirus-produced Influenza Virus-like Particles  
in Mammalian Cells Protect Mice from Lethal  
Influenza Challenge*

*2011. Viral Immunol. 24:1-9*

*Tang, X-C, Lu, H-R, Ross, TM*



## Baculovirus-Produced Influenza Virus-like Particles in Mammalian Cells Protect Mice from Lethal Influenza Challenge

Xian-Chun Tang,<sup>1,2</sup> Hai-Rong Lu,<sup>1</sup> and Ted M. Ross<sup>1,2</sup>

### Abstract

Influenza virus-like particles (VLPs) are effective vaccines against influenza infection, which can be produced either in insect cells by recombinant baculovirus (BV) infection or in mammalian cells by DNA plasmid transfection. However, VLPs produced from baculovirus/insect cells are difficult to purify due to baculovirus contamination; VLPs produced by plasmid transfection are limited by scale-up capability. In this study, a BacMam BV, in which three CMV-promoters drive the hemagglutinin, neuraminidase, and matrix of influenza virus was constructed. This baculovirus can deliver these genes into mammalian cells/hosts and subsequently influenza VLPs can be produced and secreted from transduced cells. Transduction conditions were optimized and influenza VLPs were purified from transduced 293T cells. Mice were vaccinated with BV transduction-produced VLPs, plasmid transfection-produced VLPs, and BacMam BV. Two vaccinations of each vaccine induced high hemagglutination-inhibition (HAI) titers and prevented influenza virus infection. In contrast, following a single vaccination, all mice vaccinated with each vaccine had significantly lower lung viral titers compared to unvaccinated mice. Remarkably, mice vaccinated with a single dose of BV transduction-produced VLPs survived challenge, whereas mice vaccinated with one dose of BacMam BV- or plasmid transfection-produced VLPs had 60–80% survival. This finding is particularly significant for producing easily purified VLPs. The BacMam system is an alternative strategy for VLP production, which is easy to scale up and purify. Besides, BacMam BV can be used as a gene delivery vector to produce VLPs *in vivo*, to stimulate immune responses.

### Introduction

**I**NFLUENZA INFECTION IS A MAJOR THREAT TO HUMAN HEALTH. Vaccination is still the best method to prevent influenza infection. Current influenza vaccines are produced in embryonated chicken eggs, but the efficiency of this method is limited. New strategies for influenza vaccines have focused on the development of cell culture-based production. Virus-like particles (VLPs) are a promising vaccine approach because they stimulate both humoral and cellular immune responses (1–3). Influenza VLPs can be readily produced in insect or mammalian cells via the simultaneous expression of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins (4). The baculovirus expression vector system (BEVS) has been widely used to produce VLPs for a variety of viruses due to its high expression level, eukaryotic processing feature, and scale-up capability (5). In the last decade, various influenza VLPs have been produced with the baculovirus/insect cell expression system (6–10). However, separating progeny

baculovirus particles from the influenza VLPs is still the biggest challenge for this vaccine approach because baculoviruses, which replicate efficiently in insect cells ( $>10^8$  pfu/mL), are similar in size to influenza VLPs (6,10). Another method of producing influenza VLPs is co-transfection of plasmids encoding HA, NA, and M1 genes of influenza virus into mammalian cells (4). This method produces VLPs that are easily purified, but this strategy is inefficient, expensive, and difficult to scale up.

In 1983, Volkman *et al.* found that baculovirus infected 35 vertebrate cell lines, but without detectable baculovirus replication (11). Subsequently, mammalian cells transduced by baculovirus could efficiently express some proteins under the transcriptional control of mammalian promoters (12–14). Many cell types can be transduced by baculovirus, including cell lines derived from human, non-human primate, rabbit, rodent, porcine, bovine, and fish hosts (15). In addition, baculovirus can transduce non-dividing cells (16) and primary cells *in vivo* (17). Recombinant baculoviruses containing

<sup>1</sup>Center for Vaccine Research and <sup>2</sup>Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.

mammalian expression cassettes are referred to as BacMam baculoviruses. Due to their high efficiency and low cytotoxicity during the gene delivery process, BacMam baculoviruses have been used as novel vectors for gene therapy and vaccine development (18–24).

In this study, we constructed a BacMam baculovirus containing HA, NA, and M1 expression cassettes that were driven by cytomegalovirus (CMV) promoters. We speculated that BacMam baculoviruses would deliver these influenza genes into mammalian cells and result in the production of influenza VLPs. Since baculoviruses cannot replicate in mammalian cells, this strategy would not produce any baculovirus particles during influenza VLP production. After transduction of mammalian cells *in vitro*, we found that influenza VLPs can be easily generated and purified. In addition, since BacMam baculoviruses can transduce primary cells *in vivo* without cytotoxicity, these baculoviruses can potentially be used as a safe gene delivery vector to produce influenza VLP *in vivo*. Mice were immunized with purified VLPs produced from baculovirus-transduced mammalian cells, or directly immunized with this BacMam baculovirus. Both induced influenza-specific immune responses and provided mice sterilizing protection against influenza challenge.


## Materials and Methods

### Cells and viruses

*Spodoptera frugiperda* (Sf9) cells were propagated at 28 °C in Sf-900II serum-free medium (Invitrogen, Carlsbad, CA). Cells were infected by recombinant baculoviruses at a multiplicity of infection (MOI) of 0.1–1.0, and virus supernatants were collected 4 d post-infection. The influenza virus used in this study was a mouse-adapted influenza virus, A/Puerto Rico/8/1934 (PR8, H1N1).

### Plasmids and recombinant baculovirus construction

In order to construct multiple genes expressing recombinant baculoviruses, pFastBac Dual plasmid (Invitrogen) was modified to contain two CMV promoters (p2CMV) and two multiple cloning sites based on a vector we previously modified (25). CMV promoter and HSV tk/SV40 poly A signal sequences were amplified by overlapping PCR and inserted into the pFastBac vector backbone. At the same time two compatible restriction sites (*Asc* I and *Mlu* I) were introduced into p2CMV as shown in Fig. 1A and Supplementary Fig. 1 (see online supplementary material at <http://www.liebertonline.com>). The M1 gene segment from PR8 was



**FIG. 1.** Construction of five-unit transfer vector that can express influenza HA, NA, and M1, as well as GFP and VSVG. (A) Dual-CMV promoters transfer vector with two multiple cloning sites, two compatible restriction sites (*Asc* I and *Mlu* I), and two polyA signal sequences (HSV tk and SV40 pA). (B) Stepwise construction of pVLP/GFP/VSVG. The fragment containing HA and GFP was excised using *Asc* I and *Avr* II, and ligated into the compatible sites of pNA/M1 to obtain a four-unit plasmid, pVLP/GFP. VSVG was excised using *Mlu* I and *Avr* II and ligated into pVLP/GFP to get the five-unit plasmid pVLP/GFP/VSVG.

codon optimized for mammalian cell expression and synthesized by GENEART (Regensburg, Germany). HA and NA of the PR8 virus, green fluorescent protein (GFP), and vesicular stomatitis virus glycoprotein (VSVG) genes were amplified by PCR. A flag tag was added at the C-terminal of NA. Transfer vectors were constructed as indicated in Fig. 1B. Briefly, NA and MI were cloned into one p2CMV vector, and HA and EGFP were cloned into another p2CMV; then the fragment containing HA and GFP was excised using *Asc* I and *Avr* II, and ligated into the compatible sites of pNA/MI to obtain the four-unit plasmid pSVP/GFP; VSVG was cloned into another vector, p2PH (25), then excised with *Mlu* I and *Avr* II and ligated into pSVP/GFP to get plasmid pSVP/GFP/VSVG. All recombinant baculoviruses (BV-HA/GFP, BV-VLP/GFP, and BV-VLP/GFP/VSVG) were generated using the Bac-to-Bac system (Invitrogen). The recombinant virus selection and amplification were performed following standard protocols.

#### Purification of recombinant baculoviruses

The recombinant baculoviruses were produced by infecting Sf9 cells at an MOI of 0.1. Supernatants were collected 4 d after infection and were clarified by centrifugation at 3000 g for 10 min at 4 °C to remove cell debris. Viral particles were precipitated via ultracentrifugation (27,000 rpm using a Sorvall SW28 rotor) for 4 h at 4 °C. The pellets were subsequently resuspended in phosphate-buffered saline (PBS) and stored at 4 °C. The viral titer was determined using the BacPAK Baculovirus Rapid Titer Kit (Clontech, Mountain View, CA) and was expressed as infectious units per milliliter (ifu/mL).

#### Optimization of baculovirus transduction

To optimize the transduction efficiency, human embryonic kidney cells (293T) were seeded onto 6-well plates at a density of  $5 \times 10^5$  cells/well in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and incubated at 37 °C overnight. Before transduction, the medium was removed and the cells were washed twice with PBS. The cells were transduced with BV-VLP/GFP or BV-VLP/GFP/VSVG at different MOI (20, 40, 60, 80, and 100) in 0.5 mL PBS. The cells were incubated at 28 °C for a range of periods (1, 2, 4, 6, and 8 h). Following incubation, the viral inocula were removed, followed by two washes with PBS, and then 2 mL complete DMEM (cDMEM) with or without 5 mM sodium butyrate (Sigma-Aldrich, St. Louis, MO) were added. The transduced cells were cultured at 37 °C for 72 h. To compare baculovirus transduction and plasmid transfection, 293T cells were seeded onto 6-well plates at a density of  $1 \times 10^6$  cells/well in cDMEM and incubated at 37 °C overnight. The cells were transfected with 1 µg plasmid pVLP/GFP and 5 µL lipofectamine 2000 in 0.5 mL OPTI-MEM (Invitrogen). After 5 h incubation at 37 °C, the transfection medium was replaced with 2 mL cDMEM. The cells were cultured at 37 °C for 72 h. The expression of GFP was monitored daily by fluorescence microscopy.

#### Western blot and hemagglutination assays for VLP production

Supernatants from transduced or transfected cells were harvested after 72 h of culture and were clarified by centrifugation at 3000 g for 10 min at 4 °C to remove cell debris. The supernatants were subjected to Western blot analysis. The

supernatants from BV-VLP transduced or pVLP-transfected 293T cells were examined for functional VLPS by hemagglutination assay. Briefly, 50 µL of serial twofold dilutions were prepared in PBS, followed by incubation with 50 µL of 1% turkey red blood cells (tRBCs; Lampire Biologicals, Pipersville, PA) at 25 °C for 30 min. The extent of hemagglutination was inspected visually, and the highest dilution capable of agglutinating red blood cells was determined.

#### VLP production and purification

293T cells were transduced with BV-VLP/GFP/VSVG in PBS at an MOI of 60. The transduced cells were cultured in cDMEM containing 5 mM sodium butyrate for 72 h at 37 °C. The VLP produced from baculovirus transduction was represented VLP-BV. Another VLP produced following transient transfection was used as a control. Briefly, 293T cells were transiently transfected with a plasmid (pVLP) encoding MI, NA, and HA of PR8 virus, and incubated for 72 h at 37 °C. Culture supernatants (200 mL) from transduced or transfected cells were collected and were clarified by centrifugation at 3000 g for 10 min at 4 °C to remove cell debris. VLPS were precipitated via ultracentrifugation as described above. The pellets were resuspended in 1 mL PBS and loaded onto 20–60% sucrose gradients, and sedimented by ultracentrifugation for 18 h at 27,000 rpm at 4 °C. Fractions containing influenza VLPS were collected and diluted in PBS followed by ultracentrifugation again. The pellets were resuspended in PBS and stored at 4 °C. Baculovirus residues were checked with the BacPAK Baculovirus Rapid Titer Kit. Protein concentration was determined by bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, IL). All VLPS used in this study were based on total protein. The hemagglutination titer of VLPS was examined with an HA assay.

#### Mouse immunization and challenge

Female BALB/c mice (6–8 wk old) were purchased from Harlan Sprague Dawley (Indianapolis, IN). The mice (8 groups, 10 mice per group) were vaccinated: (1) once or twice with 3 µg VLP-BV representing VLPS derived from BV-VLP/GFP/VSVG transduction; (2) once or twice with 3 µg VLP-tsif representing VLP derived from pVLP transfection; (3) once or twice with  $1 \times 10^8$  ifu BV-VLP representing purified BV-VLP/GFP/VSVG; (4) twice with  $1 \times 10^8$  ifu BV representing purified wild-type baculovirus; and (5) with PBS. All vaccines were administered intramuscularly to the mice without any adjuvants.

For virus challenge, ketamine-anesthetized mice were intranasally infected with 1500 pfu of A/PR/8/1934 virus (equivalent to  $10 \times$  the 50% lethal dose [ $LD_{50}$ ]) in 50 µL of PBS at 3 wk after the final immunization. For measurement of virus replication in the lungs, five mice from each group were sacrificed on day 3 post-challenge. The other five mice were monitored daily for clinical signs of influenza infection (i.e., weight loss, ruffling fur, or inactivity) and body weight was recorded each day. Mice that lost greater than 20% of body weight were euthanized.

#### Hemagglutination inhibition (HAI) titer in sera and viral titer in lungs

Blood samples were collected from anesthetized mice via retro-orbital plexus puncture at 2 wk after each immunization.

After the blood samples were clotted and centrifuged, serum samples were collected. The HAI assay was used to assess the functional antibodies to HA able to inhibit agglutination of erythrocytes as previously described (3).

Three days after challenge, five mice from each group were euthanized. The lungs were harvested and were homogenized by passing them through a cell strainer (BD Biosciences, Bedford, MA) in 1 mL of PBS. The homogenates were centrifuged at 1000×g for 10 min. The lung supernatants were collected for plaque assay on Madin-Darby canine kidney (MDCK) cells as previously described (3).


## Results

### Optimization of transduction conditions

Previous studies reported that many factors affect the efficiency of baculovirus transduction, including cell lines, transduction medium, incubation time, MOI, VSVG, and sodium butyrate (26–28). Initially, we investigated the protein expression after baculovirus transduction in several cell lines, such as Vero, HeLa, MDCK, HEK293, and 293T, and found that 293T is the most susceptible cell line and yields the highest protein expression (data not shown). As previously reported, PBS had the highest transduction efficiency as the transduction medium (26). Two hours is long enough for baculovirus transduction into 293T cells. Therefore, transduction was conducted in PBS for 2 h followed by two

washes with PBS or DMEM. Then, the effect of MOI was investigated by transducing 293T cells with BV-VLP/GFP at different MOIs. Following 72 h of incubation, supernatants were harvested and NA expression was determined by Western blot (Fig. 2A). The intensity of each band in the Western blot was analyzed with ImageJ software (<http://rsb.info.nih.gov/ij/index.html>) (29). NA expression increased with higher MOI, and saturated at MOI greater than 60. Therefore, we used MOI of 60 for further investigation.

Previous studies demonstrated that VSVG can affect baculovirus transduction both *in vitro* and *in vivo* (30), and sodium butyrate can enhance gene expression in baculovirus-transduced cells (28). Therefore, the effects of VSVG and butyrate on baculovirus transduction of 293T cells were examined. At MOI of 60, 293T cells were transduced with BV-VLP/GFP or BV-VLP/GFP/VSVG. After transduction, the cells were cultured with or without sodium butyrate. Under the same transduction and culture conditions, the cells transduced with BV-VLP/GFP/VSVG showed a higher level of fluorescence intensity than with BV-VLP/GFP, indicating that these cells were more efficiently transduced (Fig. 2B and C) (30). Furthermore, the addition of 5 mM sodium butyrate enhanced GFP expression (Fig. 2C and D). In addition, plasmid transfection results in a high level of GFP expression (Fig. 2E), but the cells transfected with DNA plasmid had more dead/dying cells compared to cells transduced with baculovirus (Fig. 2F and G) (31).



**FIG. 2.** Optimization of BV transduction conditions. (A) 293T cells were transduced with different MOIs of BV-VLP/GFP. NA expression was analyzed by Western blot probed with flag-tag antibody. The intensity of bands was analyzed with ImageJ software. The first lane (MOI = 20) was used as baseline. (B) 293T cells transduced with BV-VLP/GFP at MOI = 50, no sodium butyrate. (C) 293T cells transduced with BV-VLP/GFP/VSVG at MOI = 50, no sodium butyrate. (D and F) 293T cells transduced with BV-VLP/GFP/VSVG at MOI = 50, with 5 mM sodium butyrate. (E and G) 293T cells transfected with pVLP/GFP (1  $\mu$ g DNA/10<sup>6</sup> cells). Round and gray cells in E and G are dead/dying cells. Color images available online at [www.liebertonline.com/vim](http://www.liebertonline.com/vim)

### Influenza VLP production

To investigate whether the HA, NA, and M1 can be expressed simultaneously in baculovirus-transduced or plasmid-transfected mammalian cells, 293T cells were transduced with BV-VLP/GFP/VSVG at an MOI of 60, or transfected with pVLP/GFP. As shown in Fig. 3A, three bands corresponding to the molecular weights of HA, NA, and M1 were detected in the supernatants of BV-VLP/GFP/VSVG-transduced and pVLP/GFP-transfected cells, but not in the supernatant of wild-type BV-transduced cells.

HA on viral particles or VLPs has the ability to agglutinate red blood cells, while soluble HA cannot agglutinate RBCs, and the hemagglutination titer can reflect the concentration of viral particles (32). Therefore, the functional VLPs can be examined by hemagglutination assay. The supernatants from 293T cells transduced with BV-VLP without VSVG had no detectable HA titer (Fig. 3B). However, the addition of VSVG in BacMam BV increased the HA titer to 1:8. The addition of 5 mM sodium butyrate to the culture medium increased the HA titer to 1:128, which was 4 times higher than 293T cells directly transfected with plasmid pVLP/EGFP. In addition, following sucrose gradient purification, there was no detectable baculovirus in the purified VLP products by plaque assay, although baculovirus DNA could be detected by PCR (data not shown).

### Analysis of the immune response

The immunogenicity of purified VLPs and BacMam baculovirus were examined in BALB/c mice by intramuscular injection at week 0 and/or 3. Serum samples were collected 2 wk after each vaccination (weeks 2 and 5), and evaluated for the ability to inhibit influenza virus-induced hemagglutination of tRBCs (HAI), which is a main indicator for the HA-specific immune response. The seroprotection rate (defined as the percentage of subjects with an HAI titer  $\geq 1:40$ ) is a well-accepted criterion for the evaluation of influenza vaccine efficacy. A seroprotection rate  $>70\%$  is one requirement for an influenza vaccine, according to the EU Committee for Human Medicinal Products (CHMP) (33).

After one immunization with VLP-BV, 80% of mice had detectable HAI titers ( $\geq 1:10$ ) against PR8 virus; 35% of mice had an HAI titer  $\geq 1:40$ . After one immunization with VLP-tsf, 35% of mice had detectable HAI titers, while none had an HAI titer  $\geq 1:40$ . After one immunization with BV-VLP, 50% of mice had detectable HAI titers, while 10% of mice had an HAI titer  $\geq 1:40$ . After the second vaccination, a significant rise in HAI titers of all immunized mice could be observed. The average HAI titers of mice vaccinated with VLP-BV, VLP-tsf, and BV-VLP were 1:240, 1:100, and 1:112, respectively (Fig. 4). The seroprotection rates for all three vaccines ranged between 80 and 100%, and met the CHMP requirement for immunogenicity. Remarkably, mice




FIG. 3. VLP production from BV transduction or plasmid transfection. (A) Western blot assay of VLP produced from BV transduction (with BV-VLP/GFP/VSVG and sodium butyrate) and plasmid transfection. Mouse anti-PR8 HA polyclonal antibody (1:1000), mouse anti-flag tag monoclonal antibody (1:5000; Sigma-Aldrich), and mouse anti-M1 monoclonal antibody (1:200; AbD Serotec, Raleigh, NC) were mixed for detecting PR8 HA, NA, and M1 in one blot. (B) Hemagglutination activity of VLP produced by plasmid transfection ( $1 \mu\text{g DNA}/10^6$  cells) or BV-VLP transduction (MOI = 60). Color images available online at [www.liebertonline.com/vim](http://www.liebertonline.com/vim)




FIG. 4. Hemagglutination-inhibition (HAI) titers. Mice were immunized once ( $1^\circ$ ) or twice ( $2^\circ$ ) intramuscularly with VLP derived from BV transduction (VLP-BV), VLP derived from plasmid transfection (VLP-tsf), BV producing PR8 VLP (BV-VLP), wild-type BV (wt BV), and PBS at a 3-week interval (10 mice/group). Blood samples were taken 2 wk after each vaccination. Serum HAI antibody titers were assessed against PR8 virus. Bars indicate geometric mean titer (GMT)  $\pm$  SEM.

vaccinated with VLP-BV had significantly higher HAI titers compared to mice vaccinated with VLP-tsf, after both priming and boosting immunization. As expected, all mice vaccinated with wt BV and mock vaccinated had no detectable HAI titers.

#### Protection from lethal viral challenge

To evaluate the protective efficacy of each vaccine, all vaccinated mice were challenged intranasally with a lethal dose of mouse-adapted PR8 virus. Lung viral titers were determined at day 3 post-challenge. Mice vaccinated with wt BV or PBS had high viral lung titers ( $\sim 1 \times 10^6$  pfu/mL), while the mice that received only one vaccination with VLP-BV, VLP-tsf, or BV-VLP had significantly lower viral lung titers ( $2 \times 10^4$  to  $2 \times 10^5$  pfu/mL) (Fig. 5). There were no significant differences between the three different vaccines. All mice that received two vaccinations had undetectable viral titers ( $< 10$  pfu/mL) in their lungs.

All mice vaccinated with wt BV or PBS had signs of morbidity (e.g., ruffling fur, shivering, and inactivity), and had lost greater than 20% of their original body weight by days 8–9 post-challenge (Fig. 6). All mice vaccinated once with VLP-BV were protected with an average of 7% weight loss (open triangles in Fig. 6). Eighty percent of mice vaccinated once with VLP-tsf were protected against influenza challenge, and 60% of mice vaccinated with BV-VLP were protected, even though some mice showed signs of sickness. However, all mice survived without any signs of sickness or weight loss following two vaccinations with VLP-BV, VLP-tsf, or BV-VLP.

#### Discussion

VLPs mimic the overall structure of parental virus particles without packaging infectious genetic material (34). It is a

promising approach to the production of vaccines due to its low risk and high immunogenicity (35). VLP vaccines have been produced from yeast-, insect-, mammalian-, and plant-based systems for a variety of viral pathogens (5). VLPs produced from mammalian cells have several advantages, such as ease of purification and similar post-translational modifications and cytoplasmic trafficking processes as wild-type viruses. However, mammalian-based production systems are hampered by high costs and difficulties with production scale-up. The use of yeast and insect expression systems are inexpensive and relatively easy to scale-up, but the VLP purification is always a challenge because VLPs produced in yeast cells are usually not secreted, and VLPs produced in insect cells are accompanied by baculovirus particles (10,36). Baculoviruses are rod-shaped particles roughly 70 nm  $\times$  320 nm in size (37,38), which are similar in size to influenza virions. Many methods have been developed to improve the purification of VLPs derived from baculovirus/insect-cell systems, including density-gradient ultracentrifugation, size-exclusion chromatography, and affinity chromatography. These methods are efficiently purifying some small, non-enveloped VLPs, such as norovirus (38 nm) and human papillomavirus (40–50 nm) (5,39), but they are not efficient for other larger VLPs, such as HIV (100–120 nm) or influenza VLPs (80–120 nm) (6,40–42).

In this study, we developed a new strategy to produce influenza VLPs in mammalian cells with baculovirus vector. BacMam baculoviruses can be produced using a standard method in insect cells. Gene expression in transduced cells can last over 16 days (43). Due to its rapid and facile gene expression in various mammalian cells, the BacMam system has been used as a substitute for direct plasmid transfection (44). Influenza VLPs can be produced by simultaneously expressing HA, NA, and M1 in insect/mammalian cells. To




FIG. 5. Virus titers in lungs at day 3 post-challenge. Mice were immunized once (1°) or twice (2°) intramuscularly with VLP-BV, VLP-tsf, BV-VLP, wt BV, and PBS. At week 3 after the last immunization, the immunized mice were intranasally infected with a lethal dose of mouse-adapted PR8 virus (10 LD<sub>50</sub>). Lung samples from individual mice in each group (five mice per group) were collected on day 3 post-challenge, and each sample was diluted in 1 mL PBS. The titers are presented as log<sub>10</sub> pfu per mL (\*\**p* < 0.01 compared with the wt BV 2° and PBS groups).

ensure gene uptake and expression in target cells, we developed a new BacMam baculovirus carrying all information necessary to induce influenza VLP production. The resulting constructs, BV-VLP/EGFP and BV-VLP/EGFP/VSVG, allowed for the production of influenza VLPs. Transduction efficiency was optimized and VLP production was characterized. Since baculovirus cannot replicate in mammalian cells as it does in insect cells (11), the purification of VLPs

produced from the BacMam system is much easier than VLPs produced from insect cells. The BacMam system is also easy to scale up by using bioreactors such as the baculovirus/insect-cell expression system (44). Therefore, the BacMam system combines the advantages of both baculovirus/insect cell expression and DNA plasmid transfection methods: it is inexpensive, rapid, and facile for experiments for gene overexpression, and is easy to scale up and purify. Of




FIG. 6. Protection of mice from lethal PR8 challenge. Mice were immunized once (1°) or twice (2°) intramuscularly with VLP-BV, VLP-tsf, BV-VLP, wt BV, and PBS. At week 3 after the final immunization, the mice were intranasally infected with a lethal dose of mouse-adapted PR8 virus (10 LD<sub>50</sub>) (five mice per group). The mice were monitored daily for 13 d. (A) Percent survival after challenge. (B) Body weight changes after challenge.

course, there are also some limitations, such as repetitious washing of transduced cells that would be labor-intensive for suspension culture; two-tiered banking systems for both mammalian and insect cells are needed to implement this strategy.

Vaccination of mice with *in vitro*-produced influenza VLPs or with BacMam BV induced equally high antibody responses following two vaccinations (HAI titers 1:20–1:640). Remarkably, VLPs produced via BV transduction induced significantly higher HAI titers than VLPs produced via plasmid transfection (Fig. 4). This effect may be because VLPs produced via plasmid transfection contain a higher content of cellular proteins. During direct transfection of culture cells with plasmids, the transfection reagents are potentially cytotoxic, which may result in a high degree of cell death and subsequent cell debris contamination of the VLP preparation. However, the BacMam BV transduction process is not associated with cytotoxicity, even at high MOI (>500) (31). At equal protein concentrations, the VLPs produced via BV transduction have 2–4 times higher HA titers than VLPs produced via plasmid transfection, suggesting a higher portion of influenza VLPs with functional HA on the particles compared to VLPs produced via plasmid transfection. An additional reason could be that baculovirus DNA may remain in the VLP products derived from the BacMam system, which could serve as adjuvant for this vaccine. Baculovirus has strong adjuvant effects even at low concentrations ( $10^3$  pfu), and baculoviral DNA, but not protein, has adjuvant activity (45). We found that baculovirus DNA was detectable by PCR from the purified VLPs, although no baculovirus could be detected by plaque assay (data not shown).

To evaluate the protection induced by VLP vaccines, all vaccinated mice were challenged with a homogeneous, mouse-adapted influenza virus (A/PR/8/1934), administered at a lethal dose. The viral clearance in lungs provides a sensitive indicator for assessing protective efficacy. At 3 d post-challenge, all mice in the control groups showed high lung viral titers. Mice vaccinated two times with VLP-BV, VLP-tsfc, and BV-VLP had no detectable virus post-challenge. Mice receiving one vaccination had two- to 50-fold reductions in viral lung titers compared to unvaccinated or wt BV vaccinated mice (Fig. 5). These results indicate that for all three vaccines, two vaccinations can induce strong immune responses that are sufficient to prevent infection. In contrast, one vaccination reduces viral replication, but does not prevent infection. As for the protection seen after one vaccination, the results indicated that one vaccination with VLP-BV provided 100% protection, while one vaccination with VLP-tsfc or BV-VLP conferred 80% and 60% protection, respectively. Although BV-VLP is a little less effective in protection compared to other VLPs, it is still a promising vaccine strategy because of its ease of scale-up. Since BV cannot infect mammals and does not cause cytopathic effects (11,18), safety issues are greatly reduced. Of course, more studies are needed to address its safety. Better protection should be achievable by giving higher doses. Recently, it was demonstrated that high doses of BV delivering influenza HA protected chickens against avian influenza virus challenge, while a low dose did not elicit protection (21). Therefore, protection with a single vaccination would be expected if a higher dose of VLP-tsfc or BV-VLP is administered.

When considered together with previous data, the results of our current studies suggest that BacMam system-derived influenza VLPs represent a promising and safe vaccine candidate for protection against influenza infections. Due to its low cytotoxicity and high gene delivery efficiency, the BacMam baculovirus represents a significant advance, and it is a promising alternative vaccine strategy. The major drawback of directly using BV as a gene delivery vector is that it can induce immune responses against the BV vector, which will limit the repeat use of this vector. Future studies to evaluate the potential benefits of using this strategy in controlling other infectious diseases are needed.

### Acknowledgments

This project was funded in part by a grant from the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations, or conclusions. We thank Dr. Jared D. Evans for helpful suggestions.

### Author Disclosure Statement

No competing financial interests exist.

### References

- Pinto LA, Edwards J, Castle PE, *et al.*: Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. *J Infect Dis* 2003;188:327–338.
- Emeny RT, Wheeler CM, Jansen KU, *et al.*: Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. *J Virol* 2002;76:7832–7842.
- Ross TM, Mahmood K, Crevar CJ, *et al.*: A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. *PLoS One* 2009;4:e6032.
- Haynes JR: Influenza virus-like particle vaccines. *Exp Review Vaccines* 2009;8:435–445.
- Grgacic EV, and Anderson DA: Virus-like particles: passport to immune recognition. *Methods* 2006;40:60–65.
- Pushko P, Tumpey TM, Bu F, *et al.*: Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. *Vaccine* 2005;23:5751–5759.
- Quan FS, Huang C, Compans RW, and Kang SM: Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. *J Virol* 2007;81:3514–3524.
- Bright RA, Carter DM, Daniluk S, *et al.*: Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. *Vaccine* 2007;25:3871–3878.
- Bright RA, Carter DM, Crevar CJ, *et al.*: Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. *PLoS One* 2008;3:e1501.
- Haynes JR, Dokken L, Wiley JA, *et al.*: Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. *Vaccine* 2009;27:530–541.
- Volkman LE, and Goldsmith PA: *In vitro* survey of auto-grapha californica nuclear polyhedrosis virus interaction



- with nontarget vertebrate host cells. *Appl Environmental Microbiol* 1983;45:1085-1093.
12. Carbonell LF, Klowden MJ, and Miller LK: Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells. *J Virol* 1985;56:153-160.
  13. Hofmann C, Sandig V, Jennings G, *et al.*: Efficient gene transfer into human hepatocytes by baculovirus vectors. *Proc Natl Acad Sci USA* 1995;92:10099-10103.
  14. Boyce FM, and Bucher NL: Baculovirus-mediated gene transfer into mammalian cells. *Proc Natl Acad Sci USA* 1996;93:2348-2352.
  15. Kost TA, and Condreay JP: Recombinant baculoviruses as mammalian cell gene-delivery vectors. *Trends Biotechnol* 2002;20:173-180.
  16. van Loo ND, Fortunati E, Ehlert E, *et al.*: Baculovirus infection of nondividing mammalian cells: mechanisms of entry and nuclear transport of capsids. *J Virol* 2001;75:961-970.
  17. Sarkis C, Serguera C, Petres S, *et al.*: Efficient transduction of neural cells *in vitro* and *in vivo* by a baculovirus-derived vector. *Proc Natl Acad Sci USA* 2000;97:14638-14643.
  18. Pieroni L, and La Monica N: Towards the use of baculovirus as a gene therapy vector. *Curr Opin Molec Therapeutics* 2001;3:464-467.
  19. Chuang CK, Sung LY, Hwang SM, *et al.*: Baculovirus as a new gene delivery vector for stem cell engineering and bone tissue engineering. *Gene Therapy* 2007;14:1417-1424.
  20. Boulaire J, Zhao Y, and Wang S: Gene expression profiling to define host response to baculoviral transduction in the brain. *J Neurochem* 2009;109:1203-1214.
  21. Wu Q, Fang L, Wu X, *et al.*: A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. *Molec Immunol* 2009;46:2210-2217.
  22. Facciabene A, Aurisicchio L, and La Monica N: Baculovirus vectors elicit antigen-specific immune responses in mice. *J Virol* 2004;78:8663-8672.
  23. Strauss R, Huser A, Ni S, *et al.*: Baculovirus-based vaccination vectors allow for efficient induction of immune responses against *Plasmodium falciparum* circumsporozoite protein. *Mol Ther* 2007;15:193-202.
  24. Tani H, Abe T, Matsunaga TM, *et al.*: Baculovirus vector for gene delivery and vaccine development. *Future Virol* 2008;3:35-43.
  25. Tang XC, Lu HR, and Ross TM: Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. *Vaccine* 2010;28:6821-6831.
  26. Hsu CS, Ho YC, Wang KC, and Hu YC: Investigation of optimal transduction conditions for baculovirus-mediated gene delivery into mammalian cells. *Biotechnol Bioengineering* 2004;88:42-51.
  27. Tani H, Limn CK, Yap CC, *et al.*: *In vitro* and *in vivo* gene delivery by recombinant baculoviruses. *J Virol* 2003;77:9799-9808.
  28. Condreay JP, Witherspoon SM, Clay WC, and Kost TA: Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. *Proc Natl Acad Sci USA* 1999;96:127-132.
  29. Abramoff M, Magelhaes P, and Ram S: Image Processing with ImageJ. *Biophotonics International* 2004;11:36-42.
  30. Barsoum J, Brown R, McKee M, and Boyce FM: Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein. *Human Gene Ther* 1997;8:2011-2018.
  31. Kenoutis C, Efrose RC, Swevers L, *et al.*: Baculovirus-mediated gene delivery into mammalian cells does not alter their transcriptional and differentiating potential but is accompanied by early viral gene expression. *J Virol* 2006;80:4135-4146.
  32. Killian ML: Hemagglutination assay for the avian influenza virus. *Methods Molec Biology* 2008;436:47-52.
  33. 1997 Committee for Human Medicinal Products: Note for Guidance on Harmonisation of Requirements for Influenza Vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medicinal Products.
  34. Ludwig C, and Wagner R: Virus-like particles-universal molecular toolboxes. *Curr Opin Biotechnol* 2007;18:537-545.
  35. Roy P, and Noad R: Virus-like particles as a vaccine delivery system: myths and facts. *Human Vaccines* 2008;4:5-12.
  36. Shiosaki K, Takata K, Nishimura S, *et al.*: Production of hepatitis B virion-like particles in yeast. *Gene* 1991;106:143-149.
  37. Robertson JS, Harrap KA, and Longworth JF: Baculovirus morphogenesis: the acquisition of the virus envelope. *J Invertebrate Pathol* 1974;23:248-251.
  38. Vicente T, Peixoto C, Carrondo MJ, and Alves PM: Purification of recombinant baculoviruses for gene therapy using membrane processes. *Gene Therapy* 2009;16:766-775.
  39. Garland SM, Hernandez-Avila M, Wheeler CM, *et al.*: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med*. 2007;356:1928-1943.
  40. Rueda P, Fominaya J, Langeveld JP, *et al.*: Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. *Vaccine* 2000;19:726-734.
  41. Kosukegawa A, Arisaka F, Takayama M, *et al.*: Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. *Biochimica Biophysica Acta* 1996;1290:37-45.
  42. Hu YC, Bentley WE, Edwards GH, and Vakharia VN: Chimeric infectious bursal disease virus-like particles expressed in insect cells and purified by immobilized metal affinity chromatography. *Biotechnol Bioengineering* 1999;63:721-729.
  43. Hu YC, Tsai CT, Chang YJ, and Huang JH: Enhancement and prolongation of baculovirus-mediated expression in mammalian cells: focuses on strategic infection and feeding. *Biotechnol Progress* 2003;19:373-379.
  44. Scott MJ, Modha SS, Rhodes AD, *et al.*: Efficient expression of secreted proteases via recombinant BacMam virus. *Protein Expression Purification* 2007;52:104-116.
  45. Hervas-Stubbs S, Rueda P, Lopez L, and Leclerc C: Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. *J Immunol* 2007;178:2361-2369.

Address correspondence to:

Dr. Ted M. Ross  
9047 Biomedical Science Tower 3  
3501 Fifth Avenue  
Pittsburgh, PA 15261

E-mail: tmr15@pitt.edu

Received March 3, 2011; accepted April 7, 2011.

# **APPENDIX 4**

*Dengue Virus*

*2010. Clin Lab Med. 30(1):149-160*

*Ross, TM*

## Dengue virus

Ted M. Ross, Ph.D.

Associate Professor, Center for Vaccine Research and Department of Microbiology and Molecular Genetics,  
University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Corresponding author for proof and reprints:

Ted M. Ross, Ph.D.  
Center for Vaccine Research  
Department of Microbiology and Molecular Genetics  
9047 BST3  
3501 Fifth Avenue  
Pittsburgh, PA 15261  
Tel: (412) 648-8666  
Fax: (412) 624-4440  
Email: [tmr15@pitt.edu](mailto:tmr15@pitt.edu)


Keywords: Dengue virus, flavivirus, infection, xxx

### Abstract

Dengue viruses cause a spectrum of diseases by the four serotypes. Dengue is the most prevalent arthropod-borne virus affecting humans today. Due in part to population growth and uncontrolled urbanization in tropical and subtropical countries, breeding sites for the mosquitoes that transmit dengue virus have proliferated. In turn, successful vector control programs have been eliminated, often due to lack of governmental funding. Dengue viruses have evolved rapidly, as they have spread worldwide, and genotypes associated with increased virulence has spread across Asia and the Americas. This chapter will describe the virus, clinical and epidemiological, and treatments/vaccines associated with dengue infection.

## Overview

Dengue fever (DF), the most prevalent arthropod-borne viral illness in humans, is caused by the dengue virus (DENV). The four serotypes of DENV (DENV 1-4) are transmitted to humans primarily by the *Aedes aegypti* mosquito. DENV, is a member of the *Flaviviridae* family and is related to the viruses that cause yellow fever and the Japanese, St. Louis, and West Nile encephalitides [1]. Infection by DENV causes a spectrum of clinical diseases that range from an acute debilitating, self-limited febrile illness, known as dengue fever (DF) to a life-threatening hemorrhagic and capillary leak syndrome of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). DENV causes an estimated 25 to 100 million cases of DF and 250,000 cases of DHF per year worldwide, with 2.5 billion people at risk for infection [2, 3]. At present, no approved antiviral treatment or vaccine is in use, and therapy is supportive in nature.



Epidemic DHF first appeared in the 1950s in Southeast Asia, and by 1975 it had become a leading cause of hospitalization and death among children in many countries in that region. In the 1980s, DHF began a second expansion into Asia, and in countries where DHF is endemic, the epidemics have become progressively larger over the last 15 years (CDC, <http://www.cdc.gov/ncidod/dvbid/dengue>).

The Americas have seen the most dramatic rises in the emergence of dengue cases. The mosquito vector for dengue was eradicated in most of the region as part of the Pan American Health Organization's (PAHO) yellow fever eradication campaign in the 1950s and 1960s. The *Aedes aegypti* eradication program was officially discontinued in the United States and other Western Hemisphere regions, leading to re-infestation of the mosquito vector in most countries during the 1980s and 1990s. By 1997, the geographic distribution of *Aedes aegypti* was wider than its distribution before the eradication program (Figure 1). Dengue is now endemic in

much of the Western Hemisphere (Figure 2). Hyperendemicity, the presence of multiple circulating serotypes, is wide-spread in most countries and epidemics caused by multiple serotypes are more frequent.


## Recent Dengue in the U.S.A.

- Dengue epidemics occurred in the USA in the 1800s and the first half of the 1900s
- Recent indigenous transmission
  - Texas:
    - 1980: 23 cases, first locally acquired since 1945
    - 1986: 9 cases, 1995: 7 cases, 1997: 3 cases, 1998: 1 case, 1999: 18 cases, 2005: 25 cases
  - Hawaii:
    - 2001-2002: 122 cases (first since 1944)

- The first indigenous transmission of dengue in the United States since the 1940s occurred in Texas in 1980.
- Other recent clusters in the United States also occurred in Texas, where 25 locally acquired cases occurred in 2005.
- A dengue outbreak occurred in Hawaii during 2001-2002. In this case *Aedes albopictus* mosquitoes were responsible for virus transmission. in homes.

There are four grades of DHF. For all grades the four criteria for DHF must be met.

1. In Grade 1, fever and nonspecific constitutional symptoms are present and the only hemorrhagic manifestation is provoked, that is, a positive tourniquet test (which will soon be described).
2. In Grade 2, in addition to the Grade I manifestations, there is spontaneous bleeding.
3. Grades 3 and 4 are Dengue Shock Syndrome. Grade 3 is incipient shock with signs of circulatory failure.
4. In Grade 4, the patient has profound shock, with undetectable pulse and blood pressure.



**Figure 1: Reinfestation of *Aedes aegypti* in the Americas.** Unfortunately, the success of the eradication campaign was not sustained. Beginning in the early 1970s, it began to be disbanded, and many countries channeled their limited resources into other areas. Consequently, *Aedes aegypti* began to reinfest the countries from which it had been eradicated. Comparing the 1970 with the 2006 map, we see the mosquito reestablishing itself throughout Central America and most of South America. As the mosquito has spread, the number and frequency of dengue epidemics have increased, as has dengue hemorrhagic fever activity in the Americas.

Source: PAHO, 2001

### Virology

DENV is an enveloped virus with a single-stranded, positive-sense 10.7 kilobase RNA genome [4], which is translated as a single polyprotein and then cleaved into three structural proteins (C, prM/M, E) and seven non-structural (NS) proteins by virus- and host-encoded proteases. In primary DENV infection, virus enters target cells after the envelope (E) protein adheres to cell surface receptors, such as DC-SIGN on dendritic cells [5]. Viral uptake occurs by receptor-mediated endocytosis. Endosomal acidification induces a conformational change in the E protein resulting in fusion of the viral and endosomal membranes and nucleocapsid release into the

cytoplasm [6, 7]. Virus assembly occurs at the endoplasmic reticulum (ER), and virions are exocytosed via Golgi-derived secretory vesicles [8].

### Epidemiology

Following the bite of a mosquito, usually *Aedes aegypti* or *Aedes albopictus* [2], DENV can cause a range of illnesses from mild to severe. There are four distinct serotypes of DENV. Primary infection with one DENV serotype provides lifelong immunity to that specific serotype. However, when an individual is infected with a different serotype of DENV, there is an increased risk of severe dengue disease [9]. This can occur with all four serotypes, therefore, in regions with multiple endemic serotypes, the risk of severe disease is higher.

### Pathogenesis

The pathogenesis of DHF/DSS, the most severe form of DENV infection, reflects a complex interplay of the host immune response and the viral determinants of virulence [2, 10, 11]. Epidemiological studies have suggested an immune system linkage as there is an increased risk of DHF with secondary infection and in children within the first year of life born to DENV-immune mothers [12-15]. From these observations, the hypothesis of antibody-dependent immune enhancement of infection (ADE) emerged. In support of the ADE pathogenesis concept, antibody enhancement of DENV infection in monocytes *in vitro* correlated with increased risk for DHF [15, 16], and peak viremia was increased in patients with severe secondary DENV infection [17, 18]. Differences in specific genetic determinants among viral isolates [19-21] may also affect virulence as some DENV strains fail to cause severe disease [22, 23]. Finally, a pathologic cytokine response that occurs after extensive T cell activation may contribute to the capillary leak syndrome associated with DHF [11]. Elevated levels of cytokines, including IFN-gamma, TNF-alpha, and IL-10, to some extent correlate with severe disease [24-28]; and disease severity has been associated with activation of CD8<sup>+</sup> T cells and the expansion of serotype-reactive low-affinity DENV-specific T cells that produce high levels of vasoactive cytokines [29-33].

### Clinical Presentations

Dengue fever may present in many forms; as an undifferentiated febrile illness with a maculopapular rash, particularly in children, flu-like symptoms, or as classic Dengue with two or more symptoms, such as fever, headache, bone or joint pain, muscular pain, rash, pain behind the eyes, petechial hemorrhaging. Often, there is prolonged fatigue and depression. During dengue epidemics, hemorrhagic complications may also appear, such as bleeding from the gums, nosebleeds, and bruising. Case fatalities due to DF are low, but case fatality due to


DHF can be high. There is no specific treatment for dengue fever except for symptomatic treatment, rest, and rehydration.

DHF is characterized by spontaneous bleeding, plasma leakage, fever, and thrombocytopenia. Four clinical manifestations need to be observed to be classified as DHF. These include: 1) fever, 2) hemorrhagic episodes with the presence of at least one of the following: a positive tourniquet test; petechiae, ecchymoses, or purpura; or bleeding from mucosa, gastrointestinal tract, injection sites, or others), 3) plasma leakage due to increased capillary permeability, and 4) thrombocytopenia ( $100,000 \text{ mm}^3$  or less). Moderate to marked thrombocytopenia with concurrent hemoconcentration is a distinctive clinical laboratory finding of DHF. However, in order to distinguish DHF from DF, an observation of plasma leakage manifested by a rising hematocrit value (*i.e.*, hemoconcentration) must be observed.

The normal course of DHF lasts between 7-10 days, and with appropriate intensive maintenance of the circulating fluid volume, mortality may be reduced to less than 1%. Only severe DF and DHF cases should be hospitalized. Serological tests are necessary to confirm cases of dengue. However, these tests may take several days [34, 35]. Developing countries may not have the resources to perform these expensive confirmatory assays and therefore, many suspected cases of dengue are not fully diagnosed. In severe cases of DHF, the patient's condition may suddenly deteriorate after a few days of fever; the temperature will drop, followed by signs of circulatory failure; and the patient may rapidly go into a critical state of shock (dengue shock syndrome) and die within 12-24 hours, or quickly recover following appropriate volume replacement therapy.

Dengue shock syndrome (DSS) is the most severe form of DHF, and is characterized by the presence of all four DHF clinical manifestations, as well as circulatory failure. All three manifestations of circulatory failure must be present: rapid and weak pulse, narrow pulse pressure or hypotension for age of patient, and cold, clammy skin and altered mental state.





## Diagnosis

Establishing a laboratory diagnosis of dengue infection is critical for diagnosis of dengue. A major challenge for disease surveillance and case diagnosis is that the dengue viruses produce asymptomatic infections and a spectrum of clinical illness ranging from a mild, nonspecific viral syndrome to fatal hemorrhagic disease. Important risk factors for DHF include the strain and serotype of the infecting virus, as well as the age, immune status, and genetic predisposition of the patient. The most common method to detect the virus is culture or detection of anti-dengue antibodies by serology. Virus can be cultured *in vitro* or by detection of viral RNA and specific dengue virus antigens. Countries that do not have access to sophisticated laboratory tests rely on identification of early clinical and/or simple laboratory indicators that can provide a reliable diagnosis of dengue prior to hospitalization. Early distinction between dengue and other febrile illnesses could help identify patients that should be monitored for signs of DHF.



## Differential Diagnosis

Febrile illnesses such as measles, typhoid fever, leptospirosis, and severe acute respiratory syndrome (SARS) can produce symptoms similar to DF [36-41]. At presentation, these illnesses may share similar clinical features, including headache, myalgia, and rash.

The differential diagnosis of dengue includes:

- Influenza
- Measles
- Rubella
- Malaria
- Typhoid fever
- Leptospirosis
- Meningococemia
- Rickettsial infections
- Bacterial sepsis and
- Other viral hemorrhagic fevers.

## Treatment and long-term outcomes.

There are no specific anti-virals that can kill the virus. However supportive care and treatment can go a long way to treat DF. Paracetamol and other anti-pyretics can be used to treat fever. Bone pain should be treated by analgesics or pain killing tablets. During episodes of DHF/DSS, the mortality rate in the absence of hospitalization can be as high as 50%. With proper treatment, such as intravenous fluid replacement, the mortality rate is greatly reduced.

## Vaccines and Immunity

Multiple correlates of protection have been described for dengue. However, the primary correlate appears to be long-term homotypic protection [42, 43] or short-term heterotypic protection [42, 44]. The majority of protective antibodies are directed at the surface E glycoprotein [45, 46], however, antibodies to the M and NS1 proteins show some protective efficacy [47]. Passively transferring antibodies from a seroconverted animals results in decreased infection and disease following challenge [45, 47]. In addition, maternal antibodies decrease disease in infants [15, 48]. Using *in vitro* neutralization assays, antibodies directed against the E protein prevent virus infection [49]. Antibodies that block viral attachment or prevent fusion to target cells neutralize virus infection [50, 51]. In addition to neutralization, antibodies that

mediate cell-mediated cytotoxicity reduce virus infection in both complement independent [52, 53] and complement dependent mechanisms [54]. Cellular immune responses are generally weakly protective [55]. However, these responses are critical for viral clearance [56, 57]. Innate immune responses directed against non-structural proteins, such as NS4B (a putative IFN antagonist), appears to mediate viral escape [58].

Currently, no DENV vaccine is approved by the U.S. Food and Drug Administration. Four related, but serologically distinct DENV can cause disease. Non-neutralizing, cross-reactive antibodies may contribute to DHF pathogenesis via antibody dependent enhancement, an effective vaccine must induce high-titer neutralizing antibodies against all four strains [59, 60]; failure to do so could increase the risk of severe disease upon natural challenge. To circumvent this problem, tetravalent live-attenuated candidate vaccines are in varying stages of development [61-65]. In clinical trials, tetravalent serologic responses were observed in some individuals, but many developed do not develop high titer neutralizing antibodies despite multiple immunizations [66, 67]. Subunit based vaccines, as purified proteins or DNA plasmid, are alternative vaccine strategies. Repeated immunization of purified recombinant DENV DIII or DIII-encoding plasmids induced protective antibody in mice, albeit at relatively low neutralizing titers [68-72].

Both live attenuated vaccines and non-replicating vaccines, such as inactivated virus vaccines, virus-like particles or DNA vaccines have been developed for dengue (Table X). These vaccines elicit protective neutralizing antibodies. These vaccines can elicit long-lasting immunity against the specific serotype of DENV. However, they are poorly cross-reactive against infection with another subtype of DENV.

Table 1 | A partial list of dengue vaccine candidates that are under development

**Vaccine type Vaccine developer(s) Clinical testing status Refs**

Live attenuated WRAIR/GSK Biologicals Tetravalent, Phase II 57,116

Live attenuated Mahidol University/sanofi pasteur No current testing 77

Live attenuated, chimeric NIAID, NIH Monovalent (DENV-1 – 4), Phase I/II 73,89

Live attenuated, chimeric Acambis/sanofi pasteur Tetravalent, Phase I 74,92

Live attenuated, chimeric CDC/InViragen Preclinical 93

Inactivated virus WRAIR Preclinical 97

Subunit Hawaii Biotech Begins 2007 97

DNA Navy Medical Research Center Monovalent (DENV-1), Phase I 99

GSK, GlaxoSmithKline; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health;

WRAIR, Walter Reed Army Institute of Research

Type	Sponsor	Stage of Development
<b>Live Attenuated</b>		
tetravalent	Mahidol Univ/Sanofi/Pasteur	Phase I
tetravalent	WRAIR/GSK	Phase II
<b>Chimeric</b>		
Chimerivax (17D YF)	Acambis/Sanofi-Pasteur	Phase I
DENV-2 (16681, PDK53)	CDC/InViragen	Preclinical
DENV-2/4d30 (all serotypes)	NIAID, NIH	Phase I/II
DENV-1	US FDA	Phase I
<b>DNA</b>		
Several approaches	Various	
(i.e. Domain III, prM/E, NS1)	NMRC/Univ Pittsburgh	Phase I/Preclinical
<b>Inactivated</b>		
Several approaches	WRAIR	Preclinical
<b>SVP/VLPs</b>		
Subunit/Recombinant		
Baculovirus (E, NS1)	Various	
Replication-defective AV (E)	Replivax-UTMB/Acambis	Preclinical
Yeast (C/prM/E, E-IIBsAg)	various	Preclinical
E. coli (E, E-NS1)	Various	Preclinical
Drosophila cells	Hawaii Biotech	Phase I
DNA	Univ Pittsburgh	Preclinical

### Figure Legends

**Figure SRa.** A world map denoting the areas that had WNV human disease prior to 2003. Kunjin, the lineage Ib WNV, is also shown. *Image reprinted with permission [Solomon et al., 2003]. GET COPYRIGHT PERMISSIONS*

**Figure SR1.** The number of confirmed human cases of WN disease in the United States in 2008.

[http://www.cdc.gov/ncidod/dvbid/westnile/Mapsactivity/surv&control08Maps\\_PrinterFriendly.htm](http://www.cdc.gov/ncidod/dvbid/westnile/Mapsactivity/surv&control08Maps_PrinterFriendly.htm)

**Figure SR2.** A simplified diagram of the WNV transmission cycle. The maintenance of WNV in nature depends upon many avian and mosquito species. Humans and other incidental hosts (like horses) become infected when WNV-infected mosquito takes a bloodmeal from them.

**Figure SR3.** Timecourse of WNV infection and antibody response in humans as estimated from blood donations. WNV genomes are detected by commercially available kit by TMA assay. IgM and IgG are measured by ELISA (enzyme-linked immunosorbant assay). ID-TMA: individual donation transcription-mediated activation performed once (1x) or 6 times (6x). ID-NAT: individual donation nucleic acid test. MP-NAT: minipooled nucleic acid test. *Figure reprinted with permission [Busch et al., 2008].*  
(NEED TO GET PERMISSIONS)

## References

1. Burke, D. S. and Monath, T. P., *Flaviviruses*, in *Fields Virology*, D.M. Knipe and P.M. Howley, Editors. 2001, Lippincott Williams &Wilkins: Philadelphia. p. 1043-1125.
2. Halstead, S. B. (1988) Pathogenesis of dengue: challenges to molecular biology. *Science* 239: 476-481.
3. Monath, T. P. (1994) Dengue: the risk to developed and developing countries. *Proc Natl Acad Sci U S A* 91: 2395-2400.
4. Chambers, T. J., Hahn, C. S., Galler, R., and Rice, C. M. (1990) Flavivirus genome organization, expression, and replication. *Annu Rev Microbiol* 44: 649-688.
5. Tassaneeritthep, B., Burgess, T., Granelli-Piperno, A., Trumpheller, C., Finke, J., et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. *J Exp Med*: In press.
6. Heinz, F., Auer, G., Stiasny, K., Holzmann, H., Mandl, C., et al. (1994) The interactions of the flavivirus envelope proteins: implications for virus entry and release. *Arch.Virol.* 9(5): 339-348.
7. Heinz, F., Stiasny, K., Puschner-Auer, G., Holzmann, H., Allison, S., et al. (1994) Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with the protein prM. *Virology* 198: 109-117.
8. Mackenzie, J. M., Jones, M. K., and Westaway, E. G. (1999) Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells. *J Virol* 73: 9555-9567.
9. Solomon, T. and Mallewa, M. (2001) Dengue and other emerging flaviviruses. *J Infect* 42: 104-115.
10. Rothman, A. L. (2004) Dengue: defining protective versus pathologic immunity. *J Clin Invest* 113: 946-951.

11. Rothman, A. L. and Ennis, F. A. (1999) Immunopathogenesis of Dengue hemorrhagic fever. *Virology* 257: 1-6.
12. Halstead, S. B. and Simasthien, P. (1970) Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. *Yale J Biol Med* 42: 276-292.
13. Halstead, S. B., Nimmannitya, S., and Cohen, S. N. (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. *Yale J Biol Med* 42: 311-328.
14. Halstead, S. B. (1990) Global epidemiology of dengue hemorrhagic fever. *Southeast Asian J Trop Med Public Health* 21: 636-641.
15. Kliks, S. C., Nimmannitya, S., Nisalak, A., and Burke, D. S. (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. *Am J Trop Med Hyg* 38: 411-419.
16. Kliks, S. C., Nisalak, A., Brandt, W. E., Wahl, L., and Burke, D. S. (1989) Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. *Am J Trop Med Hyg* 40: 444-451.
17. Libraty, D. H., Endy, T. P., Houg, H. S., Green, S., Kalayanarooj, S., et al. (2002) Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. *J Infect Dis* 185: 1213-1221.
18. Vaughn, D. W., Green, S., Kalayanarooj, S., Innis, B. L., Nimmannitya, S., et al. (2000) Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity. *J Infect Dis* 181: 2-9.
19. Leitmeyer, K. C., Vaughn, D. W., Watts, D. M., Salas, R., Villalobos, I., et al. (1999) Dengue virus structural differences that correlate with pathogenesis. *J Virol* 73: 4738-4747.
20. Cologna, R. and Rico-Hesse, R. (2003) American genotype structures decrease dengue virus output from human monocytes and dendritic cells. *J Virol* 77: 3929-3938.
21. Pryor, M. J., Carr, J. M., Hocking, H., Davidson, A. D., Li, P., et al. (2001) Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. *Am J Trop Med Hyg* 65: 427-434.
22. Watts, D. M., Porter, K. R., Putvatana, P., Vazquez, B., Calampa, C., et al. (1999) Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. *Lancet* 354: 1431-1434.
23. Messer, W. B., Vitarana, U. T., Sivananthan, K., Eivtigala, J., Preethimala, L. D., et al. (2002) Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. *Am J Trop Med Hyg* 66: 765-773.
24. Green, S., Vaughn, D. W., Kalayanarooj, S., Nimmannitya, S., Suntayakorn, S., et al. (1999) Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. *J Infect Dis* 179: 755-762.
25. Hober, D., Poli, L., Roblin, B., Gestas, P., Chungue, E., et al. (1993) Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. *Am J Trop Med Hyg* 48: 324-331.
26. Hober, D., Nguyen, T. L., Shen, L., Ha, D. Q., Huong, V. T., et al. (1998) Tumor necrosis factor alpha levels in plasma and whole-blood culture in dengue-infected patients: relationship between virus detection and pre-existing specific antibodies. *J Med Virol* 54: 210-218.
27. Hober, D., Delannoy, A. S., Benyoucef, S., De Groote, D., and Wattre, P. (1996) High levels of sTNFR p75 and TNF alpha in dengue-infected patients. *Microbiol Immunol* 40: 569-573.

28. Bethell, D. B., Flobbe, K., Cao, X. T., Day, N. P., Pham, T. P., *et al.* (1998) Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. *J Infect Dis* 177: 778-782.
29. Mongkolsapaya, J., Duangchinda, T., Dejnirattisai, W., Vasanawathana, S., Avirutnan, P., *et al.* (2006) T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? *J Immunol* 176: 3821-3829.
30. Mongkolsapaya, J., Dejnirattisai, W., Xu, X. N., Vasanawathana, S., Tangthawornchaikul, N., *et al.* (2003) Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. *Nat Med* 9: 921-927.
31. Green, S., Pichyangkul, S., Vaughn, D. W., Kalayanarooj, S., Nimmannitya, S., *et al.* (1999) Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. *J Infect Dis* 180: 1429-1435.
32. Zivna, I., Green, S., Vaughn, D. W., Kalayanarooj, S., Stephens, H. A., *et al.* (2002) T cell responses to an HLA-B\*07-restricted epitope on the dengue NS3 protein correlate with disease severity. *J Immunol* 168: 5959-5965.
33. Bashyam, H. S., Green, S., and Rothman, A. L. (2006) Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. *J Immunol* 176: 2817-2824.
34. Schwartz, E., Mileguir, F., Grossman, Z., and Mendelson, E. (2000) Evaluation of ELISA-based sero-diagnosis of dengue fever in travelers. *J Clin Virol* 19: 169-173.
35. Schwartz, E., Moskovitz, A., Potasman, I., Peri, G., Grossman, Z., *et al.* (2000) Changing epidemiology of dengue fever in travelers to Thailand. *Eur J Clin Microbiol Infect Dis* 19: 784-786.
36. Flannery, B., Pereira, M. M., Velloso, L. d. F., Carvalho, C. d. C., De Codes, L. G., *et al.* (2001) Referral pattern of leptospirosis cases during a large urban epidemic of dengue. *Am J Trop Med Hyg* 65: 657-663.
37. Watt, G., Jongsakul, K., Chouriyagune, C., and Paris, R. (2003) Differentiating dengue virus infection from scrub typhus in Thai adults with fever. *Am J Trop Med Hyg* 68: 536-538.
38. Karande, S., Gandhi, D., Kulkarni, M., Bharadwaj, R., Pol, S., *et al.* (2005) Concurrent outbreak of leptospirosis and dengue in Mumbai, India, 2002. *J Trop Pediatr* 51: 174-181.
39. Dietz, V. J., Nieburg, P., Gubler, D. J., and Gomez, I. (1992) Diagnosis of measles by clinical case definition in dengue-endemic areas: implications for measles surveillance and control. *Bull World Health Organ* 70: 745-750.
40. Wilder-Smith, A., Earnest, A., and Paton, N. I. (2004) Use of simple laboratory features to distinguish the early stage of severe acute respiratory syndrome from dengue fever. *Clin Infect Dis* 39: 1818-1823.
41. Wilder-Smith, A., Foo, W., Earnest, A., Sremulanathan, S., and Paton, N. I. (2004) Seroepidemiology of dengue in the adult population of Singapore. *Trop Med Int Health* 9: 305-308.
42. Sabin, A. B. (1952) Research on dengue during World War II. *Am J Trop Med Hyg* 1: 30-50.
43. Halstead, S. B. (1974) Etiologies of the experimental dengues of Siler and Simmons. *Am J Trop Med Hyg* 23: 974-982.
44. Guirakhoo, F., Kitchener, S., Morrison, D., Forrat, R., McCarthy, K., *et al.* (2006) Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. *Hum Vaccin* 2: 60-67.
45. Kaufman, B. M., Summers, P. L., Dubois, D. R., and Eckels, K. H. (1987) Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. *Am J Trop Med Hyg* 36: 427-434.

46. Bray, M., Zhao, B. T., Markoff, L., Eckels, K. H., Chanock, R. M., *et al.* (1989) Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. *J Virol* 63: 2853-2856.
47. Kaufman, B. M., Summers, P. L., Dubois, D. R., Cohen, W. H., Gentry, M. K., *et al.* (1989) Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. *Am J Trop Med Hyg* 41: 576-580.
48. Pengsaa, K., Luxemburger, C., Sabchareon, A., Limkittikul, K., Yoksan, S., *et al.* (2006) Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. *J Infect Dis* 194: 1570-1576.
49. Russell, P. K., Nisalak, A., Sukhavachana, P., and Vivona, S. (1967) A plaque reduction test for dengue virus neutralizing antibodies. *J Immunol* 99: 285-290.
50. Crill, W. D. and Roehrig, J. T. (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. *J Virol* 75: 7769-7773.
51. Roehrig, J. T., Bolin, R. A., and Kelly, R. G. (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. *Virology* 246: 317-328.
52. Garcia, G., Arango, M., Perez, A. B., Fonte, L., Sierra, B., *et al.* (2006) Antibodies from patients with dengue viral infection mediate cellular cytotoxicity. *J Clin Virol* 37: 53-57.
53. Laoprasopwattana, K., Libraty, D. H., Endy, T. P., Nisalak, A., Chunsuttiwat, S., *et al.* (2005) Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. *J Infect Dis* 192: 510-519.
54. Falgout, B., Bray, M., Schlesinger, J. J., and Lai, C. J. (1990) Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. *J Virol* 64: 4356-4363.
55. Calvert, A. E., Huang, C. Y., Kinney, R. M., and Roehrig, J. T. (2006) Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. *J Gen Virol* 87: 339-346.
56. Bukowski, J. F., Kurane, I., Lai, C. J., Bray, M., Falgout, B., *et al.* (1989) Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. *J Virol* 63: 5086-5091.
57. Kurane, I., Meager, A., and Ennis, F. A. (1989) Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. *J Exp Med* 170: 763-775.
58. Munoz-Jordan, J. L., Laurent-Rolle, M., Ashour, J., Martinez-Sobrido, L., Ashok, M., *et al.* (2005) Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. *J Virol* 79: 8004-8013.
59. Barrett, A. D. (2001) Current status of flavivirus vaccines. *Ann N Y Acad Sci* 951: 262-271.
60. Halstead, S. B. and Deen, J. (2002) The future of dengue vaccines. *Lancet* 360: 1243-1245.
61. Guirakhoo, F., Arroyo, J., Pugachev, K. V., Miller, C., Zhang, Z. X., *et al.* (2001) Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. *J Virol* 75: 7290-7304.
62. Huang, C. Y., Butrapet, S., Pierro, D. J., Chang, G. J., Hunt, A. R., *et al.* (2000) Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. *J Virol* 74: 3020-3028.
63. Durbin, A. P., Karron, R. A., Sun, W., Vaughn, D. W., Reynolds, M. J., *et al.* (2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. *Am J Trop Med Hyg* 65: 405-413.



64. Markoff, L., Pang, X., Hounh Hs, H. S., Falgout, B., Olsen, R., *et al.* (2002) Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. *J Virol* 76: 3318-3328.
65. Bhamarapravati, N. and Sutee, Y. (2000) Live attenuated tetravalent dengue vaccine. *Vaccine* 18 Suppl 2: 44-47.
66. Edelman, R., Wasserman, S. S., Bodison, S. A., Putnak, J. R., Eckels, K. H., *et al.* (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. *Am J Trop Med Hyg* 69: 48-60.
67. Sun, W., Edelman, R., Kanesa-thasan, N., Eckels, K. H., Putnak, J. R., *et al.* (2003) Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. *Am J Trop Med Hyg* 69: 24-31.
68. Khanam, S., Etemad, B., Khanna, N., and Swaminathan, S. (2006) Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. *Am J Trop Med Hyg* 74: 266-277.
69. Mota, J., Acosta, M., Argotte, R., Figueroa, R., Mendez, A., *et al.* (2005) Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. *Vaccine* 23: 3469-3476.
70. Hermida, L., Rodriguez, R., Lazo, L., Silva, R., Zulueta, A., *et al.* (2004) A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. *J Virol Methods* 115: 41-49.
71. Simmons, M., Nelson, W. M., Wu, S. J., and Hayes, C. G. (1998) Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. *Am J Trop Med Hyg* 58: 655-662.
72. Simmons, M., Murphy, G. S., and Hayes, C. G. (2001) Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. *Am J Trop Med Hyg* 65: 159-161.

# **APPENDIX 5**

*West Nile Virus*

*2010. Clin Lab Med. 30(1):47-65*

*Rossi SL, Ross TM, Evans JD*

# West Nile Virus

Shannan L. Rossi, PhD, Ted M. Ross, PhD, Jared D. Evans, PhD\*

## KEYWORDS

- West Nile virus • Flavivirus • Infection
- Pathogenesis • Diagnosis

## OVERVIEW

Since its isolation in Uganda in 1937, West Nile virus (WNV) has been responsible for thousands of cases of morbidity and mortality in birds, horses, and humans. Historically, epidemics were localized to Europe, Africa, the Middle East, and parts of Asia and primarily caused a mild febrile illness in humans. However, in the late 1990s, the virus became more virulent and spread to North America. In humans, the clinical presentation ranges from asymptomatic (approximately 80% of infections) to encephalitis/paralysis and death (less than 1% of infections). There is no FDA (Food and Drug Administration)-licensed vaccine for human use, and the only recommended treatment is supportive care. Individuals that survive infection often have a long recovery period. This article reviews the current literature summarizing the molecular virology, epidemiology, clinical manifestations, pathogenesis, diagnosis, treatment, immunology, and protective measures against WNV and WNV infections in humans.

## VIROLOGY AND MOLECULAR BIOLOGY OF WNV

West Nile virus is a positive-stranded RNA virus in the family Flaviviridae (genus *Flavivirus*), that includes other human pathogens, such as dengue, yellow fever, and Japanese encephalitis viruses.<sup>1,2</sup> The virion consists of an envelope surrounding an icosahedral capsid approximately 50 nm in size. The approximately 11-kilobase genome encodes a single open reading frame, which is flanked by 5' and 3' untranslated regions. The polyprotein of approximately 3000 amino acids is cleaved into 10 proteins by cellular and viral proteases (Fig. 1). Three of these proteins are the structural components required for virion formation (capsid protein [C]) and assembly into viral particles (premembrane [prM] and envelope [E] proteins). The other 7 viral proteins are nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) and are all necessary for genome replication. NS3 contains an ATP-dependent

This work was supported by T32 Grant #A1060525-04 from the National Institute of Health (SR), W81XWH-BAA-06-1 and W81XWH-BAA-06-2 (TMR), and CVR Funds (JE).

Department of Microbiology and Molecular Genetics, Center for Vaccine Research, University of Pittsburgh, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA

\* Corresponding author.


E-mail address: Evansj2@cvr.pitt.edu (J.D. Evans).

Clin Lab Med ■ (2009) ■-■

doi:10.1016/j.cll.2009.10.006

labmed.theclinics.com

0272-2712/09/\$ - see front matter © 2009 Elsevier Inc. All rights reserved.



61  
62  
63  
64  
65

**Fig. 1.** WNV genome. A representation of the WNV genome including the 3 structural proteins that make up virion particle and the 7 nonstructural proteins necessary for virus replication and immune evasion.

66  
67  
68  
69  
70  
71  
72  
73  
74

helicase and in conjunction with the NS2B protein, a serine protease, which is required for virus polyprotein processing. NS5 is a methyltransferase and RNA-dependent RNA polymerase. The other NS proteins are small, generally hydrophobic proteins of disparate functions. NS1 is a secreted glycoprotein implicated in immune evasion.<sup>3</sup> NS2A plays a role in virus assembly and inhibiting interferon (IFN)- $\beta$  promoter activation.<sup>4,5</sup> NS4A is responsible for a rapid expansion and modification of the endoplasmic reticulum (ER) that helps establish replication domains.<sup>5-8</sup> NS4B blocks the IFN response.<sup>9-12</sup> All the NS proteins seem to be necessary for efficient replication.<sup>13</sup>

75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92

**[Q6]** The flavivirus life cycle consists of 4 principal stages: attachment/entry, translation,  
**[Q7]** replication, and assembly/egress (reviewed in {Clyde, 2006 #103,<sup>2</sup>}). WNV enters cells via receptor-mediated endocytosis, and is transported into endosomes. The WNV receptor is unknown. Several cell-surface proteins are potential WNV receptors (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin [DC-SIGN], integrin  $\alpha_v\beta_3$ ),<sup>14-16</sup> and the receptor required for WNV binding and entry may vary by cell type. Acidification of the endosomal compartment causes a conformational change in the E protein, resulting in fusion of the viral and endosomal membranes and release of the virus nucleocapsid into the cytoplasm.<sup>17,18</sup> The viral RNA is translated and the polyprotein is processed. Genome replication is carried out in specific domains established by the viral proteins.<sup>19,20</sup> As stated earlier, viral proteins cause massive expansion and modification of the ER. Two domains are important in replication and virus protein processing: vesicle packets and convoluted membranes, respectively (**Fig. 2**).<sup>20-25</sup> Following replication and translation, genomes are packaged into virions, which mature through the ER-Golgi secretion pathway.<sup>19,20,26,27</sup> Progeny viruses are released by exocytosis.


## 93 94 95

### PHYLOGENY

The most current phylogenetic studies based on complete or partial genome sequences indicate 5 lineages of WNV.<sup>28</sup> The virus that entered North America belongs to lineage I (clade Ia). This lineage also contains viruses found in Europe,

[Q1]

96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121



122 **Fig. 2.** WNV isolated from brain tissue from an infected crow. The tissue was cultured in  
123 a Vero cell for a 3-day incubation period. The Vero cells were fixed in glutaraldehyde, dehy-  
[Q12] drated, placed in an Epon resin, thin sectioned, placed on a copper grid, and stained with  
[Q13] uranyl acetate and lead citrate. The grids were then placed in the electron microscope  
[Q14] and viewed. Total magnification, image 65,625x. (Courtesy of Bruce Cropp, microbiologist, [Q15]  
[Q14] Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention  
[CDC].)

124  
125

126 the Middle East, and Africa. The genome of Kunjin virus, the Australian strain of WNV,  
127 is also in the lineage I group (clade Ib). Lineage II contains WNV mainly of African  
128 origin. Although there are exceptions, in general, lineage I (clade Ia) viruses can cause  
129 severe human neurologic disease, whereas lineage I (clade Ib) and lineage II viruses  
130 generally cause a mild, self-limiting disease. Not much is known about the viruses  
131 that comprise lineage III, IV, and V.

132

### 133 EPIDEMIOLOGY

134

135 WNV is maintained in nature in a cycle between birds and mosquitoes (**Fig. 3**).  
136 Although many different species of mosquito are capable of maintaining this cycle,  
137 the *Culex* species play the largest role in natural transmission (**Fig. 4**). Not all infected  
138 mosquitoes feed preferentially on birds, which can lead to other animals, including hu-  
139 mans, becoming infected. Humans (and horses) are incidental or "dead-end" hosts in  
140 this cycle, because the concentration of virus within the blood (viremia) is insufficient  
141 to infect a feeding naïve mosquito. Other natural modes of WNV transmission have  
been documented but occur rarely. WNV transmission can occur between infected

142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192

print & web 4C/FPO




Fig. 3. The WNV transmission cycle. The maintenance of WNV in nature depends on many avian and mosquito species. Humans and other incidental hosts (like horses) become infected when WNV-infected mosquito takes a bloodmeal from them.

mother and newborn via the intrauterine route<sup>29-31</sup> or possibly by breast-feeding.<sup>32</sup> A recent study of pregnant women who became infected with WNV during the 2003 to 4 transmission in the United States suggested that adverse side effects in the newborn infant due to WNV infection of the mother are rare, and those cases with infant illness/infection/mortality may be associated with WNV infection that occurred while the mother was infected within 1 month prepartum.<sup>33</sup>

Within the human population, the virus can spread between individuals by more artificial means. In the early 2000s, patients that received tainted blood or organs from viremic donors became infected.<sup>34-37</sup> These events highlighted the need to safeguard blood and organ donations from potentially viremic, yet healthy, donors, and relatively few infections via this route of transmission have been reported since 2004.

The epidemiology of WNV is continuously changing. The virus was initially isolated from a febrile woman in Uganda in 1937.<sup>38</sup> Since then, few outbreaks of WNV in human or horse populations have been recorded until the beginning of the 1990s. When disease was observed in humans, symptoms were typically mild and neurologic complications were rare.<sup>39,40</sup> The exceptions were outbreaks in Israel in the early 1950s and France in the 1960s, which were characterized by encephalitis in humans and horses. A series of outbreaks in the 1990s brought WNV into the spotlight; epidemics in Algeria, Morocco, Tunisia, Italy, France, Romania, Israel, and Russia were associated with uncharacteristically severe human disease, including neurologic



Fig. 4. *Culex* mosquito. The *Culex* species of mosquito, the most common vector of WNV, feeding. (Courtesy of US Geological Survey.)

193 complications and death.<sup>39,41–43</sup> In the summer of 1999, a cluster of patients with  
194 encephalitis in New York City signaled the entry of WNV into North America. The  
195 sequence of the 1999 New York strain of WNV is closest in identity to a viral isolate  
196 from Israel,<sup>44</sup> but how the virus traversed the Atlantic Ocean is still a mystery. In the  
197 past decade, there have been thousands of reported human cases of WNV disease  
198 (WN fever and WN encephalitis) accompanied by more than 1000 deaths (**Table 1**).  
199 The geographic range of the virus currently extends north into Canada, west across  
200 all 48 contiguous states, and south into Mexico, the Caribbean, and Central and South  
201 America (**Figs. 5 and 6**) (Blitvich, 2008 #876). Since 2007, in addition to ongoing circu-  
202 lation of WNV in the Western Hemisphere, there have been outbreaks or isolations of  
203 WNV in Volgograd (Russia) (Platonov, 2008 #877), South Africa (Venter, 2009 #878),  
204 Hungary (Krisztalovics, 2008 #879), Romania (Popovici, 2008 #880), and Italy (Rossini,  
205 2008 #881)(see **Fig. 5**). In 2008 alone, there were 1338 cases of WNV disease reported  
206 to the Centers for Disease Control and Prevention (CDC) and resulted in 43 deaths  
207 within the United States ([http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount08\\_detailed.htm](http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount08_detailed.htm)).  
208

209

210

211

#### 211 **CLINICAL PRESENTATION**

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

#### 235 **PATHOGENESIS**

236

237

238

239

240

241

242

243

Understanding the full range of WNV pathogenesis in humans has been difficult, mainly because of the difference in virulence between WNV strains, the high prevalence of asymptomatic or subclinical infections, and the relative infrequency of laboratory-confirmed human infections. Little has been published about human infections with WNV of limited virulence. Most of our current knowledge regarding WNV pathogenesis resulted from animal models (mostly rodent) infected under controlled conditions with a known amount of needle-inoculated virus, which may not accurately reflect the course of a natural infection in humans. Nevertheless, many documented

244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294

**Table 1**  
**Summary of confirmed human cases of WN disease in the United States, 1999–2008<sup>a</sup>**

Year	No. States Reporting <sup>b</sup>	Total Cases	Deaths	CFR <sup>c</sup>	Neurologic Involvement <sup>d</sup>	WN Fever <sup>e</sup>	Other Symptoms
1999	1	62	7	11.29%	59	3	0
2000	3	21	2	9.52%	19	2	0
2001	10	66	10	15.15%	64	2	0
2002	39 + DC	4156	284	6.83%	2946	1160	50
2003	45 + DC	9862	264	2.68%	2866	6830	166
2004	40 + DC	2539	100	3.94%	1142	1269	128
2005	43 + DC	3000	119	3.97%	1294	1607	99
2006	43 + DC	4269	177	4.15%	1459	2616	194
2007	43	3630	124	3.42%	1217	2350	63
2008	45 + DC	1356	44	3.24%	687	624	45

Abbreviations: CDC, Centers for Disease Control and Prevention; CFR, case fatality rate; DC, District of Columbia.

<sup>a</sup> Data obtained from the CDC, accessed on May 13, 2009.

<sup>b</sup> The number of states reporting CDC-confirmed cases of WNV infections in humans.


<sup>c</sup> CFR determined as percentage of deaths from total CDC-confirmed reported cases.

<sup>d</sup> Neurologic involvement is comprised of encephalitis, meningitis.

<sup>e</sup> WN fever; febrile illness with no neurologic involvement.



295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309




310 **Fig. 5.** Distribution of WNV. Countries with historic or recent (2007 to present) WNV activity  
311 (isolations from mosquitoes, birds, horses, or humans) are highlighted in red and blue,  
312 respectively.

313  
314  
315 accounts follow the course of infection in humans suffering from WN fever and WN  
316 encephalitis resulting from a virulent lineage I WNV infection.

317 WNV-infected mosquitoes transmit the virus to humans following a bloodmeal from  
318 the host. During this process, mosquito saliva contaminated with WNV is deposited in  
319 the blood and skin tissue. Virus contained within the skin is presumed to infect resident  
320 dendritic cells, such as Langerhans cells (MHCII+/NLDC145+/E-cadherin+ cells),  
321 which then traffic to the draining lymph node.<sup>51,52</sup> Shortly thereafter, virus amplifies  
322 in the tissues and results in a transient, low-level viremia lasting a few days, and it typi-  
323 cally wanes with the production of anti-WNV IgM antibodies.<sup>53</sup> Following viremia, the  
324 virus infects multiple organs in the body of the host, including the spleen, liver, and  
325 kidneys. Eight days after onset of symptoms, WNV was detected in the urine (viruria)  
326

327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343



344 **Fig. 6.** The number of confirmed human cases of WNV disease in the United States in 2008.  
345 (Courtesy of CDC.)

of a patient with encephalitis,<sup>54</sup> which is consistent with animal (hamster) experiments demonstrating viremia<sup>54</sup> and the presence of viral infection in the kidneys.<sup>55,56</sup>

[Q8] On entering the central nervous system (CNS), WNV causes severe neurological disease. WNV may enter the brain through a combination of mechanisms that facilitates viral neuroinvasion, such as direct infection with or without a breakdown of the blood-brain barrier (BBB) or virus transport along peripheral neurons. High viremia may easily lead to an infection of the brain if the BBB is disrupted, and it is correlated with severity of infection in experimentally infected mice.<sup>57</sup> Viremia and high viral titers in the periphery alone do not predict neuroinvasion. Host proteins, such as death-associated protein kinase-related 2 (Drak2), intercellular adhesion molecule 1 (ICAM-1), macrophage migration inhibitory factor (MIF), and matrix metalloproteinase 9 (MMP-9), have all been implicated in altering BBB permeability during WNV infection.<sup>58-61</sup> The virus may pass into the CNS without disrupting the BBB.<sup>62</sup> The host's response to infection may also contribute to WNV pathogenesis. Studies from experimentally infected mice suggest that the innate immune sensing molecule toll-like receptor 3 (TLR3) may play a role in WNV invasion of CNS,<sup>63</sup> possibly by mediating the upregulation of tumor necrosis factor (TNF)- $\alpha$ , thereby resulting in capillary leakage and increased BBB permeability.<sup>64</sup> The proinflammatory chemokines/cytokines, monocyte chemoattractant protein 5 (MCP-5), MIF, IFN- $\gamma$ -inducible protein 10 (IP-10), monokine induced by IFN- $\gamma$  (MIG), IFN- $\gamma$ , and TNF- $\alpha$ , were all upregulated in the brains of experimentally infected mice, suggesting that the host immune response may be at least partially responsible for neurologic symptoms of the disease.<sup>58,65</sup> However, an increase in BBB leakage does not accurately predict WNV-induced mortality in hamsters, nor does lethal infection increase BBB permeability in all strains of mice.<sup>66</sup> WNV may enter the brain by direct infection and retrograde spreading along neurons in the periphery.<sup>67</sup> Entering the brain via infected peripheral neurons is a likely route, because the level of viremia is low and leakage into the CNS by a breakdown of the BBB is less likely compared with animals with a high titer of circulating WNV in the blood. The discrepancies observed regarding BBB compromise suggest that further research is required to determine the exact mechanism through which WNV enters the CNS.

## DIAGNOSIS

Diagnosis of WNV infection depends on several factors, including environmental conditions, behaviors, and clinical symptoms. Patient history provides crucial clues to diagnosis. For example, if a patient presents with clinical symptoms, including fever and headache, one must consider the distribution of WNV and its mosquito vector. WNV infection must be considered in endemic areas, especially during the summer months. Furthermore, the patient history should suggest exposure to mosquitoes through outdoor activities. An initial physical examination should confirm clinical symptoms of fever, headache, myalgia, or the more severe meningitis and flaccid paralysis. The presence of mosquito bites on the skin also helps diagnosis.

To confirm the initial diagnosis, specific laboratory tests must be ordered (**Table 2**). To date, the most consistent way to verify WNV infection is serology.<sup>47,49</sup> WNV antigen-specific enzyme-linked immunosorbent assay (ELISA) confirms infection. Serological tests include acute or convalescent samples of serum or CSF to determine the WNV-specific antibody profile by ELISA. The best test involves IgM-specific ELISA (MAC-ELISA) in which serum is collected within 8 to 21 days after the appearance of clinical symptoms. This test is commercially available and relatively inexpensive.<sup>34</sup> Also, serology can be performed to analyze immune responses. The presence of

**Table 2**  
**Laboratory tests and diagnosis of WNV infection**

Test	Positive Results
CBC	Anemia, lymphopenia, thrombocytopenia
IgM-specific ELISA	WNV-specific IgM antibodies detected
PRNT	Known virus stock growth inhibited in tissue culture by serum, indicating neutralizing antibodies
NAT	PCR amplification shows presence of WNV genome RNA
Virus isolation/plaque assay	Serum or CSF contain virus as seen in plaque assay
CSF analysis	Antibodies and/or virus present in ELISA or plaque assay, Elevated protein and increased polymorphonuclear cells, negative gram stain
EMG/NCS	Severe effects on anterior horn cells

Abbreviations: CBC, complete blood count; ELISA, enzyme-linked immunosorbent assay; EMG, electromyogram; NAT, nucleic acid testing; NCS, nerve conduction studies; PCR, polymerase chain reaction; PRNT, plaque reduction neutralization test.

[Q18]

reactive lymphocytes or monocytes in CSF samples indicates WNV neurologic infection. More dramatically, a massive influx of polymorphonuclear cells occurs. In patients with WNV neuroinvasion, more than 40% of cells in the CSF are neutrophils.<sup>68</sup> Plaque reduction and neutralization tests allow for identification of virus specificity. A virology test can directly confirm the presence of virus. Serum or CSF is collected, and virus is amplified within permissive cells and sequenced. This test is time-consuming and expensive. Finally, molecular biological tools can be used to confirm the presence of virus. The nucleic acid test is a powerful tool for detecting WNV genomes. Serum or CSF collected during the initial phases of virus infection can be directly amplified or used to detect viral RNA by quantitative reverse transcription polymerase chain reaction with virus-specific primers.


Magnetic resonance imaging suggests abnormalities in the brain and meninges of WNV-infected patients presenting with CNS disease (Fig. 7).<sup>46,69,70</sup> The regions of the CNS most commonly affected are basal ganglia, thalami, brain stem, ventral horns, and spinal cord. However, most of these studies were performed retrospectively. Thus, the results do not provide predictive capabilities to WNV infection.

#### DIFFERENTIAL DIAGNOSIS

Several diseases manifest as symptoms similar to WNV, including bacterial meningitis and those caused by the encephalitis viruses, such as the Japanese and Murray Valley encephalitis virus. Therefore, differential diagnosis is crucial to determining WNV infection. A differential diagnosis is required when a patient presents with unexplained febrile illness, encephalitis or extreme headache, or meningitis. Thus far, the only manner to differentiate between causes of encephalitis/meningitis is diagnostic and serological laboratory tests to identify the specific pathogen causing the symptoms.

#### TREATMENT AND LONG-TERM OUTCOMES

Currently, patients infected with WNV have limited treatment options. The primary course of action is supportive care. There is no FDA-licensed vaccine to combat



print &amp; web 4C/FPO

Fig. 7. Radiographic and neuropathologic findings in WNV encephalitis. (A) Coronal fluid-attenuated inversion recovery (FLAIR) magnetic resonance image shows an area of abnormally increased signal in the thalami, substantia nigra (extending superiorly toward the subthalamic nuclei), and white matter. (B) Corresponding tissue section from the same patient at autopsy 15 days later stained with Luxol fast blue-periodic acid Schiff for myelin shows numerous ovoid foci of necrosis and pallor throughout the thalamus and subthalamic nucleus (arrows). (C) Axial proton density image at the level of the midbrain shows a bilaterally increased signal in the substantia nigra (arrows). (D) Corresponding tissue section at autopsy stained with Luxol fast blue-periodic acid Schiff illustrates multifocal involvement of the substantia nigra (arrows), with nearly 50% of the area destroyed; the red nuclei are clearly affected. (E) Axial FLAIR image at the level of the lateral ventricle bodies shows a bilaterally increased signal within the white matter. A scan performed approximately 5 months earlier demonstrated an abnormal signal in the left periventricular white matter. This signal increased once WNV encephalitis developed, and the lesions in the right cerebral white matter (left side of photograph) were new. (F) Photomicrograph taken from the right periventricular white matter immunostained with the HAM56 antibody shows numerous macrophages in perivascular areas (lower right) and diffusely throughout the white matter (center). (From Kleinschmidt-DeMaster BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. *Arch Neurol* 2004;61:1210–20; with permission.)

497

498 WN disease in humans, despite the research of many laboratories and institutions and  
499 the vaccines available for use in horses.

500 Furthermore, there is no effective antiviral to combat WNV infection. Two classical  
501 antiviral compounds, IFN and ribavirin, showed promising results in vitro,<sup>71,72</sup> but it is  
502 unclear if these compounds are effective in patients.<sup>73-77</sup> Passively transferring anti-  
503 WNV immunoglobulin has been shown to be effective in mouse and hamster models<sup>78</sup>  
504 and may be helpful in patients.<sup>79,80</sup>

505 Long-term complications (1 year or more postinfection) are common in patients  
506 recovering from WNV infection. The most common self-reported symptom is fatigue  
507 and weakness, although myalgia, arthralgia, headaches, and neurologic complica-  
508 tions, such as altered mental depression, tremors, and loss of memory and concentra-  
509 tion, are not uncommon.<sup>81</sup> There is also evidence from animal models<sup>55,82,83</sup> and  
510 human autopsies<sup>84,85</sup> that the virus may persist in some individuals, as measured  
511 by isolation of virus or viral genomes or antigen months after infection or symptom  
512 presentation. Experimentally infected hamsters show long-term neurological  
513 sequelae, which seems to coincide with the presence of viral antigen and genome  
514 within areas of the brain showing neuropathology.<sup>83</sup> Although the direct evidence of  
515 persistence in humans is limited at this time, many patients have long-lasting WNV-  
516 specific IgM titers in the serum and CNS, suggesting that persistent infections may  
517 be more common than previously indicated.<sup>86-88</sup>

518  
519

520 **Table 3**  
521 **WNV vaccines. A partial list of licensed and preclinical vaccines against WNV**

Type	Antigen	Sponsor	Stage of Development
Chimeric (vector)			
Recombitek (canarypox)	WNV-prM-E	Merial	Licensed for horses
ChimeriVax (yellow fever virus)	WNV-prM-E	Acambis	Phase II
WNV-DENV4 (dengue virus 4)	WNV-prM-E	NIAID/NIH	Phase II
DNA			
WNV-DIII	WNV-DIII	Multiple laboratories	Preclinical
WNV-E	WNV-E	Multiple laboratories	Preclinical
WNV-prM-E	WNV-prM-E	Multiple laboratories	Preclinical
Inactivated/killed			
Inovator	Whole virus	Fort Dodge Animal Health	Licensed for horses
Subviral particles/viruslike particles			
WNV-prM-E	WNV-prM-E	Multiple laboratories	Preclinical

522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548

Abbreviations: NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health.

Data from <http://www.fortdodge livestock.com>, <http://www.merial.com>, <http://www.intervetusa.com>, <http://www.clinicaltrials.gov>.

**IMMUNITY**

The innate and adaptive immune responses mounted against WNV are critically important for controlling infection. Type I IFNs ( $\alpha$  and  $\beta$ ) are important for limiting virus levels, reducing neuronal death, and increasing survival.<sup>57</sup> The amount of IFN made by the host in response to infection seems to be at least partly dependent on the strain or virulence of the virus; mice infected with lineage I WNV with attenuating mutations produce less type I IFN than mice infected with virulent lineage I WNV.<sup>89</sup> Furthermore, WNV strains that are more resistant to the effects of IFN (like some virulent lineage I viruses) are more virulent than IFN-sensitive strains (like lineage II strains).<sup>90</sup>

The adaptive immune response also plays a role in controlling infection. Studies using WNV-infected genetically engineered knockout mice indicate that T-<sup>91-96</sup> and B-<sup>97</sup> cells are critical for controlling infection. CD8+ T-cell recruitment to the brain by neurons expressing the chemokine CXCL10 and by CD40-CD40 ligand interactions help reduce the viral burden in the brain and increase survival in experimentally infected mice.<sup>94,98</sup> B cells are activated within the lymph nodes of WNV-infected mice 48 to 72 hours after infection in an IFN- $\alpha$ / $\beta$ -signaling dependent manner, and B cells secreting WNV-specific IgM were detected on day 7 postinfection.<sup>99</sup> IgM is critically important for the control of early WNV infection, and passive transfer of WNV-specific IgM could protect IgM-deficient mice from lethal WNV infection.<sup>100</sup> Approximately 3 to 4 days after WNV-specific IgM is detectable, anti-WNV IgG titers are measurable in patients.<sup>53</sup> IgG is the predominant antibody, most probably conferring long-term immunity against WNV re-infection. Although not enough data exist, immunity against WNV in convalescent patients is presumed to be lifelong.

**VACCINATION**

Although no FDA-approved vaccine exists for human use, there are effective, licensed vaccines for the treatment of horses. This success has encouraged others to develop these and other strategies for human vaccines. Currently, there are several ongoing clinical trials.

There are several strategies being pursued for WNV vaccine development (Table 3). The first strategy is inoculation of multiple doses of inactivated virus.<sup>101,102</sup> Fort Dodge Animal Health developed this strategy by formalin-inactivating whole virus. This formulation has been approved for horses. The second strategy involves the production of WNV antigens from a heterologous virus backbone. The vectors being used are canarypox (Recombitek), yellow fever virus (ChimeriVax), and dengue 4 (WNV-DEN4).<sup>103-106</sup> The Recombitek vaccine has been licensed for use in horses. The third approach is DNA vaccination. WNV structural antigens (prM-E) are expressed from DNA plasmids.<sup>107</sup> The final strategy is inoculation with purified viral proteins.<sup>108-111</sup> These proteins can be produced in mammalian cell culture, bacteria, or yeast. A recent study by Seino and colleagues<sup>112</sup> compared the efficacy of 3 available vaccines. Their study showed that horses vaccinated with the live, chimeric virus in the yellow fever or canarypox vectors had fewer clinical signs of WNV disease than animals receiving inactivated virus.

**SUMMARY**

In summary, WNV infection is a serious threat to public health, especially to the immunocompromised and the elderly. The virus is maintained in an enzootic cycle between mosquitoes and birds, with humans and other mammals as incidental hosts. Since its

600 introduction to the Western hemisphere in 1999, WNV has spread across North and  
 601 South America in fewer than 10 years. Most human infections are asymptomatic.  
 602 However, clinical manifestations range from fairly mild febrile illness to very severe  
 603 neurological sequelae, including acute flaccid paralysis and encephalitis. Currently,  
 604 the virus is the most significant cause of viral encephalitis in the United States. Efficient  
 605 diagnosis of WNV infection requires a detailed history, including potential exposure to  
 606 contaminated mosquitoes, and sensitive serological and virology assays. Recent  
 607 studies have explained virus-host interactions, including pathogenesis and immune  
 608 evasion. Lastly, there are no prophylactic or therapeutic measures that exist to  
 609 combat the diseases caused by WNV infection, which warrants future research.

#### 611 REFERENCES

- 612
- 613 1. Gould EA, Solomon T. Pathogenic flaviviruses. *Lancet* 2008;371(9611):500–9.
  - 614 2. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. In: HP,  
 615 Knipe DM, editors. *Fields virology*. Philadelphia: Lippincott Williams, Wilkins;  
 2001. p. 991–1041.
  - [Q9] 3. Schlesinger JJ. Flavivirus nonstructural protein NS1: complementary surprises.  
 616 *Proc Natl Acad Sci U S A* 2006;103(50):18879–80.
  - 617 4. Leung JY, et al. Role of nonstructural protein NS2A in flavivirus assembly. *J Virol*  
 [Q10] 2008;82(10):4731–41.
  - 618 5. Mackenzie JM, et al. Subcellular localization and some biochemical properties  
 619 of the flavivirus Kunjin nonstructural proteins NS2A and NS4A. *Virology* 1998;  
 245(2):203–15.
  - 620 6. Egloff MP, et al. An RNA cap (nucleoside-2'-O)-methyltransferase in the flavivi-  
 621 rus RNA polymerase NS5: crystal structure and functional characterization.  
 622 *EMBO J* 2002;21(11):2757–68.
  - 623 7. Khromykh AA, Kenney MT, Westaway EG. Trans-Complementation of flavivirus  
 624 RNA polymerase gene NS5 by using Kunjin virus replicon-expressing BHK  
 625 cells. *J Virol* 1998;72(9):7270–9.
  - 626 8. Speight G, et al. Gene mapping and positive identification of the non-structural  
 627 proteins NS2A, NS2B, NS3, NS4B and NS5 of the flavivirus Kunjin and their  
 628 cleavage sites. *J Gen Virol* 1988;69(Pt 1):23–34.
  - 629 9. Evans JD, Seeger C. Differential effects of mutations in NS4B on West Nile virus  
 630 replication and inhibition of interferon signaling. *J Virol* 2007;81(21):11809–16.
  - 631 10. Liu WJ, et al. Inhibition of interferon signaling by the New York 99 strain and Kun-  
 632 jin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation  
 633 by nonstructural proteins. *J Virol* 2005;79(3):1934–42.
  - 634 11. Munoz-Jordan JL, et al. Inhibition of alpha/beta interferon signaling by the NS4B  
 635 protein of flaviviruses. *J Virol* 2005;79(13):8004–13.
  - 636 12. Munoz-Jordan JL, et al. Inhibition of interferon signaling by dengue virus. *Proc*  
 637 *Natl Acad Sci U S A* 2003;100(24):14333–8.
  - 638 13. Khromykh AA, Sedlak PL, Westaway EG. cis- and trans-acting elements in  
 639 flavivirus RNA replication. *J Virol* 2000;74(7):3253–63.
  - 640 14. Chu JJ, Ng ML. Interaction of West Nile virus with alpha v beta 3 integrin medi-  
 641 ates virus entry into cells. *J Biol Chem* 2004;279(52):54533–41.
  - 642 15. Chu JJ, Ng ML. Infectious entry of West Nile virus occurs through a clathrin-  
 643 mediated endocytic pathway. *J Virol* 2004;78(19):10543–55.
  - 644 16. Medigeshi GR, et al. West Nile virus entry requires cholesterol-rich membrane  
 645 microdomains and is independent of alphavbeta3 integrin. *J Virol* 2008;  
 82(11):5212–9.

- 646 17. Modis Y, et al. Structure of the dengue virus envelope protein after membrane  
647 fusion. *Nature* 2004;427(6972):313–9.
- 648 18. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the  
649 flavivirus life cycle. *Nat Rev Microbiol* 2005;3(1):13–22.
- 650 19. Mackenzie JM, Westaway EG. Assembly and maturation of the flavivirus Kunjin  
651 virus appear to occur in the rough endoplasmic reticulum and along the secre-  
652 tory pathway, respectively. *J Virol* 2001;75(22):10787–99.
- 653 20. Westaway EG, Ng ML. Replication of flaviviruses: separation of membrane  
654 translation sites of Kunjin virus proteins and of cell proteins. *Virology* 1980;  
655 106(1):107–22.
- 656 21. Westaway EG, Mackenzie JM, Khromykh AA. Replication and gene function in  
657 Kunjin virus. *Curr Top Microbiol Immunol* 2002;267:323–51.
- 658 22. Westaway EG, et al. Ultrastructure of Kunjin virus-infected cells: colocalization of  
659 NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-  
660 induced membrane structures. *J Virol* 1997;71(9):6650–61.
- 661 23. Ng ML, et al. Immunofluorescent sites in Vero cells infected with the flavivirus  
662 Kunjin. *Arch Virol* 1983;78(3–4):177–90.
- 663 24. Bartenschlager R, Miller S. Molecular aspects of Dengue virus replication.  
664 *Future Microbiol* 2008;3:155–65.
- 665 25. Welsch S, et al. Composition and three-dimensional architecture of the dengue  
666 virus replication and assembly sites. *Cell Host Microbe* 2009;5(4):365–75.
- 667 26. Miyanari Y, et al. The lipid droplet is an important organelle for hepatitis C virus  
668 production. *Nat Cell Biol* 2007;9(9):1089–97.
- 669 27. Miyanari Y, et al. Hepatitis C virus non-structural proteins in the probable  
670 membranous compartment function in viral genome replication. *J Biol Chem*  
671 2003;278(50):50301–8.
- 672 28. Bondre VP, et al. West Nile virus isolates from India: evidence for a distinct  
673 genetic lineage. *J Gen Virol* 2007;88(Pt 3):875–84.
- 674 29. Centers for Disease Control and Prevention (CDC). Intrauterine West Nile virus  
675 [Q11] infection—New York, 2002. *MMWR Morb Mortal Wkly Rep* 2002;51(50):1135–6.
- 676 30. From the Centers for Disease Control and Prevention. Intrauterine West Nile  
677 virus infection—New York, 2002. *JAMA* 2003;289(3):295–6.
- 678 31. Alpert SG, Ferguson J, Noel LP. Intrauterine West Nile virus: ocular and  
679 systemic findings. *Am J Ophthalmol* 2003;136(4):733–5.
- 680 32. Hinckley AF, O’Leary DR, Hayes EB. Transmission of West Nile virus through  
681 human breast milk seems to be rare. *Pediatrics* 2007;119(3):e666–71.
- 682 33. O’Leary DR, et al. Birth outcomes following West Nile Virus infection of pregnant  
683 women in the United States: 2003–2004. *Pediatrics* 2006;117(3):e537–45.
- 684 34. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. *Ann Intern*  
685 *Med* 2002;137(3):173–9.
- 686 35. Iwamoto M, et al. Transmission of West Nile virus from an organ donor to four  
687 transplant recipients. *N Engl J Med* 2003;348(22):2196–203.
- 688 36. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus  
689 through blood transfusion in the US, 2002. *Transfusion* 2003;43(8):1007–17.
- 690 37. Centers for Disease Control and Prevention (CDC). Detection of West Nile virus  
691 in blood donations—United States, 2003. *MMWR Morb Mortal Wkly Rep* 2003;  
692 52(32):769–72.
- 693 38. Smithburn KC, Hughes TP, Burke AW, et al. A neurotropic virus isolated from the  
694 blood of a native of Uganda. *Am J Trop Med Hyg* 1940;20:471–92.
- 695 39. Murgue B, et al. West Nile in the Mediterranean basin: 1950–2000. *Ann N Y*  
696 *Acad Sci* 2001;951:117–26.



- 697 40. Hayes CG. West Nile virus: Uganda, 1937, to New York City, 1999. *Ann N Y Acad Sci* 2001;951:25–37.
- 698
- 699 41. Bin H, et al. West Nile fever in Israel 1999–2000: from geese to humans. *Ann N Y*
- 700 *Acad Sci* 2001;951:127–42.
- 701 42. Platonov AE, et al. Outbreak of West Nile virus infection, Volgograd Region,
- 702 Russia, 1999. *Emerg Infect Dis* 2001;7(1):128–32.
- 703 43. Tsai TF, et al. West Nile encephalitis epidemic in southeastern Romania. *Lancet*
- 704 1998;352(9130):767–71.
- 705 44. Lanciotti RS, et al. Origin of the West Nile virus responsible for an outbreak of
- 706 encephalitis in the northeastern United States. *Science* 1999;286(5448):2333–7.
- 707 45. Mostashari F, et al. Epidemic West Nile encephalitis, New York, 1999: results of
- 708 a household-based seroepidemiological survey. *Lancet* 2001;358(9278):261–4.
- 709 46. Brilla R, et al. Clinical and neuroradiologic features of 39 consecutive cases of
- 710 West Nile Virus meningoencephalitis. *J Neurol Sci* 2004;220(1–2):37–40.
- 711 47. Hayes EB, Sejvar JJ, Zaki SR, et al. Virology, pathology, and clinical manifesta-
- 712 tions of West Nile virus disease. *Emerg Infect Dis* 2005;11(8):1174–9.
- 713 48. Petersen LR, Roehrig JT, Hughes JM. West Nile virus encephalitis. *N Engl J Med*
- 714 2002;347(16):1225–6.
- 715 49. Tyler KL. West Nile virus infection in the United States. *Arch Neurol* 2004;61(8):
- 716 1190–5.
- 717 50. Campbell GL, et al. West Nile virus. *Lancet Infect Dis* 2002;2(9):519–29.
- 718 51. Byrne S, Halliday GM, Johnston LJ, et al. Interleukin-1 beta but not tumor
- 719 necrosis factor is involved in West Nile virus-induced Langerhans cell migration
- 720 from the skin in C57BL/6 mice. *J Invest Dermatol* 2001;117(3):702–9.
- 721 52. Johnston L, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes
- 722 following cutaneous infection with an arbovirus. *J Invest Dermatol* 2000;
- 723 114(3):560–8.
- 724 53. Busch MP, et al. Virus and antibody dynamics in acute West Nile virus infection.
- 725 *J Infect Dis* 2008;198(7):984–93.
- 726 54. Tonry JH, et al. Persistent shedding of West Nile virus in urine of experimentally
- 727 infected hamsters. *Am J Trop Med Hyg* 2005;72(3):320–4.
- 728 55. Tesh RB, et al. Persistent West Nile virus infection in the golden hamster: studies
- 729 on its mechanism and possible implications for other flavivirus infections.
- 730 *J Infect Dis* 2005;192(2):287–95.
- 731 56. Ding X, et al. Nucleotide and amino acid changes in West Nile virus strains
- 732 exhibiting renal tropism in hamsters. *Am J Trop Med Hyg* 2005;73(4):803–7.
- 733 57. Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West
- 734 Nile virus infection by restricting cellular tropism and enhancing neuronal
- 735 survival. *J Virol* 2005;79(21):13350–61.
- 736 58. Arjona A, et al. Abrogation of macrophage migration inhibitory factor decreases
- 737 West Nile virus lethality by limiting viral neuroinvasion. *J Clin Invest* 2007;
- 738 117(10):3059–66.
- 739 59. Dai J, et al. Icam-1 participates in the entry of West Nile virus into the central
- 740 nervous system. *J Virol* 2008;82(8):4164–8.
- 741 60. Wang P, et al. Matrix metalloproteinase 9 facilitates West Nile virus entry into the
- 742 brain. *J Virol* 2008;82(18):8978–85.
- 743 61. Wang S, et al. Drak2 contributes to West Nile virus entry into the brain and lethal
- 744 encephalitis. *J Immunol* 2008;181(3):2084–91.
- 745 62. Verma S, et al. West Nile virus infection modulates human brain microvascular
- 746 endothelial cells tight junction proteins and cell adhesion molecules: transmigration
- 747 across the in vitro blood-brain barrier. *Virology* 2009;385(2):425–33.

- 748 63. Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile  
749 virus entry into the brain causing lethal encephalitis. *Nat Med* 2004;10(12):  
750 1366–73.
- 751 64. Diamond MS, Klein RS. West Nile virus: crossing the blood-brain barrier. *Nat*  
752 *Med* 2004;10(12):1294–5.
- 753 65. Garcia-Tapia D, et al. West Nile virus encephalitis: sequential histopathological  
754 and immunological events in a murine model of infection. *J Neurovirol* 2007;  
755 13(2):130–8.
- 756 66. Morrey JD, et al. Increased blood-brain barrier permeability is not a primary  
757 determinant for lethality of West Nile virus infection in rodents. *J Gen Virol*  
758 2008;89(Pt 2):467–73.
- 759 67. Samuel MA, et al. Axonal transport mediates West Nile virus entry into the  
760 central nervous system and induces acute flaccid paralysis. *Proc Natl Acad*  
761 *Sci U S A* 2007;104(43):17140–5.
- 762 68. Tyler KL, et al. CSF findings in 250 patients with serologically confirmed West  
763 Nile virus meningitis and encephalitis. *Neurology* 2006;66(3):361–5.
- 764 69. Petropoulou KA, et al. West Nile virus meningoencephalitis: MR imaging find-  
765 ings. *AJNR Am J Neuroradiol* 2005;26(8):1986–95.
- 766 70. Ali M, et al. West Nile virus infection: MR imaging findings in the nervous system.  
767 *AJNR Am J Neuroradiol* 2005;26(2):289–97.
- 768 71. Rossi SL, et al. Adaptation of West Nile virus replicons to cells in culture and use  
769 of replicon-bearing cells to probe antiviral action. *Virology* 2005;331(2):457–70.
- 770 72. Anderson J, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West  
771 Nile virus in vitro. *Emerg Infect Dis* 2002;8(1):107–8.
- 772 73. Chan-Tack KM, Forrest G. Failure of interferon alpha-2b in a patient with West  
773 Nile virus meningoencephalitis and acute flaccid paralysis. *Scand J Infect Dis*  
774 2005;37(11–12):944–6.
- 775 74. Chowers MY, et al. Clinical characteristics of the West Nile fever outbreak, Israel,  
776 2000. *Emerg Infect Dis* 2001;7(4):675–8.
- 777 75. Kalil AC, et al. Use of interferon-alpha in patients with West Nile encephalitis:  
778 report of 2 cases. *Clin Infect Dis* 2005;40(5):764–6.
- 779 76. Sayao AL, et al. Calgary experience with West Nile virus neurological syndrome  
780 during the late summer of 2003. *Can J Neurol Sci* 2004;31(2):194–203.
- 781 77. Weiss D, et al. Clinical findings of West Nile virus infection in hospitalized  
782 patients, New York and New Jersey, 2000. *Emerg Infect Dis* 2001;7(4):654–8.
- 783 78. Morrey JD, et al. Efficacy of orally administered T-705 pyrazine analog on lethal  
784 West Nile virus infection in rodents. *Antiviral Res* 2008;80(3):377–9.
- 785 79. Ben-Nathan D, et al. Using high titer West Nile intravenous immunoglobulin from  
786 selected Israeli donors for treatment of West Nile virus infection. *BMC Infect Dis*  
787 2009;9:18.
- 788 80. Saquib R, et al. West Nile virus encephalitis in a renal transplant recipient: the  
789 role of intravenous immunoglobulin. *Am J Kidney Dis* 2008;52(5):e19–21.
- 790 81. Sejvar JJ. The long-term outcomes of human West Nile virus infection. *Clin Infect*  
791 *Dis* 2007;44(12):1617–24.
- 792 82. Pogodina VV, et al. Study on West Nile virus persistence in monkeys. *Arch Virol*  
793 1983;75(1–2):71–86.
- 794 83. Siddharthan V, et al. Persistent West Nile virus associated with a neurological  
795 sequela in hamsters identified by motor unit number estimation. *J Virol* 2009;  
796 83(9):4251–61.
- 797 84. Penn RG, et al. Persistent neuroinvasive West Nile virus infection in an immuno-  
798 compromised patient. *Clin Infect Dis* 2006;42(5):680–3.

- 799 85. Brenner W, et al. West Nile Virus encephalopathy in an allogeneic stem cell  
800 transplant recipient: use of quantitative PCR for diagnosis and assessment of  
801 viral clearance. *Bone Marrow Transplant* 2005;36(4):369–70.
- 802 86. Kapoor H, et al. Persistence of West Nile Virus (WNV) IgM antibodies in cere-  
803 brospinal fluid from patients with CNS disease. *J Clin Virol* 2004;31(4):  
804 289–91.
- 805 87. Prince HE, et al. Persistence of West Nile virus-specific antibodies in viremic  
806 blood donors. *Clin Vaccine Immunol* 2007;14(9):1228–30.
- 807 88. Roehrig JT, et al. Persistence of virus-reactive serum immunoglobulin m anti-  
808 body in confirmed west nile virus encephalitis cases. *Emerg Infect Dis* 2003;  
809 9(3):376–9.
- 810 89. Rossi SL, et al. Mutations in West Nile virus nonstructural proteins that facilitate  
811 replicon persistence in vitro attenuate virus replication in vitro and in vivo.  
812 *Virology* 2007;364(1):184–95.
- 813 90. Keller BC, et al. Resistance to alpha/beta interferon is a determinant of West Nile  
814 virus replication fitness and virulence. *J Virol* 2006;80(19):9424–34.
- 815 91. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus  
816 infection. *J Virol* 2004;78(15):8312–21.
- 817 92. Shrestha B, Samuel MA, Diamond MS. CD8+ T cells require perforin to clear  
818 West Nile virus from infected neurons. *J Virol* 2006;80(1):119–29.
- 819 93. Shrestha B, et al. Gamma interferon plays a crucial early antiviral role in protec-  
820 tion against West Nile virus infection. *J Virol* 2006;80(11):5338–48.
- 821 94. Sitati EM, Diamond MS. CD4+ T-cell responses are required for clearance of  
822 West Nile virus from the central nervous system. *J Virol* 2006;80(24):  
823 12060–9.
- 824 95. Wang T, et al. IFN-gamma-producing gamma delta T cells help control murine  
825 West Nile virus infection. *J Immunol* 2003;171(5):2524–31.
- 826 96. Wang Y, et al. CD8+ T cells mediate recovery and immunopathology in West  
827 Nile virus encephalitis. *J Virol* 2003;77(24):13323–34.
- 828 97. Diamond MS, et al. B cells and antibody play critical roles in the immediate  
829 defense of disseminated infection by West Nile encephalitis virus. *J Virol*  
830 2003;77(4):2578–86.
- 831 98. Klein RS, et al. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of  
832 West Nile virus encephalitis. *J Virol* 2005;79(17):11457–66.
- 833 99. Purtha WE, et al. Early B-cell activation after West Nile virus infection requires  
834 alpha/beta interferon but not antigen receptor signaling. *J Virol* 2008;82(22):  
835 10964–74.
- 836 100. Diamond MS, et al. A critical role for induced IgM in the protection against West  
837 Nile virus infection. *J Exp Med* 2003;198(12):1853–62.
- 838 101. Ng T, et al. Equine vaccine for West Nile virus. *Dev Biol (Basel)* 2003;114:221–7.
- 839 102. Samina I, et al. An inactivated West Nile virus vaccine for domestic geese-  
840 efficacy study and a summary of 4 years of field application. *Vaccine* 2005;23(41):  
841 4955–8.
- 842 103. Arroyo J, et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical  
843 evaluation of safety, immunogenicity, and efficacy. *J Virol* 2004;78(22):  
844 12497–507.
- 845 104. Minke JM, et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes  
846 of West Nile virus protects horses against a West Nile virus-mosquito challenge.  
847 *Arch Virol Suppl* 2004;18:221–30.
- 848 105. Monath TP, et al. A live, attenuated recombinant West Nile virus vaccine. *Proc*  
849 *Natl Acad Sci U S A* 2006;103(17):6694–9.

- 850 106. Pletnev AG, et al. Molecularly engineered live-attenuated chimeric West Nile/  
851 dengue virus vaccines protect rhesus monkeys from West Nile virus. *Virology*  
852 2003;314(1):190–5.
- 853 107. Davis BS, et al. West Nile virus recombinant DNA vaccine protects mouse and  
854 horse from virus challenge and expresses in vitro a noninfectious recombinant  
855 antigen that can be used in enzyme-linked immunosorbent assays. *J Virol*  
856 2001;75(9):4040–7.
- 857 108. Chu JH, Chiang CC, Ng ML. Immunization of flavivirus West Nile recombinant  
858 envelope domain III protein induced specific immune response and protection  
859 against West Nile virus infection. *J Immunol* 2007;178(5):2699–705.
- 860 109. Ledizet M, et al. A recombinant envelope protein vaccine against West Nile  
861 virus. *Vaccine* 2005;23(30):3915–24.
- 862 110. Lieberman MM, et al. Preparation and immunogenic properties of a recombinant  
863 West Nile subunit vaccine. *Vaccine* 2007;25(3):414–23.
- 864 111. Qiao M, et al. Induction of sterilizing immunity against West Nile Virus (WNV), by  
865 immunization with WNV-like particles produced in insect cells. *J Infect Dis* 2004;  
866 190(12):2104–8.
- 867 112. Seino KK, et al. Comparative efficacies of three commercially available vaccines  
868 against West Nile Virus (WNV) in a short-duration challenge trial involving an  
869 equine WNV encephalitis model. *Clin Vaccine Immunol* 2007;14(11):1465–71.
- 870